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ABSTRACT
The human carcinoma cell line RPMI 2650 produces autocrine 
factors These are detected by the ability of RPMI 2650 
conditioned medium (CM) to stimulate growth in soft agar of 
RPMI 2650 cells plated at low density The autocrine activity 
in crude CM can be fractionated by ultrafiltration into a 
lower molecular weight (MW) fraction (Rl-30), which 
concentrates molecules in the X,000-30,000 kDa range, and a 
higher MW fraction (R30) with molecules greater than 30,000 
kDa in a more concentrated form Rl-30 is labile to acid, base 
and heat treatment, whereas R30 is stable to (and sometimes 
activated by) these treatments Boiling of R30, however, 
renders it labile to acid-, base- and trypsin-treatments CM
can be separated into a weakly heparin-bindmg fraction (with 
stability properties similar to Rl-30), and a non-heparin 
binding fraction (with stability properties similar to R30) 
RPMI 2650 cells secrete TGF-a- and TGF-B-hke molecules, but 
the Rl-30 can be distinguished from these TGFs, and from most 
other known growth factors, by the unusual combination of acid 
lability and weak affinity for heparin Since the 
R30/non-heparin binding fraction is rendered labile by boiling 
or acid treatment, it may represent a bound or 
conformâtlonally stable form of a growth factor Growth 
factor production from RPMI 2650 cells was successfully scaled 
up to a 2 litre scale
TABLE OF CONTENTS
INTRODUCTION
1.1 Growth Control 1
1 1.1 Transforming Growth Factors and epidermal growth
factor 5
1 1.2 Platelet derived growth factor 11
1 1 3  Insulin-like growth factor family 12
1 1 4  Heparin-binding growth factors 15
1 1.5 Miscellaneous growth factors 18
1 1 5  1 Non-FGF heparin binding growth factors 18
1 1 5.2 Platelet derived endothelial cell growth factor 19
1 1 5.3 Bombesin 19
1 1 5  4 Melanoma growth stimulating activity (MGSA) 20
1 1 5  5 Hepatocyte growth factor (HGF) 20
1 1 6  Interleukin family and haemopoietic growth factors 21
1 2 Autocrine Growth Regulation 22
1 2.1 Growth factor control of embryogenesis 23
1 2  2 Growth factor control of wound healing 24
1 2  3 Growth factor control of cancer 25
1 2  4 Autocrine control and TGFs 27
1 2  5 Autocrine control and PDGF 30
1 2.6 Autocrine control and IGF 31
1 2  7 Autocrine control and heparin binding growth factors 33
1 2  8 Autocrine control and bombesm/GRP 35
1 2  9 Autocrine control and the interleukins and
haematopoietic growth factors 36
1 3 Background and aims of the work described in this thesis 38
2 0 MATERIALS AND METHODS
2 1 Media Preparation 39
2 1.1 Water 39
2.1 2 Glassware 39
2 1 3 Siliconisation 39
2 1 4 Sterilisation 39
2.1 5 Growth Media 40
2 1.6 Serum 40
2.1 7 Sterility 41
2 2 Cell lines 42
2 3 Maintenance of cell lines in culture 43
2.3 1 Cell culturing 43
2.3 » 2 Feeding 43
2 3 3 Trypsinisation 43
2.3 4 Cell counting 44
2 4 Long term storage of cell 44
2 4 1 Cell freezing 44
2 4 2 Cell thawing 44
2 5 Contamination 45
2 5 1 Microbial 45
2 5 2 f Mycoplasma 45
2 5 3 Cell line 45
2 6 Collection of Conditioned Media (CM) 46
2 6 1 Roller bottle culture 46
2 6 2 Microcarrier culture 46
2 6 2 1 Sampling and counting 47
2 6 3 Suspension culture 47
2 6 3 1 Sampling and counting 48
r
2 7 Large Scale Culture 48
2 7 1 Bioreactor system and control package 48
2 7 2 Vessel Preparation 49
2 7 3 Inoculation 53
2 7 4 Collection of CM 54
2 7 5 Sampling 54
2 7 6 pH electrode maintenence 54
2 7 7 DO electrode maintenence 54
2 8 1 Ultrafiltration 54
2 8 2 Diafiltration 55
2 8 3 Dialysis 55
2 8 4 Lyophilisation 55
2 9 Soft agar assays 55
2 9 1 Cell pretreatment 56
2 9 2 Assay protocol 56
2 9 3 Colony counting 57
2 10 Purification of CM 58
2 10 1 Ion exchange chromatography 58
2 10 2 Hydrophobic interaction chromatography 59
2 10 3 Heparin sepharose chromatography 59
2 10 3 1 Step Elution 59
2 10 3 2 Gradient Elution 59
2 11 Stability of CM 60
2 11 1 Temperature stability 60
2 11 2 pH stability 60
2 11 3 Protease stability 60
2 12 Pure growth factors 61
2 12 1 Source , 61
2 12 2 Preparation 61
2 8 Processing of CM 54
3.0 RESULTS
3 1 Development of the soft agar assay system 63
3 1 1  Effect of cell loading 63
3 1 2  Effect of indicator cell pretreatment 64
3 1.3 Different serum batches 65
3 1.4 Reasons for improvements in assay reliability 67
3 2 Stimulation of RPMI 2650 cells in soft agar by pure
growth factors 67
3 2 1 Effect of bovine serum albumin (BSA) in the
RPMI 2650 soft agar assay 68
3 2 2 Insulin, insulin-like growth factors I and II 68
3 2 3 Acidic and basic fibroblast growth factors
{aFGF and bFGF) 70
3 2 4 Transforming growth factor beta (TGF-13) 72
3 2 5 Interleukins 1-alpha and beta (IL-la and IL-lfl) 74
3 2 6 Epidermal growth factor (EGF) and transforming
growth factor alpha (TGF-a) 75
3 2 7 Platelet-derived growth factor (PDGF) 76
3.3 Presence of Growth factors in the RPMI 2650 conditioned
media 77
3 3 1 Standard curve of TGF-a activity m  the NRK
soft agar assay 77
3 3 2 Standard curve of TGF-Æ activity in the NRK-49F
soft agar assay 79
3 3 3 Effect of pure growth factors m  the transforming
growth factor a and Î3 soft agar assay systems 82
3 3 3 1 TGF-a assay 82
3 3 3 2 TGF-/3 assay 84
3 3 Stimulation of RPMI 2650 cells in soft agar by
conditioned media from various cell lines 88
3 5 Characterisation of the RPMI 2650 autocrine
stimulatory activity 89
3 5 1 Concentration of the autocrine activity 89
3 5 2 Collection of conditioned medium 92
3 5 3 Temperature stability 94
3 5 4 PH stablility 97
3.5 5 PH stability of the heat stable activity 100
3 5 6 Heat stability of the acid- and base- stable
activities 101
3 5 7 Protease stability of the autocrine activity 104
3 6 Ultrafiltration of the conditioned medium 106
3 6 1 Fractionation of the autocrine activity by
ultrafiltration 106
3 6 2 Temperature stability of fractionated CM 108
3 6 3 Acid and base stabilities of the fractionated CM 110
3 6 4 Boiling R30 fraction at low pH 112
3 6 5 Effect of boiling on protease stability of the R30
fraction 113
3 6 6 Diafiltration of the R30 and boiled R30 samples 115
3 6 7 Fractionation of TGF-a-like activity 117
3 6 8 Fractionation of TGF-/3-like activity 118
3 7 Purification of the RPMI 2650 autocrine activity 121
3.7 1 Effect of dialysis on the autocrine activity 121
3 7 2 Effect of dialysis on TGF-a activity 122
3 7 3 Ion-exchange chromatography 123
3 7 4 Hydrophobic interaction chromatography 125
3 7 5 Heparin sepharose chromatography 127
3.7 5 1 Step Elution 127
3 7 5 2 Diafiltration of fractions eluted from heparin
sepharose 130
3 7 5 3 Gradient elution 132
3 8 Further characterisation of heparin binding and
non-heparin binding fractions 134
3 8 1 Temperature stability of fractions eluted from
heparin sepharose 134
3 8 2 pH stability of fractions eluted from heparin
sepharose 136
3 8 3 Affinity of autocrine activity (fractionated by
ultrafiltration) for heparin sepharose 138
3 8 4 Heparin sepharose affinity of TGF-f3-like activity
fractionated by ultrafiltration 140
3 9 Scale-up of growth and autocrine factor production
from RPMI 2650 cells 142
3 9 1 Growth of RPMI 2650'-cells on different microcarrier
bead types 142
3 9 1 1  Glass, plastic and collagen coated Biospheres 142
3 9 1 2  Cytodex 1, 2 and 3 145
3 9 1 3  Autocrine activity in CM collected from RPMI 2650
microcarrier cultures 147
3 9 2 Growth optimisation and autocrine activity production
from RPMI 2650 cells in suspension cultures 150
3 9 2 1 Culture Medium 150
3 9 2 2 Serum Batch Testing in suspension cultures 153
3 9 2 3 Effect of agitation on growth factor activity 155
3 9 3 Scale-up of RPMI 2650 cells using a 2L Biostat MC 157
4.0 DISCUSSION
4 1 The RPMI 2650 Autocrine Assay System 165
4 2 The Autocrine Activity 176
4 3 Purification 189
4 4 Scale-up of the growth and autocrine factor production
from RPMI 2650 cells 200
5 0 CONCLUSIONS AND FUTURE DIRECTION OF THE PROJECT 213
6 0 ACKNOWLEDGEMENTS 214
7 0 REFERENCES 215
8 0 APPENDICES 253
1 0 INTRODUCTION
GROWTH CONTROL
Multicellular organisms have evolved highly coordinated mechanisms 
to control cellular interactions The initial discovery of 
epidermal growth factor (Carpenter and Cohen, 1979) has been 
followed by the identification of more than 20 different 
polypeptide growth factors, which act in vivo by stimulating fetal 
and placental growth during development (Ohlsson, 1989), 
regulating growth and differentiation of continuously regenerating 
tissues e g  in haematopoiesis (Metcalf, 1985) and stimulating 
tissue repair processes (ten Dijke and Iwata, 1989)
In vivo, the arrangement of developing tissues and the control of 
repair processes require the spatial confinement of growth factor 
activities Circulating growth factors (PDGF, TGF-fl, and the IGFs) 
are usually in latent form e g. in complexes with binding 
proteins Growth factors of the FGF family and certain hemopoietic 
factors are anchored by interaction with the extracellular matrix 
These systems allow presentation of the factors in organised 
microenvironments within which growth control is finely tuned
Growth factors are currently believed to elicit their responses at 
a cellular level by binding to a specific membrane receptor 
resulting in a cascade of reactions, the precise mechanisms of 
which remain to be deciphered Receptors for the major classes 
of growth factors consist of an external ligand domain which 
specifically binds to a selected portion of the growth factor
This external domain is linked, via a hydrophobic stretch of ammo
acids, to an internal domain which often incorporates a protein 
tyrosine kinase catalytic domain (reviewed by Cadena and Gill, 
1992) The mechanism of activation is thought to be due to
dimerization as has been shown to be the case for platelet-derived 
growth factor (PDGF) type B receptor (Heldin et al , 1989) and 
epidermal growth factor (EGF) (Schessinger, 1986) Models of the 
various receptor tyrosine kinases are shown diagramatically below
The spacing of the cysteine residues in their external domains
defines either immunoglobulin-like domains, m  the case of PDGF
1
and EGF receptor families, or cysteine-rich clusters The known 
ligands for each receptor family also show conservation of 
cysteine clusters, but are otherwise dissimilar (Aaronson, 1991)
The receptors that constitute each family and growth factors which 
bind to them are listed in the table below
POGf EOF f C f  H u m  »O f
Figure 1 1 Schematic diagram of transmembrane tryosine kinase 
receptors The open circles illustrate immunoglobulin-like repeats 
Dashed boxes indicate cysteine-rich domains Solid boxes indicate 
conserved tyrosine kinase domains (Aaronson,1991)
/
TABLE 1 Transmembrane Tryosine Kinase Families
Receptor
Prototype
Family members Ligands
PDGF PDGF-a, PDGF-J3, 
M-CSFR (c-fms), 
c-kit
PDGFAA, PDGFBB, 
PDGFAB, c-sis, 
M-CSF
EGF EGFR, c-erbB, 
ERBB2, ERBB3, neu
EGF, TGF-a, 
Amphiregulin,
FGF FGFRl (fig),
FGFR2 (bek), FGFR3, 
FGFR4
aFGF, bFGF, 
INT-2, FGF-5, 
hst/K-FGF, 
FGF-6, KGF
Insulin IR, IGF-IR, 
c-ros
Insulin, IGF-I
HGF HGFR, met HGF
Abbreviations: PDGF = Platelet-derived growth factor, M-CSF =
Macrophage colony stimulating factor, EGF = epidermal growth 
factor, FGF = fibroblast growth factor, I = insulin, IGF = 
insulin-like growth factor, HGF = hepatocyte growth factor R 
refers to receptor
The complete list of substrates of these transmembrane tyrosine 
kinases has yet to be deciphered It has been shown that some 
substrates are protein (serine, threonine or tyrosine) kinases 
(Hunter et al , 1985, Morrison et al , 1988, Ralston and Bishop,
1985, Gould and Hunter, 1988) Although the receptor, itself, is 
often the major tyrosine phosphorylated species observed after the 
receptor is activated by ligand binding (Kock et al , 1991)
A second post-binding event is the phosphorylation of 
phospholipase C which stimulates phosphatidyl-inositol turnover 
leading to the degradation of phosphatidyl-inositol biphosphate 
and release of diacylglycerol and insoitol triphosphate (ITP) 
Diacylglycerol activates protein kinase C (Nishizuka, 1988) by 
binding to it and raising its affinity for calcium ITP increases 
the cytoplasmic calcium ion levels (Berridge and Irvine, 1984).
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Formation of the ligand-receptor complex can also result in 
phosphorylation of Ras guanosine triphosphatase activating protein 
(GAP) which regulates the function of the Ras protein (McCormick, 
1989) Ras, a 21 kDa protein, is a critical component of 
intracellular signalling It binds guanosine triphosphate (GTP) 
tightly catalysing the removal of phosphate from GTP to form the 
inactive guanosine diphosphate Interaction of this complex with 
GAP, results in increased GTPase activity
A third post-binding event is the rapid induction and transient 
expression of a number of primary response genes (reviewed by 
Herschman, 1991) including c-fos, c-]un and c-myc The proteins
encoded by these genes include transcriptional modulators, 
structural proteins, cytokines and proteins of as yet unknown 
function
Binding of ligands to receptor types distinct from membrane 
spanning tyrosine kinases is known to stimulate cell 
proliferation One class includes the receptors for interleukin 
2, 3, 4, 5, 6 and 7, granulocyte-macrophage colony stimulating
factor (GM-CSF), G-CSF and erythropoietin (Nicola and Metcalf, 
1991) These receptors are membrane glycoproteins with a single 
hydrophobic transmembrane domain Their external domains are 
similar in size, with conserved cysteine residues at their amino 
termini Their intracellular domains, however, are not similar 
They vary m  length and possess no tyrosine kinase domain The 
signal transduction pathways of these receptors have not been 
elucidated. It is known, however, that ligand binding results 
in increased levels of GTP-bound ras (Shiraishi et al , 1987),
although they are distinct from G-protein linked receptors A 
number of high affinity cytokine receptors have a two chain 
structure The interleukin 2 receptor, for example, consists of 
two subchains a and Æ Each bind IL-2 with low affinity, but the 
aiî complex binds IL-2 with high affinity (Waldmann, 1991) Other 
two chain receptors include the receptors for IL-5 (Takatsu, 
1991), IL-6 (Taga et al , 1989), GM-CSF (Cosman et al , 1990)
and IL-9 (Hilton, 1992)
Another class of molecules (to which bombesin belongs) capable of 
causing mitogenic stimulation of certain cell types, are 
neurotransmitters (Lin et al., 1991) These receptors are
different from the ones mentioned above They consist of an 
extracellular amino terminal domain linked to a looped cytoplasmic 
carboxyl-terminal by seven transmembrane domains The 
intracellular domain contains regulatory serine and threonine 
residues and is coupled to a G-protein
In the course of this introduction, I will give a brief overview 
of each of the main families of growth factors and cytokines, and 
show how each are implicated in different systems as autocrine 
growth regulators
1 1.1 TRANSFORMING GROWTH FACTORS AND EPIDERMAL GROWTH FACTOR
Transforming growth factor (TGFs) are peptides that affect the 
growth and phenotype of cultured cells and bring about phenotypic 
properties in non-malignant fibroblast cells that resemble those 
of malignant cells (Keski-Oja et al , 1987). Two main classes of 
TGFs have been extensively studied, TGF-a and TGF-13. More 
recently epithelial TGF has been isolated and characterised 
(Halper and Moses, 1987) Other members of this structurally and 
functionally related family include amphiregulin (Shoyab and
Plowman, 1991) and vaccinia virus growth factor (Brown et al ,
1985).
Epidermal growth factor (urogastrone), a fully sequenced 
polypeptide of 53 ammo acids (Carpenter and Cohen, 1979), 
contains 6 cysteine residues which form 3 disuphide bonds (Savage
et al , 1972, Savage et al , 1973) It is synthesised in a large
precursor form (Gray et al , 1983) (133 kd) which consists of the
EGF moiety (53 amino acids) flanked by a stretch of 976 amino
acids at its ammo terminal end that contains 7 peptides, with 
sequences that are similar but not identical to EGF (Scott et al ,
1983), and 188 amino acids at its carboxy terminal.
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Transforming growth factor alpha (TGFa), a 50 amino acid 
polypeptide (5 7 kD), (Derynck et al , 1984) has 40% homology 
with EGF with conservation of all 6 cysteine residues (Marquardt 
et al , 1984) and has been shown to possess very similar chain
folds (Montelione et al , 1989, Harvey et al , 1991) Larger
forms of TGFa, arising from incomplete cleavage and/or 
heterogenous glycosylation, have been described (Texido et al ,
1988)
TGF-a is synthesised as a larger precursor (pro-TGF-a) containing 
a 23 amino acid hydrophobic signal sequence followed by the mature 
unglycosylated growth factor sequence, a second hydrophobic domain 
(which spans the plasma membrane) and finally a cysteine rich 
domain at the carboxyl terminal (Lee et al , 1985, Texido et al , 
1988, Bringman et al , 1987, Gentry et al , 1987) Pro-TGF-a
has been cloned and expressed m  E colz (Derynck et al , 1984)
Newly synthesised pro-TGF-a is resistant to cleavage until it 
reaches the plasma membrane (Texido et al , 1990) Cleavage of 
the TGF-a precursor in CHO cells that express a transfected 
pro-TGF-a occurs in two steps (Pandiella and Massague, 1990). In 
the first step, pro-TGF-a rapidly (t^=15 minutes) loses the 
N-terminal sequence that precedes the TGF-a segment In the 
second step, pro-TGFa is cleaved at the C terminus releasing 
soluble TGF-a into the medium and leaving the 
transmembrane/cytoplasmic fragment associated with the cell This 
second step is rate limiting and so leads to the accumulation of 
pro-TGF-a on the cell surface, much of which turns over without 
ever being converted to the soluble factor
TGF-a and EGF bind to a common cell surface receptor, the 
TGF-a/EGF receptor (175 kDa) (Ullrich et al , 1984), a 1186-amino 
acid transmembrane phosphorylated glycoprotein The ligand binding 
site located in the extracellular 621-amino acid portion of the 
molecule, is separated by a 23-amino acid hydrophobic membrane 
spanning section from the 524-amino acid intracelluar region of 
the molecule which contains protein tyrosine activity (encoded by 
the erbB protooncogene).
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The presence of two distinct EGF/TGF-a receptors (high and low 
affinity) have been identified using Scatchard analysis (Shoyab et 
al., 1979, Boonstra et al , 1985) and blocking antibody studies
(Defize et al , 1989) Recently, Berkers et al (1991) have shown 
that, in addition to the high affinity receptor in HeLa cells, 
there are two low affinity receptors which exhibit different 
kinetics
In general EGF and TGF-a elict the same effects For example the 
stimulation of DNA synthesis in several cell lines (Schreiber et 
al,, 1986), induction of anchorage independent growth (Anzano et 
al., 1983; Salomon et al., 1987), induction of eyelid opening 
in newborn mice (Tam, 1985) or inhibition of parathyroid 
hormone-reponsive adenylate cyclase in osteoblasts (Guiterrez et 
al , 1987)
In other situations, however, TGF-a is more potent TGF-a is 3-10 
times more potent than EGF in releasing calcium ions from bone 
cells in culture and bone resorption (Stern et al , 1985) In
vivo. TGF-a has a more potent effect inducing neovascularization 
(Schreiber et al , 1986) It is more potent than EGF in causing 
transient ruffling of the cell membrane in normal rat kidney cells 
(Myrdal et al , 1986) and increasing rate of migration and
monolayer growth m  keratinocytes (Barrandon and Green, 1987) 
While TGF-a and EGF bind the receptor with similar affinities, 
antibody experiments have shown that the binding is not the same 
(Winkler et al., 1989). The more rapid clearance of intracellular 
TGF-a than EGF after internalisation (Ebner and Derynck, 1991) 
has been suggested as a mechainsm for their differences in 
potency
Transforming growth factor beta (TGFfl) is produced as a 390 amino 
acid inactive precursor that is cleaved to a 112 amino acid 
monomer (12 5 kD) (Derynck et al., 1985) Two monomers linked by 
disulphide bonds form the biologically active 25 kD form (Assoian 
et al , 1983) TGFJ3 is found in three homologous forms in humans, 
each conserving 9 cysteine residues (Ten Dijke et al., 1988) Two
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other forms have also been found in chicken cells (Jakowlow et 
al.f 1988) and frogs (Kondaiah et al., 1990) and designated 
TGF/34 and TGFJ35 respectively
TGF-J3 in itself represents a large family of factors with diverse 
activities (reviewed by Massague, 1990) A number of molecules 
have been identified that have 25-40% homology with TGFI3 and 
conserve at least 7 or the 9 cysteine residues These include 
Mullerian inhibiting substance (Cate et al , 1986, Blake et al.,
1988), inhibins and activins (Mason et al., 1985), Drosophilia 
decapentaplegic gene (Padgett et al , 1987), BMP-2b and BMP-3 
(Worzney et al., 1988), Vg-1 (from Xenopus) (Weeks et al., 1987) 
and the Vgr-1 gene product (Lyons et al , 1989)
In vivo, all three forms of TGF-13 have been found in a wide 
variety of normal adult mouse tissues Some forms are expressed 
at higher levels than others in different tissues TGF-J31 and 132 
were found to be expressed in spleen, lung and placenta, while 
TGF-133 is only detected in the lung and placenta (Miller et al ,
1989) Some cell lines (e g WI-38 human diploid lung
fibroblasts), secrete predominately TGF-J31, some (e g BSC-1 
monkey kidney, and MCF-7 human breast carcinoma) secrete TGF-J32, 
while others (e g NRK-49F rat kidney cells, HT-1080 human 
fibrosarcoma, NIH-3T3 rat fibroblasts and MDCK dog kidney cells) 
secrete both forms in roughly similar amounts (Danielpour et al , 
1989) TGF-J3 has been detected in human urine (Twardzik et al ,
1985), human placenta (Frolik et al , 1983) and more recently m
bovine milk (Cox et al , 1991)
TGF-J3 is synthesised in an inactive form (Lawerence et al , 1984) 
m  most transformed and non-transformed cells While normal and 
chemically transformed rat liver epithelial cells typically 
produce the latent form of TGF-13, malignant epithelial cells 
tended to secrete activated TGF-J3 de novo (Liu et al , 1988). The 
latent molecule consists of the mature TGF-fi molecule 
non-covalently bound to a N-terminal precursor glycopeptide, the 
latency-associated peptide (LAP) (Gentry et al , 1989, Gentry and 
Nash, 1990) Sequence analysis of the cDNA clones has suggested 
the existence of 2 different LAPs for TGF-B2 (Webb et al , 1988) 
Latent TGF-13, isolated from platelets and some other cells, is
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associated with a binding protein (TGF-J3-BP) (Wakefield et al ,
1989) TGF-J3-BP has been isolated and cloned (Miyazono et al , 
1988, Wakefield et al , 1988, Kanzaki et al , 1990) The
molecule is made up of multiple EGF-like repeats and hydroxylated 
asparagine residues that are capable of binding calcium ions 
Activation of the latent TGF-J3 molecule has been well documented 
(Lyons and Moses, 1990) and can be achieved by transient acid 
treatment (Pircher et al , 1984), treatment with proteases
(Lyons et al , 1988) or brief heat treatment (Brown et al , 1990) 
Removal of the carbohydrate moieties from the latent molecule also 
results in activation (Miyazano and Heldin, 1989)
TGF-fi differs from other transforming growth factors by not
competing with EGF for its receptors (Chua et al., 1983, Fanger et 
al , 1986; Like and Massague, 1986) Three classes of high
affinity transmembrane receptors have been described in detail 
(60-70, 85-95 and 280-330 kDa) (Massague et al , 1987) While
type I and II receptors have distinct sets of affinities for each 
member of the TGF-fl family, Type II receptor shows comparable 
affinities for all isotypes (Cheifetz et al , 1987) Type III 
receptor (also called betaglycan) (280-330) is a proteoglycan 
consisting of 50% heparan sulphate and chondroitin sulphate
(Segarini et al , 1989, Cheifetz et al , 1988, Cheifetz et al ,
1986) Disulphide linked complexes of type III receptors (560-600 
kDa) are the predominant form of the receptor in most mammalian 
and avian fibroblasts and epithelial cells (Massague, 1985) Some 
cell lines, however (e g myoblasts) do not express type III 
receptors (Cheifetz et al , 1986) Betaglycan also exists in
soluble forms that are released by cells into the medium and are 
found in extracellular matrices and serum (Andres et al., 1989) 
The type III receptor has recently been cloned and characterised 
(Wang et al , 1991, Lopez-Casillas et al., 1991) It is an 853
amino acid protein with a large N-terminal extracellular domain 
containing at least one site for glycosaminoglycan addition, a
single transmembrane hydophobic domain and a 41 amino acid 
cytoplasmic tail with no obvious signalling motif. Betaglycan has 
also been shown to have an affinity for bFGF, although this 
binding is via its heparan sulphate chains rather than by its core 
protein (Andres et al , 1992, Rouslahti and Yamaguchi, 1991)
Three other less characterised TGF-fi receptors have been reported 
(Cheifetz et al , 1988, O'Grady et al , 1991, Mackay and
Danielpour, 1991)
While TGF-fl was originally characterised by its ability to induce 
anchorage independent growth of normal rat kidney cells, its 
effects on most cell types are antimitogenic (Roberts et a,, 1981; 
Tucker et al , 1984) It is strongly inhibitory for many cell
types, including both normal and transformed epithelial, 
endothelial, fibroblast, neuronal, lymphoid and hematopoietic 
cells (Tucker et al , 1984, Moses et al , 1985, Roberts et
al , 1985, Shipely et al , 1986, Kehrl et al , 1986, Carr et
al , 1986, Cheifetz et al , 1987, 1990, Knabbe et al , 1987,
Ohta et al , 1987, Graycar et al , 1989) In addition, TGF-fl
plays a central role in regulating the formation of extracellular 
matrix and cell matrix adhesion processes (Roberts and Sporn, 
1990, Massague, 1990) It also plays a number of roles in 
embryogenesis (reviewed by Ohlsson, 1989; Bernard, 1990) and 
differentiation of a number of different cell types (Chakrabarty 
et al , 1989, Masui et al., 1986, Ignotz and Massague, 1985,
Allen and Boxhorn, 1987, 1989, Flonni et al , 1986, Colletta et 
al , 1989)
Transforming growth factor type-e (TGF-e) is a novel TGF which was 
first described as a growth factor possibly involved m  the 
autocrine stimulation of anchorage independent growth of carcinoma 
cells (Halper and Moses, 1983) It is present in normal and 
neoplastic tissues of mostly epithelial origin and has been 
detected in both plasma and platelets (Brown and Halper, 1988) It 
has been reported to act as a mitogen for both fibroblast and 
epithelial cells of non-neoplastic origin (Brown and Halper,
1990) TGF-e has been purified to homogeneity from bovine kidney 
(Halper and Moses, 1987) and has been characterised as an acid- 
and heat-stable polypeptide with an apparent molecular weight of 
22,000-25,000, requiring disulphide bonds for maximal activity 
Human TGF-e differs from bovine TGF-e in a number of respects 
(Dunmngton et al , 1990) Its apparent molecular weight is 59 
kDa and, unlike bovine TGF-e, is unstable to SDS Dunmngton et
al. (1990) reported the detection of a low molecular weight
bovine derived TGF-e (13-15 kDa) which appears to be an active
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truncated form of the 25 kDa form These two TGF-e forms have a 
weak affinity for heparin and can be eluted at 0 5M NaCl (Parnell 
et al , 1990), unlike human TGF-e which has no affinity for
heparin (Dunnington et al , 1990)
1 1.2 PLATELET-DERIVED GROWTH FACTOR
PDGF, a potent mitogen for all cells of mesenchymal origin, is 
produced by a range of cell types including endothelial cells, 
vascular smooth muscle cells and osteosarcoma cell lines It is a 
heat stable, 2 chain polypeptide glycoprotein (28-31 kDa) that is 
sensitive to proteases and treatment with 2-mercaptoethanol 
(Antoniades, 1981, Heldin et al , 1981; Raines and Ross, 1982) 
The chains, designated PDGF A and B have been found to be 56% 
homologous (Josephs et al , 1984). Their genes have been assigned 
to chromosomes 7 and 22 respectively (Betscholtz et al , 1986,
Swan et al., 1982) The two genes can be expressed independently, 
giving rise to three mature forms of PDGF (AA, BB, AB) (Alitalo 
et al , 1987). Both chains have eight cysteine residues, located 
in the same positions, suggesting that the homo and hetrodimenc 
forms of the molecule have similar tertiary structures The PDGF 
B chain has been shown to be identical to a carboxy-terminal piece 
of the transforming gene product (v-sis gene product) of the 
simian sarcoma virus (SSV) (Waterfield et al , 1983, Doolittle et 
al , 1983)
Two forms of PDGF receptors have been identified, both of which 
have tyrosine kinase activity PDGF receptor a is activated by 
PDGF-AA and PDGF receptor 13 by PDGF-BB and the v-sis oncogene 
product PDGF-AB can interact with both receptors, (Yarden et 
al , 1986, Matsui et al , 1989, Gronwald et al , 1988,
Claesson-Welsh et al , 1989, Hart et al , 1988, Ostman et al ,
1991) The two receptors have a similar domain organisation with 
five immunoglobulin-like domains extracellularly. There is an 
inserted sequence (approximately 100 amino acid residues) in the 
tyrosine kinase domain, splitting it in two parts (Claesson-Welsh 
et al , 1989)
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PDGF is a potent mitogen for cells of mesenchymal origin (e.g. 
fibroblasts and smooth muscle cells) but has little effect on the 
growth of epithelial or endothelial cells (Ross et al , 1986),
which lack PDGF receptors Binding of PDGF with its receptor 
rapidly induces phosphatidylinositol turnover, release of 
arachidonic acid and formation of prostaglandins (Habenicht et 
al., 1985, Berndge et al , 1984) PDGF induces synthesis of
collagenase, an important enzyme involved in wound healing, 
development and differentiation (Bauer et al , 1985, Circolo et 
al., 1991) Fibroblasts overexpressing the c-sis oncogene have 
been shown to have enhanced fibronectm levels (Allen-Hoffmann et 
al , 1990) At low concentrations, PDGF is chemotatic for
fibroblasts, monocytes and neutrophils and has been shown to 
activate monocytes and neutrophils (Deuel et al , 1982, Tzeng et
al , 1985) Although PDGF is a mitogen for rat L6 myoblasts, it 
has been shown to inhibit their differentiation (Jin et al , 
1991).
Vascular endothelial growth factor (VEGF) has been assigned to the 
PDGF gene family (Tischer et al , 1989) cDNA analysis suggests
that VEGF is synthesised in two forms (possibly due to alternative 
RNA splicing), which are 21% and 24% homologous to the A and B 
chains of PDGF and conserve all eight cysteine residues VEGF, a 
40-46 kDa glycoprotein, has been isolated from medium conditioned 
by bovine pituitary folliculo-stellate cells (Gospodarowicz et 
al , 1989) rat glioma cells (Conn et al , 1990), U-937 human
histocytic lymphoma cells (Keck et al , 1989) and from A431 human 
epidermoid carcinoma cells (Myoken et al , 1991)
1 1 3  INSULIN-LIKE GROWTH FACTOR FAMILY
The insulin like growth factor family consist of insulin, 
insulin-like growth factor I (Sm-C) and insulin-like growth factor 
II (MSA). IGF I and II are 7.5 kDa, highly conserved, single 
chain peptides consisting of four peptide domains B, C, A and D
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The two domains, A and B are homologous to the insulin A and B 
chains, and domain C is analogous to the connecting C peptide in 
proinsulin The 70 amino acid and 67 amino acid sequences in 
mature IGF-I and II have been remarkably conserved between human, 
cow, pig, rat, chicken and sheep (Rotwein, 1991) The expression 
of IGF I, and to a lesser extent IGF II, is under the control of 
growth hormone (GH) . IGF I and II are single genes products, 
localised in man on the long arm of chromosome 12 and the short 
arm of chromosome 11 respectively (Bnssenden et al , 1984,
Tncoli et al , 1984) The genes for IGF-I and II have been
described (Kajimoto and Rotwem, 1991, Rotwein and Hall, 1990) 
The gene structures are complicated with alternative promoters 
acting on multiple initiation sites, differential RNA splicing, 
and variable RNA polyadenylation sites resulting m  the production 
of multiple IGF-I and II mRNA species
IGF I is secreted in a precursor form consisting of a signal 
peptide (48, 25 or 22 residues, depending on the start methionine 
(Rotwein et al , 1987)), followed by the 70 ammo acid mature
peptide and a propeptide region at the C-terminus (E-peptide) 
which contains either 35 or 77 residues (depending on the mRNA 
transcript) (Bell et al , 1985, Ullrich et al , 1984, Rotwein et 
al , 1986). IGF II precursor consists of a signal peptide of 24
residues, the 67 amino acid residue of the mature IGF II molecule 
and an E peptide, 89 residues long (Sussenbach, 1989).
Over 95% of the IGFs present in serum are bound to binding 
proteins (IGFBP) (Zapf et al., 1975) The function of these 
proteins is not clear Using partial amino acid sequence 
information to construct oligonucleotide probes, four distinct 
classes of IGFBPs have been identified by molecular cloning
IGFBP-1 (28-30 kDa) has been isolated from HEP-G2 hepatoma cell 
line (Lee et al , 1988), human placenta (Brinkman et al , 1988), 
human decidua (Brewer et al , 1988) and rat decidua (Murphy et
al , 1990). Its gene has been cloned and mapped to the pl2-13
site on chromosome 7 (Brinkman et al , 1988) The primary
structure of IGFBP-2 was determined from cDNA clones isolated from 
BRL-3A cells (Brown et al., 1989) It has a molecular mass of 
33-35 kDa on SDS-PAGE under non-reducing conditions (Hossenlopp et
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al , 1990) IGFBP-1 and -2 contain Arg-Gly-Asp (RGD) sequences
which suggest interaction with binding to integrin on cell 
surfaces (Rouslahti and Pierschbacher, 1987) Most of the IGF in
serum is found in a 150 kDa complex consisting of either IGF I or
II bound to IGFBP-3 (53 kDa) and an acid labile third component 
(80 kDa) (Baxter and Martin, 1989) IGFBP 1 and 2 have high
affinities for IGF I and II respectively, while IGFBP3 binds both 
forms with equal affinity (Baxter and Martin, 1989) A fourth 
type of
binding protein (IGFBP 4) (25 kDa) was isolated from human bone 
cell conditioned medium (Mohan et al., 1989) Two distinct 
isoforms of IGFBP-4 were detected by N-terminal amino acid 
sequence analysis in porcine serum (Coleman et al , 1991) 
Recently a fifth binding protein (IGFBP-5) has been cloned
(Shimasaki et al , 1991) Northern analysis of IGFBP-5 m  rat
tissues demonstrated that transcription of this gene is highly 
active in kidney, although mRNA was detected in all tissues 
examined The gene for IGFBP-5 has been assigned to chromosome 5
IGFs have two types of transmembrane receptors (reviewed by 
Nissely and Lopaczynski, 1991; Kasuga et al., 1981). The Type I 
receptor is a glycosylated hetrotetramer composing of two 
extracellular alpha subunits (115 kDa, the ligand binding site)
and 2 beta subunits (90 kDa) which span the membrane and provide 
an intracellular tyrosine kinase domain The four subunits are 
linked by disulphide bonds The type II IGF receptor shows no 
structural similarity to the type I and does not have tyrosine
kinase activity The extracellular domain of the type II receptor 
is large, consisting of 15 contiguous repeats with an average size 
of 147 amino acids A single transmembrane segment connects the 
extracellular domain to a relatively short 164 amino acid 
cytoplasmic domain that lacks sequence similarity to any known 
protein (Lobel et al , 1988) The cDNA for the human
mannose-6-phosphate receptor is 99 8% homologous to the human IGF
II receptor (Oshima et al , 1988) A soluble form of the
extracelluar portion of the IGF-II/Man-6-P receptor has been 
described (Causin et al., 1988) The type I receptor binds IGF I 
with higher affinity than IGF II, while the type II receptor has a 
higher affinity for IGF II than I (Massague and Czech, 1982)
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IGF has been shown to have mitogenic effects and metabolic effects 
both in vivo and in vitro (reviewed by Humbel, 1990) The 
mitogenic effects include increased DNA and RNA synthesis, cell 
proliferation and increased body weight Both IGF I and II show 
insulin-like metabolic effects (glucose transport, stimulation of 
glycogen and lipid synthesis in adipose tissue IGFs have also 
been implicated in differentiation of cells of mesodermal origin 
(Kurtz et al., 1982). IGFs are also thought to be important in 
the development and function of the nervous system (DiCicco-Bloom 
et al , 1988)
1,1 4 HEPARIN BINDING GROWTH FACTORS
Fibroblast growth factors (FGF) are encoded by a family of genes 
containing at least seven members, acidic FGF, basic FGF, mt-2, 
K-FGF/Hst-1, FGF-5, FGF 6/Hst-2 and KGF (FGF 1 to 7) Their gene 
structures are similar (3 exons separated by 2 large introns) 
(Abraham et al , 1986, Jaye et al., 1986) and they share the
conservation of two cysteine residues, which do not appear to be 
involved in disulphide bonds (Seno et al , 1988) The FGF-related 
oncogenes differ from bFGF and aFGF in that they have signal 
sequences (implying secretion) and they are rarely found in adult 
tissues (Klagsburn, 1989, Burgess and Maciag, 1989, Rifkin and 
Moscatelli, 1989)
Basic FGF is a single chain non-glycosylated cationic polypeptide 
with a molecular weight of about 18,000 and a pi of 9.6 The 
mature form has 154 amino acid residues (Ueno et al , 1986)
although extraction under acidic conditions resulted in the 
isolation of a 146 amino form (Klagsburn et al , 1987) Higher
molecular weight forms of bFGF have been isolated (Sommer et al , 
1987, Prats et al , 1989) These multiple forms are derived from 
a single gene or mRNA whose translation is initiated at either AUG 
(18 kDa form) or CUG (21 and 22 5 kDa forms) start codons (Prats 
et al , 1989; Florkiewicz and Sommer, 1989) The smallest form
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(18 kDa) occurs predominantly in the cytosol, while the higher 
molecular weight forms are associated with the nucleus and 
ribosomes It has been shown that target signalling sequences 
within the extended amino terminal direct the processed molecule 
to its final destination (Tessler and Neufeld, 1990, Quarto et 
al , 1991, Powell and Klagsburn, 1991)
Acidic FGF is a single chain anionic polypeptide with a molecular 
weight of about 18 kDa and a pi of 5 6 (Thomas et al , 1984,
Burgess and Macaig, 1989) The pure growth factor is mitogenic 
for a variety of types of normal cells in culture including 
fibroblasts, glial cells, osteoblasts and vascular endothelial 
cells. It has been shown to share homology with human interleukin 
1 (IL-1) (Thomas, 1987). Like bFGF, amino terminal truncated 
forms have been described (Burgess et al , 1986)
The third member of the FGF family, the product of the mt-2
proto-oncogene, is expressed in adult mouse essentially only in 
the brain and during embyrogenesis (Dickson and Peters, 1989, 
Robinson, 1991) Int-2 has not yet been demonstrated to be a 
mitogen or to bind heparin and has not been detected in adult 
tissues. The protein product of mt-2 consists of 240 amino acids 
which have 44% and 38% homology to bFGF and aFGF, respectively 
(Dickson et al , 1987) Unlike aFGF and bFGF, the amino terminus 
of mt-2 has a short sequence of 18 or 19 non-charged amino acids, 
which may play some role in secretion (Dickson et al , 1989)
hst was originally identifed as an oncogene present in DNA 
isolated form a human stomach tumour (hst) and from a non- 
cancerous portion of human mucosa that had the ability to 
transform NIH 3T3 cells after transfection (Sakamoto et al , 1986, 
Yoshida et al , 1987, Taira et al , 1987) The predicted protein
consists of 206 amino acids with approximately 43%, 38% and 40%
sequence homology with bFGF, aFGF and mt-2 respectively. It has 
a 55 ammo acid N-terminal signal sequence and appears to be 
secreted. K-fgf, an oncogene derived from transfection of 
Kaposi’s sarcoma DNA into NIH 3T3 cells is identical to hst (Delli
Bovi et al , 1987) The protein, K-FGF, has been purified from
conditioned medium from the transfected NIH 3T3 cells (Delli Bovi
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et al , 1988) It is a mitogen for fibroblasts and endothelial
cells. It has an affinity for heparin, and (like aFGF) heparin 
enhances its activity
FGF-5, an oncogene isolated by transfection of human bladder 
tumour DNA into NIH 3T3 cells, encodes for a 267 ammo acid 
secreted heparin binding growth factor which exhibits 45% and 42% 
homologies with bFGF and aFGF, respectively. FGF-5 is expressed 
in neonatal brain and in some human tumour cell lines (Zhan et 
al , 1988, Haub et al., 1990) More recently the gene was found
to be expressed in exponentially growing normal human fibroblasts 
In quiescent fibroblasts, expression of FGF-5 is strongly induced 
by serum and several growth factors (PDGF, EGF and TGF-a) (Werner 
et al , 1991).
FGF-6 was cloned by sequence similarities with the hst product 
(Maries et al , 1989) Although the proteins are 70% homologous, 
FGF-6 has been mapped to chromosome 12, while hst is located near 
the gene for int-2 on chromosome 11 Translation of the FGF-6 
transcript from three alternate start sites yielded three 
mitogenic peptides with molecular weights of 21, 22 and 24 kDa It 
is suggested that these peptides could be glycosylated to give a 
single 25 kDa species (Coulier et al., 1991). The gene for FGF-6 
has been recently cloned from a normal human genomic library and 
RNA blot analysis revealed its expression in human leukemia cell 
lines (Iida et al , 1992)
Keratinocyte growth factor (KGF/FGF-7) (Rubin et al , 1989),
consists of a single polypeptide chain (28 kDa) that shares 
homology with the other members of the FGF family cDNA analysis 
suggests the present of a amino-termmal hydrophobic region which 
indicates secretion (Finch et al , 1989) KGF has been
characterised as a epithelial cell specific mitogen which is 
secreted by normal stromal fibroblasts The mitogenic signal of 
KGF is mediated by specific receptors with tyrosine kinase 
activity (Bottaro et al , 1990) which have a weaker affinity for 
basic and acidic FGF
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Two distinct classes of FGF receptors have been described 
(reviewed by Klagsbrun and Baird, 1991); high affinity receptors 
with tryosine kinase activity and lower affinity heparan sulphate 
proteoglycans. Four human genes have deen identified that encode 
distinct high affinity receptors (Houssam et al , 1990, Johnson 
et al , 1990; Keegan et al., 1991, Partanen et al , 1991)
The receptor/ligand interaction model is complicated further by 
alternative mRNA splicing giving rise to multiple proteins from 
each gene. In general, the cell surface receptors are single chain 
glycosyated polypeptides with molecular weights ranging form 110 
to 165 kDa (Neufield et al , 1985, Burgess and Macaig, 1989) On
binding aFGF or bFGF, the receptors form dimers This leads to a 
conformational change in the cytoplasmic domain with either auto- 
or cross-phosphorylation occunng FGF interaction with heparan 
sulphate proteoglycans provides a mechanism for regulation of the 
growth of capillary blood vessels in normal and pathological 
situations, while providing protection from proteolytic 
degradation (Vlodavsky et al , 1991; Saksela et al , 1988)
Prevention of bFGF binding to heparan sulphate results in 
reduction of binding to the high affinity surface receptors and 
subsequent signal transduction (Rapraeger et al , 1991) A 150 
kDa heparan sulphate proteoglycan has recently been described as a 
high affinity receptor for aFGF (Sakaguchi et al , 1991)
1 1.5 MISCELLANEOUS GROWTH FACTORS
1.1.5.1 Non-FGF Heparin binding growth factors A new family of 
growth factors have recently been described which have a strong 
affinity for heparin, but are structurally unrelated to the FGF 
family. The midkine gene (MK), expressed temporarily during the 
early stages of retinoic acid induced differentiation of embryonal 
carcinoma cells as well as during the mid-gestation period of 
mouse embyrogenesis, encodes for a 14 kDa heparin-binding protein 
(Tomomura et al , 1990, Kadomatsu et al , 1988) It is also
expressed in adult kidney (Kadomatsu et al , 1990) It’s protein 
structure is highly conserved between the human and the mouse 
(Tsutsui et al , 1991)
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The protein structure of MK has been found to be 50% homologous 
with heparin-binding growth associated molecule (HB-GAM)/ 
pleiotrophin, an 18 kDa protein produced by neonatal brain, 
osteoblasts and other cell types that promotes neurite extension 
of embryonic nerve cells and is mitogenic to fibroblasts (Li et 
al , 1990, Merenmies and Rauvala, 1990, Rauvala, 1989) MK and
HB-GAM differ m  a number of respects MK is a basic protein, 
while HB-GAM is neutral Also HB-GAM is mitogenic to both 3T3 and 
NRK cells (Li et al , 1990, Milner et al , 1989) while MK has no
mitogenic effects on NRK cells but stimulates proliferation of 3T3 
cells (Muramtsu et al , 1991).
The amino-terminal sequence of HB-GAM and MK was found to share 
50% and 66% homology, respectively, with a 19 kDa heparin 
binding protein isolated from chicken embryos (retinoic acid 
induced heparin binding protein, RI-HB) (Vingy et al , 1989, 
Raulais et al , 1991) While RI-HB showed no mitogenic activity 
on bovine epithelial lens cells (Vigny et al , 1989), fibroblast 
3T3 cells, human or bovine umbilical vein endothelial cells, it 
stimulated thymidine incorporation into PC12 cells and induced 
rapid neurite outgrowth (Raulais et al , 1991) It has yet to be 
determined if RI-HB and the MK protein are 2 distinct proteins or 
whether MK is the mammalian homologue to RI-HB
1 1 5.2 Platelet Derived Endothelial Cell Growth Factor. Platelet 
derived endothelial cell growth factor (PD-ECGF) (Miyazono et al ,
1987), is composed of 2 subforms of 44kD and 46kD (Miyazono and 
Heldin, 1989) and has been shown to be susceptibile to both heat 
and acid, but stable to reducing agents Unlike other endothelial 
mitogens, it does not bind heparin and it does not stimulate 
proliferation of fibroblasts (Miyazono et al , 1987). PD-ECGF
stimulates endothelial cell growth and chemotaxis m  vitro, and it 
exhibits angiogenic properties in vivo (Ishikawa et al , 1989)
1 1 5  3 Bombesin Bombesin, an amphibian tetracapeptide, and 
related peptides (for example gastrin-releasing peptide, GRP) 
stimulate fibroblasts and epithelial cells in culture Antibodies 
bind to the carboxyl terminal of bombesin, blocking its binding
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to its receptor and inhibiting the clonal growth of small cell 
lung cancer cells in vitro (Cuttitta et al , 1985) This
indicates the presence of an autocrine loop It has been 
reported, however, that this inhibition is not a property of all 
small cell lung cancer cells (Layton et al , 1988)
1•1.5.4 Melanoma Growth Stimulating Activity (M6SA): MGSA,
originally isolated as an autocrine growth regulator of Hs294T 
human malignant melanoma cells (Richmond and Thomas, 1986, Lawson 
et al , 1987), has been found to be produced by about 70% of the 
primary cell cultures from human melanoma biopsies (Richmond et 
al , 1986) The MGSA protein is homologous with the gro gene
product (Anisowicz et al , 1987) and it is related to
connective-tissue-activating peptide III, a mitogenic polypeptide 
that is stored in platelets and released on thrombin-induced 
platelet aggregation (Castor et al , 1983) CTAP-III belongs to
the J3-thromboglobulin super family which also includes platelet 
factor 4 (PF4), macrophage derived growth factor (MDGF), platelet 
basic protein (PBP), and interleukin 8 (among others), CTAP-III 
is derived from PBP, a biologically inactive precursor protein 
(Deuel et al , 1977, Holt et al , 1986) B-thromboglobulin is
formed following proteolytic cleavage of the amino terminal
tetrapeptide of CTAP-III, which results in the loss of its 
biological activities (synthesis of DNA, hyaluronic acid, 
sulphated glycosaminoglycan chains) (Castor et al , 1983)
1,1.5 5 Hepatocyte Growth Factor (HGF) HGF was first isolated
from rat platelets as a potent mitogen for mature hepatocytes 
(Nakamura et al , 1985) A 87 kDa form of HGF was subsequently
isolated from human lung fibroblasts and found to stimulate
proliferation in both melanocytes and endothelial cells, as well 
as epithelial cells (Rubin et al , 1991) HGF is derived from a
single-chain precursor of 728 amino acid residues and 
proteolytically processed to form a heterodimer molecule composed 
of a 69 kD a-cham and a 34 kDa B-cham, and although it exhibits 
no proteolytic activity, HGF shares structural homology with 
plasminogen (Matsumoto et al., 1991). A 145 kDa protein has been 
identifed as the receptor for HGF Immunoblot analysis revealed 
the this protein was the 13 subunit of the c-m&t proto-oncogene
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product, a membrane spanning tyrosine kinase (Bottaro et al , 
1991), It was recently reported that human HGF and human scatter 
factor (SF) are identical (Weidner et al , 1991)
1 1 6  INTERLEUKIN FAMILY AND HAEMOPOIETIC GROWTH FACTORS
Interleukins mediate the interactions between immune and 
inflamatory cells, promoting cell growth, differentiation and 
function (reviewed in Mizel, 1989). At present 11 different 
interleukins have been described in molecular detail and their 
genes have been cloned The functions of a number of the members 
of interleukin family (IL-1, IL-3, IL-4, IL-5, IL-6) overlaps
to a large extent with the haemopoietic growth factor family, 
erythropoitein (Epo), granulocyte-macrophage colony stimulating 
factor (GM-CSF), granulocyte colony stimulating factor (G-CSF) and 
macrophage colony stimulating factor (M-CSF) A summary of their 
alternative names and biochemical characteristics are presented in 
Appendices A and B Originally interleukins and haemopoietic 
growth factors were described in terms of their effects on the
immune and blood systems growth factors, (reviewed by Nicola, 
1989, Morstyn and Burgess, 1988) but it is now apparent that
these factors are produced by a wide number of cell types and have 
a variety of effects on them. Here I will give a brief overview 
of the non-haematopoietic functions of some of these factors
IL-1, for example, has been isolated from fibroblasts, endothelial 
cells, keratinocytes and smooth muscle and induces the synthesis 
of prostaglandins and collagenases by fibroblasts (Oppenheim et 
al , 1986). Binding of IL-1 to its receptor in human foreskin
fibroblasts induces increased levels of cAMP by activation of a
pertussis toxin sensitive GTP binding protein (Zhang et al ,
1988).
IL-6 has also been found in a variety of cells including 
fibroblasts, endothelial cells, keratmcytes and a number of 
tumour types Except for tumour cells that produce IL-6 
constitutively, normal cells do not produce IL-6 unless they have 
been stimulated The list of possible stimulants includes IL-1,
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PDGF and cAMP (Billiau et al , 1989). IL-6 has also been
implicated as a putative growth factor for renal cell carcinoma 
cells (Miki et al#, 1989).
IL-2 receptors have been found on endothelial cells (Hicks et al.,
1991) IL-4 has been shown to inhibit both colon and breast 
carcinoma cells in a paracrine manner (Toi et al , 1992)
Likewise GM-CSF has been implicated as having a non-hematopoietic 
function Recently, GM-CSF has been shown to be produced by human 
tracheal epithelial cells (Churchill et al , 1992) It has also 
been shown to enhance colony formation in nonhematopoietic ovarian 
cancer cells (Cimoli et al , 1991)
1 2 AUTOCRINE GROWTH REGULATION
The growth of malignant cells is generally been considered to be 
more autonomous than that of their normal counterparts (Holley et 
al , 1975) This observation was later developed into the
autocrine hypothesis for cell growth (Todaro and deLarco, 1978), 
which postulates that malignant cells have the ability to produce 
polypeptide growth factors which can act on the producer cells via 
specific cell surface receptors resulting m  a growth response 
Sporn and Todaro (1985) extended the hypothesis to normal cells 
and suggested that this mechanism may be implicated in normal 
processes e g during embyrogenesis and wound healing (Slack et 
al , 1989, Barbul et al , 1988) Thus, cells that synthesise a
growth factor, display its receptor and respond to its activation 
have the potential for autocrine growth
The classic view of autocrine control suggests that cells secrete 
biologically active growth factors into the culture medium, they 
proliferate at relatively high cell densities m  the absence of 
added factors and their growth is arrested by the presence of
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antibodies which block the response to that growth factor (Browder 
et al , 1989) Such a loop, where the growth factor is secreted, 
is termed a "public" autocrine control loop
More recently this theory has been extended to account for growth 
factors that are not secreted and remain cell-associated In 
these "private" autocrine loops, proliferation of the cells is 
not density dependent, even in the absence of exogenous factors 
and neutralizing antibodies do not prevent growth This mechanism 
of growth control is particularly important in cases where the 
growth factor or receptor is synthesised at low concentrations
1 2  1 GROWTH FACTOR CONTROL OF EMBRYOGENESIS
Growth factors control the process of embryogenesis by their
mitogenic, chemotactic and inductive properties
In the very early amphibian embryo there are only two tissue 
layers (the ectoderm and endoderm) A third layer, the mesoderm, 
is induced from the ectoderm in vitro by the action of bFGF (Slack 
et al., 1987) and possibly TGF-G2 (Kimelman et al., 1987) In 
vivo, bFGF has also been implicated m  mesoderm formation
(Gillespie et al , 1989)
Embyro research in mammalian systems concentrates mainly on
in-situ hybridisation and immunocytochemistry on embryo sections,
the culture of embryonal carcinoma (EC) cells, derived from germ 
cell tissues, or the culture of primary cells grown directly from 
pre-implantation embryos (in the presence of IL-9 to inhibit 
differentiation, (Smith et al , 1988) These studies again 
implicate TGFJ3 and FGF in embryo development Normal chicken, 
mouse and human embryo fibroblasts secrete latent TGFfi (Lawerence 
et al , 1984). High levels of TGF-J3 were found m  fetal rat
skeletal muscle, liver and lung extracts (Hill et al , 1986)
mRNA for TGFJ3 has been detected in mouse embryo hematopoietic and 
liver cells (Wilcox et al , 1988). TGF-a may play a role in lung
development (Catterton et al , 1979) In mouse embryos, the
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int-2 gene is expressed at high levels in the extraembryomc 
(perietal) ectoderm when this is formed shortly after implantation 
(Wilkinson et al., 1987). IGF-II also plays a role m  
embryogenesis, being described as the fetal growth factor in rats 
(Van Wyk, 1984)
1 2  2 GROWTH FACTOR CONTROL OF WOUND HEALING
The process of wound healing can be divided into three main 
overlapping stages inflammation, formation of granulation
tissue, matrix formation and remodeling (Ten Dijke and Iwata, 
1989)
PDGF is one growth factor whose role in the area of wound healing 
has been well documentated PDGF is released, along with TGF-fi 
and FGF, from the a-granules of platelets at the site of tissue 
injury In addition to acting mitogenically, PDGF acts as a 
chemoattractant for fibroblasts and smooth muscle cells, 
neutrophils and monocytes (Senior et al , 1983, Deuel et al , 
1982) The conversion of monocytes to macrophages is critical for 
the initiation of tissue repair They remove pathogenic organisms 
and tissue debris and release further quantities of PDGF and 
TGF-13, augmenting their effect. TGF-I3 has been reported to be 
three times more potent than PDGF as a chemoattractant for both 
monocytes and fibroblasts (Wahl et al., 1987, Postlethwaite et 
al , 1987) After injury, the macrophages are suppresssed by
TGF-J3 to protect healthy tissue being attacked by the secreted 
products of activated macrophages (Tsunawaki et al , 1988).
The second stage of wound healing is granulation This consists 
of closely packed fibroblasts, macrophages and neovasculature 
embedded in a matrix of collagen, fibronectin and hyaluronic acid 
TGF-J3, FGF and PDGF all play a part in the stimulation of
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extracellular matrix (ECM) components (Ignotz and Massagué, 1986, 
Narayanan and Page, 1983, Gospodarowicz et al , 1986) FGF
stimulates endothelial cells to produce u-PA, which is necessary 
for neovascularisation (Gospodarowicz et al , 1986), The FGF
family are potent mitogens for endotheial cells and so promote 
angiogenesis (Folkman and Klagsbrun, 1987)
Within hours of injury, epithelial cells begin to proliferate and 
migrate from the free edges of the tissue across the wound. This 
process is mediated by the members of the EGF family which are 
chemotatic and mitogenic for epithelial cells (Blay and Brown, 
1985) Once re-epithelialization is complete the epithelial cells 
revert to their non-migrating phenotype.
Finally the granulation tissue is broken down and replaced with 
connective tissue consisting of collagen and elastin fibers, 
promoted by TGF-Æ Extracellular protease activity is controlled 
by a balance of TGF-Æ and PDGF TGF-Æ controls extracellular 
protease activity by inducing the synthesis of the endothelial 
protease inhibitor, plasminogen activator inhibitor, inhibiting 
synthesis and secretion of both u- and t-type plasminogen 
activators (uPA and tPA) and the thiol protease cathepesin L 
(Laiho et al , 1986, chiang et al , 1986) PDGF, on the other
hand, stimulates production of collagenases by fibroblasts (Bauer 
et al , 1985) This protease activity combined with fibroblast 
proliferation and collagen synthesis results m  the formation of 
scar tissue (Kovacs, 1991) Recently, monclonal antibodies to 
TGF-J3 injected into the margins of skin wounds in adult rats were 
found to reduce the resulting level of scarring (Shah et al ,
1992)
1 2  3 GROWTH FACTOR CONTROL OF CANCER
Carcinogenesis is a multi-stage event Malignant growth may be the 
result of a combination of mutations in a number of the several 
gene products involved in the mitogenic pathway These mutations 
may be expressed in a number of ways (i) excessive production, 
expression or action of growth stimulators (1 1) excessive 
production or activity of receptor molecules for these factors, 
or (iü) failure of the cells to synthesise or respond to specific
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negative growth factors. The mutated genes have been designated 
oncogenes while their normal cellular counterparts are called 
proto-oncogenes Oncogenes have been found to encode for growth 
factor receptors, signal transducers and transcriptional factors 
(see table below).
TABLE 1.1 Partial list of Oncogenes (Drucker et al , 1990)
Category Oncogene
Growth Factor sist int-2
Transmembrane
receptor
erbBf neu, fms, ros, kit
Membrane Associated 
tryosme kinase
abl, src family, fes, fps
Membrane associated 
guanine nucleotide 
binding protein
K-, N-, and H-ras
Cytoplasmic senne- 
threonine kinase
raf/mil, mos
Cytoplasmic hormone 
receptor
erbh
Nuclear factors c-myc, N-myc, L-myc, fos, jun, 
myb, etSf ski
A further class of oncogenes has been described that encode for 
negative growth regulators. These genes have been termed 
"tumour-suppressor” genes, "recessive oncogenes",
"anti-oncogenes" and "growth suppressor" genes (Klein, 1987) 
Transformation can occur when these genes are mutated in such a 
way that their protein product is not expressed This results in 
the removal of normal constraints on the cells' proliferation 
thereby triggering uncontrolled neoplastic growth (reviewed by 
Marshall, 1991) This type of mutation has been linked to allele 
losses in a number of human cancers including retinoblastoma, 
osteosarcoma, Wilms' tumour and renal carcinomas
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The mitogenic response occurs in two steps, each of which is 
mediated by specific growth factors (Aaronson, 1991). Quiescent 
cells must first be advanced from the resting or GQ phase into the 
G1 phase This is achieved by the action of "competence” factors 
such as PDGF (Pledger et al , 1978) Transition through the G^
phase into the S phase is achieved by "progression” factors (for 
example, EGF, FGF, IGF-I and insulin) There is a critical period 
m  G^ where both the competence and progression factors need to be 
present for the cycle to continue (Leof et al , 1983) Transverse 
of S, G2 and M was found to be independent of added growth factors 
(Wharton, 1983) Negative growth modulators (e g TGF13) can 
antagonize the proliferative effects of growth factors in G^ 
(Moses et al , 1990)
The retinoblastoma protein, pRB, has the properties of a cell 
cycle regulatory factor. pRB is a 103 kDa nuclear protein that is 
underphosphorylated in the G^ phase of the cell cycle and 
hyperphosphorylated in the S and Gj phases (DeCapno et al ,
1989) It is hypothesised that the underphosphorylated form 
suppresses growth by restricting cell cycle progression at a 
specific point in G^ (Ludlow et al , 1989, Goodrich et al ,
1991) Laiho et al (1990) observed that TGF-fil treatment of mink 
lung epithelial cells is associated with a block of 
phosphorylation of pRB in the mid to late G1 This result 
provides an important link between TGF-J3 and the control of the 
cell cycle.
In the remaining part of this introduction, I will describe the 
main classes of growth factors and how each has been implicated in 
autocrine control loops.
1 2  4 AUTOCRINE CONTROL AND TGFs
TGF-a has been linked to the autocrine regulation of breast 
cancers (Lippman et al , 1987) All estrogen-dependent
epithelial breast cancer cell lines secrete high levels of
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TGF-a-like activity (Dickson et al f 1983) The EGF receptor has 
also been identified in breast cancer cells lines (Osborne et al , 
1982, Fitzpatrick et al , 1984, Davidson et al., 1987), and
primary breast tumours (Sainsbury et al , 1987) Ennis et al 
(1989) studied the effect of a monoclonal antibody against the EGF 
receptor in a range of EGF receptor-positive malignant and 
non-malignant transformed human breast cell lines They found 
that while some breast cell lines did not respond to exogenous EGF 
or whose growth was not inhibited by antibodies, MDA-468 human 
breast cancer cells and two transformed non-malignant breast cell 
lines appeared to exhibit TGF-a autocrine control of growth.
TGF-a is secreted into the conditioned medium of melanoma cells 
and TGF-a mRNA has been detected m  melanoma cell extracts 
(Derynck et al , 1987, Marquardt et al., 1983, Imanishi et al.,
1989) Ellem et al (1988) reported that TGF-a promoted the 
growth of both melanoma and melanocytes While TGF-a mRNA 
transcripts are generally found in melanoma cells, trace levels 
or no levels were detected m  melanocytes (Albino et al , 1991),
suggesting that mRNA for TGF-a may be used as a marker for 
melanomagenesis Some doubt was cast on the actual autocrine role 
for TGF-a/EGF m  the melanoma system Kudlow et al (1984) found 
that a monoclonal antibody against the EGF receptor did not 
inhibit the cellular growth of a melanoma cell line, although 
this would not necessarily rule out the possibility of TGF-a being 
the factor involved (Winkler et al , 1989)
Recently, evidence was put forward indicating an involvement of 
TGF-a in the autocrine growth of ovarian cancer cells lines in 
vitro (Morshige et al., 1991, Stromberg et al , 1992), in vivo
(Kurachi et al , 1991) and in primary human ovarian cancers in 
vitro (Monshige et al., 1991)
TGFa/EGF has been implicated in the normal autocrine growth of 
keratinocytes It has been shown that human keratinocytes plated 
at high densities into medium lacking TGF-a, EGF or FGF are 
capable of maintaining growth in the absence of exogeneously added 
growth factors (Shipely et al., 1989) Coffey et al (1987) 
reported that normal human keratinocyte cell lines both require 
TGF-a for proliferation and and express its mRNA* Also, TGF-a
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enhanced TGF-a gene expression Furthermore the high density
growth factor-independent growth of human keratinocytes was 
inhibited by treatment of these cultures with a monoclonal 
antibody which acts as a competitive antagonist of the human EGF
receptor (Cook et al , 1991)
TGF-a autocrine control is apparently involved in the growth of a 
range of other normal and cancer cells Tracheobronchial 
epithelial cells (Jetten, 1991) secrete and respond to TGF-a 
Aberrant growth control in certain lung carcinoma or transformed 
cells has been linked at least m  part to increased or 
constituitive expression of TGF-a (Damstrup et al , 1989) The
growth of two human lung adenocarcinoma cell lines A549 and PC-9, 
which produce TGF-a, was blocked by neutralising TGF-a antibody 
(Imanishi et al , 1989) Mydlo et al (1989) detected mRNA for
TGF-a in malignant kidney tissue specimens but not in their normal 
counterparts, which suggests a role for TGF-a in promoting 
transformation and/or proliferation of kidney neoplasms by an 
autocrine mechanism
Like TGF-a, TGF-J3 has been implicated in the autocrine growth of 
keratinocytes (Bascom et al , 1989) It reversibly arrested
keratinocytes in the G^ phase of the cell cycle, but did not 
effect entry into a differentiation pathway (Coffey et al , 1988, 
Shipley et al , 1986), These keratinocytes have been found to 
possess specific receptor sites for TGF-fl and are known to produce 
TGF-B in their conditioned media, indicating the presence of a 
growth inhibitory autocrine loop for these cells
Immunohistochemical studies using anti-TGF-fi antibodies have 
detected antigen expression among malignant but not benign glioma 
cells (Samuels et al , 1989) While TGF-fl mRNA has not been
detected in normal brain tissues, mRNA for TGF-J31 and -B2 have 
been found m  glioblastoma cultures (Bodmer et al., 1989) TGF-fl 
receptor types I, II and III have been detected m  glioma cells 
(Jennings et al , 1991) The response to TGF-J3 varied depending 
on the cell type Near-diploid gliomas were growth inhibited by 
TGF-fi, while hyperdiploid glioblastomas showed a positive 
mitogenic response Under serum free conditions, anti-TGF-B
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antibody neutralised each of these effects, demonstrating the 
basic elements m  support of an autocrine hypothesis (Jennings et 
al., 1991)
1,2.5 AUTOCRINE GROWTH AND PDGF
Autocrine control by PDGF has recently been reviewed (Browder et 
al , 1989, Westermark and Heldin, 1991) The basis of most of
the work on PDGF autocrine action is a result of research into 
v-sis, an oncogene derived from the transduction of the PDGF-B 
gene by the simian sarcoma virus (SSV) Apart from the lack of 
the enogenous signal peptide, the predicted sequence of the v-sis 
product is virtually identical to PDGF B chain (Johnsson et al.,
1984) PDGF-BB exerts the same transforming activity as SSV 
(Westermark and Heldin, 1991), SSV-transformed cells produce a 
growth factor that binds PDGF receptors and is recognised by 
antibodies to PDGF (Owen et al , 1984) and only PDGF receptor
positive cells can be transformed by SSV (Leal et al , 1985) Thus 
the autocrine role played by the v-sis gene in transformation has 
been established The mechanism of action of PDGF is however not 
as clear cut.
Unlike cultured vascular endothelial cells, which do not not 
express specific PDGF receptors, smooth muscle cells (SMC) bind 
and respond to PDGF Production of PDGF by smooth muscle cells 
appears to be developmentally regulated (Seifert et al , 1984,
Ross et al , 1986, Hahn et al., 1991) The hypothesis that
developmentally regulated production of PDGF by SMC contributes 
toward autocrine stimulation of SMC proliferation has been 
suggested but not clearly established PDGF autocrine control 
loops have been suggested for a number of other systems, although 
no definite proof has been shown These systems include the 
adrenal carcinoma cell line, SW-13 (O'Donnell et al , 1989) and
endothelial cell hyperplasia in human glioblastoma (Hermansson et 
al , 1988)
Although human glioma cells have been shown to express mRNA for 
PDGF, to synthesise all three PDGF combinations, and to express 
cell surface receptors (Hammacher et al , 1988), neutralising
antibodies do not to block its response Neither has protamine, a
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polyanionic compound that competitively inhibits extracellular 
binding of PDGF to its receptor, been shown to have an effect on 
autocrine growth or transformation (Huang and Huang, 1988). This 
contradicts earlier findings that suramin, another binding 
competitor, could inhibit v-sis mediated transformation (Hannick 
and Donoghue, 1988). It was subsequently shown that suramin can 
penetrate the cells secretory compartments and so would not 
necessarily block a cell surface interaction (Huang and Huang, 
1988)
This inability to block the autocrine response at a cell surface 
level indicates the presence of a "private" autocrine loop This 
theory has been corroberated by Munro and Pelham (1987) who 
discovered a carboxyl sequence common to several proteins which 
are retained m  the endoplasmic reticulum. When this sequence 
(Lys-Asp-Glu-Leu, or KDEL) was added to the carboxyl terminus of 
the v-sis protein, the modified protein remains fully 
transforming, although it is not secreted and cannot be detected 
on the cell surface (Browder et al , 1989) Keating and Williams
(1988) showed that autocrine activation of PDGF receptors in 
v-sis-transformed cells occured in intracellular compartments
Other data, however conflicts with the intracellular activation 
hypothesis. Binding of PDGF to its cell surface receptor results 
in tyrosine kinase activation and an increase in c-fos expression 
The intracellular activation of tyrosine kinase, however, is not 
coupled to c-/os expression, and so may be considered futile 
(Hannick and Donoghue, 1988) A intermediate model of 
transformation by PDGF is put forward by Westermark and Heldm 
(1991) They suggest that following formation of the intracellular 
receptor-ligand complex, translocation to the cell surface is a 
prerequiste for interaction with the proper substrates for the 
receptor kinase
1 2  6 AUTOCRINE CONTROL AND IGF
Insulin, IGF-I and IGF-II have all been implicated in autocrine 
mechanisms A teratoma-derived cell line, 1246-3A, produces a
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protein very similar to insulin (Yamada et al , 1988) The growth 
of this cell line could be inhibited by antibodies to insulin, 
indicating an autocrine contol mechanism.
IGF-I has been shown to be involved in the autocrine growth of a 
range of human cancer cell lines including lung carcinoma, 
osteosarcoma, breast carcinoma and ovarian cancer cell lines
CALU-6 (human lung carcinoma) produces IGF I and its growth is 
inhibited by antibodies to IGF-I (Minuto et al , 1988) In a
similar way, human pancreatic cells and an ovarian cancer cell 
line produce IGF I, are stimulated by exogenous IGF-I and their 
growth can be blocked by antibodies to the IGF-I receptor (Ohumura 
et al , 1990, Yee et al , 1991) Recently, IGF-I has been
reported as an autocrine regulator of human colon cancer cell 
differentiation and growth (Baghdiguian et al , 1992)
Differentiation of muscle cells to form postmitotic myotubes has 
been shown to be stimulated in an autocrine way by IGF-II (Flonni 
et al , 1986) The rate of spontaneous differentiation of
sublines of myogenic cells correlated with their level of 
expression of IGF-II Cells that endogenously produced high 
levels of IGF-II were not affected by exogenously added factors 
An antisense oligodeoxynbonucleotide complementary to the first 
five codons of IGF-II inhibits myogenic differentiation in the 
absence, but not in the presence, of exogenous IGF-II
An autocrine role for both IGF-I and II has been described in 
breast cancers CM from the cell line MCF-7 was found to contain 
high levels of immunoreactive IGF-I, the cells expressed mRNA for 
IGF I and exogenous IGF I could stimulate MCF-7 proliferation 
(Huff et al , 1986). Also addition of a monoclonal antibody
against IGF-I in serum free medium caused an inhibition suggesting 
that endogenous IGF-I does play an autocrine role in MCF-7 growth 
(Freed and Henngton, 1989) A number of breast cell lines have 
also been demonstrated to be stimulated by IGF-II (Karey et al , 
1988, Myal et al., 1984) Yee et al , (1988) reported that out 
of 9 human breast cancer cell lines, one expressed mRNA for 
IGF-II aIR3 / a monoclonal antibody to the IGF-I receptor 
inhibited the mitogenic effects in two human breast cancer cell
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lines, MCF-7L and MDA-231, suggesting that this receptor mediates 
the growth effects of IGF-II in these cell lines (Kent Osborne et 
al , 1989)
The interpretation of the results from the use of the IGF-I 
receptor blocking antibody experiments with the a-IR^ monoclonal 
antibody have been questioned. Although this antibody can block 
IGF-I binding to the type I IGF receptor, Steele-Perkins et 
al (1988) showed that the aIR3 is not physiologically inert and 
binding to the receptor results in receptor phosphorylation
1 2  7 AUTOCRINE CONTROL AND HEPARIN-BINDING GROWTH FACTORS
Acidic and basic FGF were originally purified from brain and 
pituitary tissue, and have subsequently been found in a variety of 
normal (Ferrara et al , 1987, Moscatelli et al , 1986, Winkles et 
al , 1987) and transformed (Moscatelli et al., 1986, Klagsburn et
al , 1986) cells Several of the malignant producer cell types
also respond to FGF e g glioma (Morrison et al , 1990) and
melanoma (Rodeck et al , 1991)
More recently, bFGF has been associated with the growth control of 
epithelial cells New and Yeoman (1992) reported the stimulatory 
effects of bFGF on human colon tumour cell lines which express 
receptors for bFGF. Immunoprécipitation studies revealed levels 
of bFGF in both conditioned media and cell lysates in each of the 
cell lines examined These results imply the existence of an 
autocrine mechanism
The expression of bFGF may be particularly important for the 
growth and proliferation of human gliomas Gliomas develop by
invasion and local spread rather than by metastasis and so, may 
be influenced by factors which stimulate the growth invasion and 
vascularization of the primary tumour m  the cranium (Morrison et 
al , 1990) Human glioma cell lines have been shown to express
the gene encoding aFGF (Libermann et al , 1987) and express and 
respond to bFGF (Morrison et al , 1990) Mornsion et al
suggest that bFGF may be involved in the autocrine control of 
glioma cells by its mitogenic effects following release from 
lyeing necrotic cells as the tumour progresses.
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Studies by Moscatelli et al. (1986) demonstrated that bFGF protein 
could be detected in a human melanoma cell line extract bFGF 
mRNA is expressed in metastatic melanoma cells but not in normal 
melanocytes (Halaban et al , 1988). Halaban et al also showed
that the mitogenic effects for normal melanocytes caused by 
bFGF-like activity in melanoma cell extracts could be blocked by 
60% by intracellular injection of anti-FGF antibodies Antisense 
oligodeoxynucleotides directed to a region around the AUG codon 
and to different sites on the bFGF mRNA added to culture medium of 
primary and metastatic melanoma cells resulted in inhibition of 
70-90% of proliferation (Becker et al , 1989) These results
provide strong evidence that bFGF is an autocrine growth factor 
for melanoma cells
Conventional public autocrine loops require that the growth factor 
is secreted from the cell to interact with the cell surface 
receptor No evidence of secretion of either bFGF or aFGF has 
been reported Neither aFGF nor bFGF has a classic signal peptide 
(Abraham et al. 1986) Also addition of blocking antibodies to 
the culture medium has no effect on growth, but injection of the 
antibodies into the cells blocked growth (Halaban et al , 1988). 
This would suggest that bFGF acts intracellularly in the melanoma 
system and thus bFGF, like PDGF, is a candidate for the private 
autocrine loop theory.
In contrast, addition of neutralising antibodies to the culture 
medium of BALB/c3T3 fibroblasts inhibited proliferation (Saseda et 
al , 1988) suggesting a public autocrine loop for this system
This extracellular autocrine loop is also supported by the fact 
that transfection of bFGF expression vectors does not result in 
transformation of NIH-3T3 cells unless the gene for bFGF was 
linked to an immunoglobulin signal sequence (Yayon et al./ 1990) 
Also significant amounts of bFGF are found extracellularly 
associated with the heparan sulfate proteoglycans of the 
extracellular matrix in vitro (Moscatelli et al., 1987; Vlodavski 
et al., 1987) and are present m  basement membranes m  vivo 
(Folkman et al , 1988, DiMano et al , 1989)
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Since no defined mechanism for bFGF release has been described, 
cell death or leakage following cell injury have been proposed as 
the mechanism for bFGF externalization (Schweigerer et al , 1987, 
Gajdusek and Carbon, 1989). Although it has also been reported 
that limited diffusion of bFGF across basement membrane and 
reconstituted endothelium occurs in the presence of heparin and 
high concentrations of bFGF (Dabin and Courtois, 1991)
The migration effects of bFGF on isolated single viable cells were 
examined by Mignatti et al (1992) From their studies they 
concluded that bFGF may be released from cells by a mechanism of 
exocytosis that does not involve the endoplasmic reticulum-Golgi 
pathway
The other members of the FGF family (int-2, hst/K-fgf and FGF-5) 
are rarely found in normal adult tissues. Instead they appear to 
be mostly expressed during embryogenesis and in tumours, i e 
during periods of intense growth Expression of int-2 has been 
reported to be amplifed in melanoma, breast cancer and squamous 
cell carcinoma of the head and neck (Adelaide et al , 1988, Zhou 
et al , 1988), which indicates that autocrine stimulation is
possible
1 2  8 AUTOCRINE CONTROL AND BOMBESIN/GRP
Gastrin releasing peptide (GRP) is the mammalian homologue of the 
amphibian neuropeptide, bombesin Nearly all small cell lung 
carcinomas (SCLC) require GRP to maintain cell growth (Moody et 
al , 1981) They secrete GRP and express its specific tyrosine
kinase receptors (Cuttitta et al , 1985, Gaudino et al , 1988)
Neutralising antibody blocks colony formation in semisolid culture 
and delays tumour growth m  nude mice injected with these cells 
(Cuttitta et al , 1985) These results indicate autocrine growth
control for most SCLC Layton et al (1988) found that the 
inhibitory effect of bombesin antagonists on SCLC cells was not
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mediated via the bomesin receptor and that not all SCLC cells were 
dependent on bombesin in vitro So, the autocrine theory does
not appear to be the complete story for the SCLC system
1 2  9 AUTOCRINE CONTROL AND THE INTERLEUKINS AND HAEMATOPOIETIC 
GROWTH FACTORS
Interleukin 6 is a cytokine that can act on a variety of cell 
types including lymphocytes, hepatocytes, haematopoietic stem 
cells and nerve cells by either acting as a growth inhibitor or an 
inducer of differentiation (Kishimoto and Hirano, 1988) IL-6 has 
also been linked to a number of different malignancies for example 
plasmacytoma and myeloma (Van Damme et al., 1987, Kawano et al ,
1988)
IL-6 has been implicated in the autocrine growth of renal
carcinomas (Miki et al , 1989) IL-6 is a growth factor for human
renal carcinoma cells in vitro Freshly isolated renal cell 
carcinomas expressed IL-6 mRNA and secreted biologically active 
IL-6 m  the presence of FCS The IL-6 activity was neutralised by 
anti-IL-6 antibodies The fact that no IL-6 was detected when the 
cells were grown in serum-free conditions, indicates that the IL-6 
autocrine mechanism is induced by serum factors
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IL-6 is a major myeloma cell growth factor (Kawano et al , 1988), 
but whether the action is autocrine or paracrine is unclear (Klien 
et al , 1989) mRNA transcripts have been widely detected in the 
bone marrow (Portier et al , 1991) but only recently the
transcripts have been detected in myeloma cells (Schwab et al ,
1991) Interferon-a (INF-a) has been shown to stimulate the 
proliferation of myeloma cells m  vitro (Ludwig et al , 1983), by 
inducing an autocrine production of IL-6 which could be blocked by 
a monoclonal antibody to IL-6 (Jourdan et al , 1991), supporting
the autocrine theory.
Acute myeloid leukemia (AML) cells, in general, secrete large 
amounts of IL-1 in vitro Proliferation of cells from AML 
patients was enhanced with human recombinant IL-la and IL-lfi and 
the spontaneous proliferation of these cells could be modulated by 
anti-IL-1 antibodies, (Cozzolino et al., 1989) These results 
suggest that IL-1 may act as an autocrine growth factor in AMLs
Autocrine growth factor production has been suggested as one of 
the mechanisms responsible for the unregulated growth of 
haematopoietic cells (Browder et al., 1989) When M-CSF cDNA and 
c-fms (M-CSF receptor) were co-transfected into NIH 3T3 cells, an 
external autocrine loop was established which was transforming and 
could be blocked by neutralising antibodies (Retenmier et al ,
1987) Macrophage-colony stimulating factor (M-CSF or CSF-1) has 
been implicated m  the autocrine proliferation of murine monocytes 
by the inhibition of growth due to the presence of either 
anti-sense oligonucleotides or neutralising antibodies 
(Birchenall-Roberts et al , 1990)
Autocrine synthesis of growth factors also seems to occur among 
immortalised cells of haemopoietic origin. Thus some T-lymphoma 
lines both secrete and respond to IL-2 and the introduction of the 
v-src oncogene stimulates autocrine production of a myeloid growth 
factor in chicken myeloid cell lines (Heldin et al , 1987)
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1 3 BACKGROUND AND AIMS OF THE WORK DESCRIBED IN THIS THESIS
In the course of research into improving conditions for the growth 
of cells in vitro. McManus and Clynes (1984) observed that the 
growth of the human carcinoma cell line, RPMI 2650, in soft agar 
was directly proportional to its plating concentration down to a 
minimum critical cell density, below which no colony formation 
occured This suggested that the cells were producing an 
autostimulatory factor Using feeder layers of RPMI 2650 cells, 
they showed that this autostimulatory factor was diffusible and 
did not require cell-cell contact
The RPMI 2650 cell line is particularly interesting since it is an 
established cell line, derived from malignant cells, with near 
normal karyotype (Moorehead, 1965) Prolonged culturing of cells 
often results m  chromosomal abberations, so that the cells may 
not be representative of the original tumour population After 
two years of continuous culture, RPMI 2650 cells exhibited a 
quasi-diploid karyotype, which is quite unique RPMI 2650 cells 
are also available at early passage, so that the cell stocks are 
closer to the original tumour sample, than is the case with many 
of the more widely studied human tumour cell lines (e g. HeLa)
Dooley (1987) subsequently developed a soft agar assay for the 
autocrine activity and determined by bioassay and radioreceptor 
work that the cells produced TGF-a and TGF-13 into their 
conditioned medium, along with an uncharacterised factor
The purpose of the work described in this thesis was to further 
characterise this autostimulatory effect, and to establish if it 
was an effect caused by a previously described autocrine growth 
factor or whether it exhibited properties unlike any of those 
assigned to other growth factors
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2 0 MATERIALS AND METHODS
2.1 MEDIA PREPARATION
2 1 1  Water
Highly purified water is critical for the successful culture of
animal cells. Water for media and reagent preparation was
extensively pretreated using either a Millipore Milli-Q ultrapure 
water system or a ELGA UMP system Water firstly passes through a 
reverse osmosis system (Milli-Q) or was double distilled (ELGA) and
passed through two pre-fliters to remove ionic and non-ionic
solutes It was then passed through two ion-exchange filters, a 
carbon filter and a 0 22pm cellulose acetate filter. The quality of 
the resulting water was monitored by an on-line conductivity meter 
and was regarded to be ’ultrapure' when its resistance was between 
10-18 megaOhms/cm.
2 1 2  Glassware
All items of glassware (media bottles, roller bottles, spinner 
flasks, glass universals, etc ) that came in contact with cells or 
media were stringently prewashed and rinsed Glassware was first 
steeped for about 2 hours in RBS (R Borghraef), a non-toxic 
detergent, before they were scrubbed manually with bottle brushes. 
Each item was then rinsed well in tap water followed by three 
separate rinses in distilled water Finally, they were rinsed in 
ultrapure water Metal bottle caps were washed and rinsed
separately.
2 1.3 Silicomsation
Spinner flasks and bioreactor vessels require silicomsation to 
prevent cell attachment and growth on the glass sufaces. This 
involves rinsing clean dry vessels in a fume cupboard with a 2% 
solution of tnmethyldichlorsilane in 1,1,1-tnchloroethane (BDH, 
Cat No. 33164) using a glass pippette The entire inner surface of 
the vessels must be coated Excess reagent was then poured off and 
the vessels were left at 37°C for 2 hours or until dry Each item 
was then rinsed extensively as in Section 2 1 2 (3x distilled, lx 
ultrapure water)
2 1 4  Sterilisation
All glassware, water for media preparation, some reagents, and 
non-stenle plastics were autoclaved before use (121°C/15 psi/20 
minutes). Unstable reagents were filter sterilised through sterile 
disposible 0 22 jum filters (Millex-GV, SLGV025BS). Large batches 
of culture medium (5L) were penstaltically pumped through a Bell 
filter (Gelman, G.14238) into sterile 500ml glass bottles.
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2 1 5  Growth Media
Liquid media was prepared from lOx stock solutions and diluted with 
ultrapure water. Either individual bottles (500 mis) or large
batches (5 litres) were prepared MEM and DME media were buffered 
with sodium bicarbonate (Riedel-de-Haen, Cat No 31437) and HEPES 
(4-(2-HydroxyEthyl)-PiperazineEthaneSulfonic acid, Sigma, Cat No. 
H9136) at the volumes indicated in Table 2.1 MEMS for use in pH 
controlled bioreactor cultures was not supplemented with HEPES The 
pH was adjusted with 1 M NaOH (BDH, Cat No 30167) to pH 7 4-7.5 
MEM and MEMS were further supplemented with non-essential amino 
acids (NEAA, Gibco, Cat No 043-1140H)
Powdered HAMS P12 media (Gibco 072-1700) was reconsituted in 95% 
total volume with ultrapure water sodium bicarbonate (1 176g/L) was 
added, and the pH adjusted to 7 2-7 3. The total volume was then 
brought up to 5 litres with ultrapure water
TABLE 2 1 Preparation of Growth media
Supplier 
Cat. No
MEM
Gibco
042-01430
DME
Gibco
042-02501
MEMS
Gibco
042-01650
Stock
Ultrapure ^ 0  
HEPES (1M) 
NaHC03 (7 5%) 
NEAA (lOOx)
500 mis 
4500 mis 
100 mis 
45 mis 
100 mis
500 mis 
4500 mis 
100 mis 
45 mis
500 mis 
4500 mis
45 mis 
100 mis
adjust to pH 7.4-7 5 with 1 M NaOH/1 M HCl
Media were stored at 4°C for up to three weeks, after sterility 
check (Section 2 1.7).
L-Glutamine (2 mM) (Gibco, Cat No 043-05030) was added to each 
media type before use (5 mls/100 mis)
Antibiotics were not used during routine cell culture MEMS was 
supplemented with 1% penicillin/streptomycin (Gibco 043-05140) for 
bioreactor cultures
2.1 6 Serum
All media were supplemented with 5% of either foetal calf serum 
(FCS) for monolayer cultures or donor horse serum (DHS) for 
suspension cultures The sera tested and their sources used are 
listed in Table 2 2
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TABLE 2 2 Serum batches used in the course of this thesis
Batch No Source Use
FCS 22 Sera Labs 701051 General culture
FCS 48 Gibco 10F67915 General culture
DHS 32 Flow 29-211-54 Suspension culture
VDHS 87 Flow 91-209-52 Suspension culture
DHS 62 Gibco 012-0762 Suspension culture
FCS 8 Flow 028020 Soft agar assays
FCS 15 Sera Labs 801017 Soft agar assays
FCS 46 M&V 4303R Soft agar assays
Table 3 1 3
FCS 46 1 M&V 4303R Soft agar assay
FCS 67 2 Sera Labs. 901022 Soft agar assay
FCS 68 3 Sera Labs 901027 Soft agar assay
FCS 69 4 Sera Labs 901094 Soft agar assay
FCS 70 5 Gibco 20G77835 Soft agar assay
NC 71 6 Gibco 10F5380 Soft agar assay
DHS 72 7 Gibco 10G3074 Soft agar assay
FCS 73 8 Northumbria 33924 Soft agar assay
FCS 74 9 Northumbria 30925 Soft agar assay
2.1.7 Sterility
Each bottle of medium was sterility checked prior to addition of 
L-glutamine and serum, by incubating a sample (5-10 mis) at 37°C for 
at least three days Blood agar (Medlabs) plates, thioglycollate 
broths (Oxoid, CM173) and Sabourand broth (Oxoid, CM143) were 
inoculated with medium and incubated for three days to one week to 
detect microbial contaminants
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TABLE 2♦3 Cell lines used in this assay
2 2 CELL LINES
Cell line Source Details
RPMI 2650 ATCC CRL 1629 Human squamous epithelial
cell carcinoma of the nasal 
septum
NRK Dr Ian Pragnell, Normal Rat Kidney fibroblasts
Beatson Institute,
Glasgow
NRK-49F ATCC CRL 15 70 Clone of NRK
HEP-“ 2 ATCC CCL 2 3 Human squamous cell carcinoma
of the larynx
MSV-3T3 ATCC CRL 1568 Moloney MSV transformed
mouse
SCC-9 ATCC CRL 1629 Human squamous cell carcinoma
of the tongue
BSC-1 ATCC CCL 26 African Green monkey kidney
PLATE 1 RPMI 2650 sub^confluent culture grown xn monolayer (Phase 
1 (150X) magnification
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2.3 Maintanence of cell lines in culture
2.3.1 Cell culturing
All the cell lines listed m  Table 2 3 are anchorage dependent cell 
lines which were rountinely grown in 25cm2 and 75 cm2 tissue culture 
flasks (Cell Cult, Cat No 32025, Costar, Cat No. 307S) in the
appropriate media (indicated in Table 2 4).
TABLE 2.4 Media used to culture cell lines (ATCC*=DME Ham's 
F12 (50 50))
Cell line Medium
RPMI 2650 MEM
NRK DME
NRK-49F DME
HEP-2 ATCC*
MSV-3T3 DME
SCC-9 ATCC
BSC-1 MEM
2.3.2 Cell feeding
As the cells grow, the culture medium becomes more acidic The 
phenol red in medium changes from red to orange, indicating that the 
pH has dropped to below pH 7 2, which can be detrimental to the 
growth of the cells At this stage the medium is replaced with 
prewarmed fresh medium supplemented with L-glutamme and serum This 
also ensures an adequate nutrient supply to the cells
2.3.3 Trypsinisation
When the monolayer culture becomes confluent, usually no further 
growth can occur as the cells become contact inhibited Other cell 
lines (e.g Hep 2) form multilayer cultures Before the cells reach 
confluency, they are subcultured (or passaged)
This was achieved by removing spent medium to a waste bottle The 
cells were then rinsed in a small quantity of phosphate buffered 
saline (PBS-A, Oxoid BR12a) to remove trace serum The cells were
enzymatically removed from the flask surface by incubating with
prewarmed 0 25% trypsin (Gibco, Cat No 043-05090) in PBS-A at 37°C 
for 5-10 minutes or until the cells detach As soon as a single 
cell suspension is obtained (probably will require shaking), serum 
supplemented medium was added Serum contains trypsin inhibitor 
The cell suspension was then transferred to a sterile universal 
(Sterlin 128A) and centrifuged at 1,000 rpm for 4 minutes The
supernatant was poured into a waste bottle and the cell pellet 
resuspended in a small volume of medium (about 5 mis) The cells 
were counted (see Section 2 3 3) and flasks reseeded at the required 
concentration The volume of the flasks was then brought up to 10
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mis (25 cm2 flask) or 30 mis (75 cm2 flask) with medium supplemented 
with serum The cells were incubated at 37°C until they required 
feeding
2.3 4 Cell Counting
A sample of single cell suspension (1 ml) was mixed well with 200¡ul 
of trypan blue (Gibco 043-05250) for 5 minutes* The cells were 
counted by loading a sample on a Waber haemocytometer (Improved 
Neubawer) slide by Pasteur pipette. Each of the four large squares 
at each corner of the grid was counted and an average count 
obtained By multiplying the count by 1 2 x 10^, the average cell 
count per ml of cell suspension was calculated Cells that take up 
the blue dye were counted as non-viable, while non-stained cells 
were viable.
2 4 LONG TERM STORAGE OF CELLS
2.4 1 Cell Freezing
Cell stocks were stored, frozen in liquid nitrogen Cells to be 
frozen must be free from contaminants and be m  good condition 
(growing exponentially) Ideally cells should be frozen at high 
concentrations (greater than 4 x 10^ cells/ml)
A single cell suspension was obtained and counted as described 
previously A solution of 10% DMSO was prepared in 25% FCS and added 
dropwise to an equal volume of cell suspension. The suspension was 
then transfered to a cryovial (Greiner, Cat No 122278 or Sterlin, 
Cat No 35001). After labelling, the vials were left in the vapour 
phase of the liquid nitrogen container for three hours and then 
immersed in the liquid phase for long term storage Adequate care 
should be taken while working with liquid nitrogen.
One vial of frozen stock was thawed shortly after freezing, to 
ensure the cells remained viable and contamination-free, during the 
freezing process
2.4.2 Cell Thawing
Vials removed from liquid nitrogen should be thawed quickly at 37°C, 
once the nitrogen has evaporated off, and added to 5 mis of cold 
growth medium containing 10% FCS. The cell suspension was then 
centrifuged at 1,000 rpm/4 minutes and the pellet resuspended in 5 
mis of medium plus 10% FCS The cell suspension was added to a
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fresh 25cm2 flask, and incubated at 37°C The following day, this 
medium was removed and replaced with 10 mis of medium supplemented 
with 5% FCS.
2 5 CONTAMINATION
2 5.1 Microbial
Microbial contamination is easily detected in cell cultures. Gross 
contamination is often associated with cell detachment and acid 
production. Lower levels of contamination may be detected by 
careful microscopic examination
Most cases of microbial contamination may be prevented by proper 
asceptic technique m  a class II vertical laminar air flow cabinet 
All reagents and media should be sterility checked before use 
(Section 2 17)
2 5 2 Mycoplasma
Mycoplasma contamination is not always obvious. Infected cells 
continue to grow but they appear granular and 'unhealthy'. During 
the course of this project the cells were rountinely checked for the 
presence of mycoplasma while they were cultured and before freezing 
If a culture was found to be contaminated, it was discarded 
immediately and fresh stocks thawed. The laminar flow cabinet was 
thoroughly cleaned and media, trypsin, etc that was used m  the 
laminar flow with the infected cells was not re-used
The procedure used to detect mycoplasma was a fluorescent DNA stain 
Mycoplasma-free stocks of NRK cells were grown overnight at 5% C02 
on sterile coverslips m  1 ml of medium at a concentration of 5 x 
102 cells/ml The following day, 1 ml of medium from a flask of 
cells that were known to be grown m  antibiotic-free medium was 
added (in duplicate). Control plates with added fresh medium were 
included The cultures were incubated for 3-4 days at 37°C/5% C02
The slides were then rinsed twice in PBS followed by a single rinse 
in a 1 1 dilution of Carnoy's reagent (Acetic acid Methanol, 1*3) 
in PBS The cells were fixed in Carnoy's reagent for 10 minutes 
The coverslips were removed and rinsed in ultrapure water Hoeschst 
33258 (Sigma Cat No. B2883) at 0 5 mg/ml m  PBS was added to the 
cells (2 mis) and left for 10 minutes at room temperature Because 
Hoescht is light sensitive, these manipulations were carried out in 
petn dishes covered in tinfoil.
Excess stain was removed by rinsing in ultrapure water and the 
slides were then mounted in glycerol The cells were observed under 
oil immersion using 405 nm light Extranuclear fluorescence 
indicated the presence of mycoplasma contamination
2.5.3 Cell line
If proper procedures are adhered to, cell line cross contamination 
should not be a problem The precautions taken against this type of 
contamination included
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* Working with only one cell line in the laminar flow cabinet at any 
one time Allowing at least 15 minutes between cell lines Swabbing 
all surfaces well with 70% IMS (Lennox, Cat No 1170) before and 
after use
* Using separate media bottles, sera, trypsin, L-glutamine and waste 
bottles for each cell line, labelling them clearly
* Ensuring all flasks and cryovials are clearly labelled and 
documented
Cross contamination of cell lines was monitored occasionally by DNA 
fingerprinting (ICI, UK)
2 6 COLLECTION OF CONDITIONED MEDIA (CM)
2.6.1 Roller bottle culture
Bellco glass roller bottles (670 cm2 internal surface area) were 
washed well and autoclaved damp at 120°C/20 minutes with the lids 
slightly open and covered in tin foil Before inoculation, the 
bottles were equilibrated at 37°C to prevent clumping 100 mis of 
medium plus 5% FCS and 1% penicillin/streptomycin (p/s) was added 
and the bottle was seeded with a single cell suspension of cells. 
The seeding concentration depends on the cell line RPMI 2650 
roller bottle cultures were inoculated from one confluent 75cm2 
flask. The bottle was then transferred to a Bellco roller bottle 
apparatus at an initial speed of 0 25 rpm for 24 hours and then 
increased to 0.75 rpm
The cells were grown for one week with feeding on day 3 at 37°C On 
day 7 medium was removed and the cells were rinsed twice with 
approximately 10 mis of PBS or medium without serum and then 50 mis 
of serum-free medium was added to the cells and incubated overnight 
This medium was discarded and replaced with 100 mis of fresh medium 
without serum, which was allowed to be conditioned by the cells for 
twenty four hours This conditioned medium was designated CM2. This 
medium was collected and replaced with another 100 mis of serum-free 
medium. The CM is stored at 4°C. This procedure was continued for 6 
days resulting m  the collection of 6 batches of CM (CM2-CM7) which 
were normally pooled, before processing
2 6 2 Microcarrier culture
The growth of RPMI 2650 on a number of different types of 
microcarner beads were studied in 250 ml and 500 ml spinner flasks 
(Techne, Cambridge, U.K )
Whatman Plastic Biospheres 8302-2001
Collagen coated Biospheres 8402-2001 
Glass coated Biospheres 8502-2001
Pharmacia Cytodex 1 
Cytodex 2 
Cytodex 3
11-32125
KF-35315
HL-24905
46
The Pharmacia beads are composed of dextran and require hydration 
before use. For each 100 mis culture, 0 3 g of microcarrier bead was 
hydrated in 30 mis of PBS for 3 hours m  a siliconised glass 
univeral (Section 2.1.3) This PBS was removed and replaced with 
fresh PBS before autoclaving. Whatman beads (0 2g/100 mis) were 
also autoclaved in siliconised glass universals, When sterile the 
PBS was removed and 30 mis of pre-warmed growth medium with 5% serum 
and 1% p/s was added The bead slurry was added to a sterile 
siliconised spinner flask The universal was rinsed out with 20 mis 
of growth medium, which was also added to the spinner flask (total 
volume, 50 mis) The flask was inoculated with an appropriate cell 
suspension (in approximately 10 mis) The spinner flask was then 
placed on a stirrer base with intermittent stirring at 37°C (30 
seconds at 30 rpm every 2 minutes) for 3 hours This procedure 
allows even cell attachment The total volume of the culture was 
brought up to 100 mis with growth medium and incubated with 
continous stirring (30 rpm) for 6 days
Conditioned medium was collected from microcarrier cultures by 
allowing the beads to settle and removing bead-free spent medium 
Because of the density of the beads they settles quite well and 
almost 90 mis of spent medium may be removed. The beads were then 
rinsed three time with 20 mis of PBS, allowing the beads to settle 
before removal The culture was then set up with 100 mis of medium 
without serum The cells conditioned this medium for three days 
after which time it was removed and stored at 4°C until further 
processing
2.6.2 1 Sampling and Counting
Samples (3 mis ) were taken from the spinner flasks after agitation 
2 mis were placed on a petn dish for microscopic examination, while 
the remaining ml was placed in an eppendorf As soon as the beads 
settled (2-3 minutes) a bead-free sample was removed (200 pi) and 
counted This count represented the number of free cells, not 
attached to the beads
The number of attached cells was estimated by the method of Sanford 
et al (1951) All the bead-free medium was removed carefully and 
the bead pellet was resuspended in 500 pi of of 0 1M citric acid 
containing 0.1% (w/v) crystal violet. The eppendorfs are mixed well 
(by Whirlimixer) and incubated for 1 hour at 37°C. This caused the 
cells to burst due the hypertonic citric acid and the nuclei were 
released and stained by crystal violet The freed nuclei could then 
be counted by haemocytometer The microcarriers did not interfere 
with the counting since they were too large to pass under the 
coverslip
2 6.3 Suspension Culture
RPMI 2650 cells were grown in suspension in 250 mis and 500 mis 
siliconised and autoclaved Techne flasks Medium supplemented with 
serum (DHS) and 1% p/s was added to the flask and incubated at 37°C 
while the cell suspension was being prepared A single cell 
suspension was prepared and added to the spinner flask so that a
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final concentration of about 1 x 10^ RPMI 2650 cells per ml was
obtained The spinner flask was incubated at 37°C with continous
stirring (20-30 rpm for a 100 ml culture)
Conditioned medium was collected from spinner flasks after 4 days by 
the following method The contents of the spinner flask were
removed to sterile universals and centrifuged at 1,000 rpm for three 
minutes The supernantant was carefully poured off so as not to
disturb the cell pellet. The pellet was resuspended in culture 
medium without serum and replaced in the spinner flask The volume 
was brought up to 100 mis The flasks were incubated at 
37°C/20-30rpm for the length of time required for conditioning 
(normally 3 days), at which time the cells were removed from the 
conditioned medium by centrifugation and were either re-set up with 
fresh serum-free medium or were discarded The CM was stored at 4°C 
until further processing.
2.6.3.1 Sampling and counting
A 2 ml homogeneous sample of cells was carefully removed from the 
suspension culture and centrifuged at 1000 rpm for 4 minutes Waste 
medium was removed and 500pl of 0 25% trypsin (Gibco, 043-05090) 
added to the cell pellet This was incubated at 37°C until a single 
cell suspension was obtained (up to 15 minutes, depending on the 
size of the cell aggregates) 500 pi of serum supplemented medium 
was added For viability counts, 200 pi trypan blue was added The 
cells were then counted on a haemocytometer (Section 2 3 3)
2 7 LARGE SCALE CULTURE
2 7 1 Bioreactor System and control package
The Biostat MC (Braun AG) mammalian cell bioreactor (working volume 
1 8 litres) was used to scale up the collection of CM from 
suspension cultures The system provides
* temperature control by circulating heated water through the 
jacket of the double walled glass culture vessel
* agitation by a top driven impeller with large adjustable 
pitch blades
* oxygen control by diffusion of nitrogen or oxygen through a 
internal basket of silicone tubing
* pH control by addition of C02 gas and sodium bicarbonate 
(1M).
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The bioreactor was monitored using the Micro-MFCS control package 
which was set up on an IBM AT PC with 640 KB memory, with a
mathematical coprocessor (80287), EGA graphic card and a EGA color
monitor, connected to a dot matrix printer. The control system is 
operated through menus, where the operations are selected by 
function keys
The main function of the package used in this project was its
on-line monitoring The computer collected analog signals from the
oxygen, pH and temperature probes and from tacometer readings on the 
impeller and converted them into digital signals which were 
displayed both graphically and numerically in a number of different 
graphic screens The readings were averaged every hour and stored m  
batch reports which could be retrieved after a batch run was 
completed
An alarm function was incorporated into the system whereby each 
parameter could be assigned limits If the measured value fell 
outside these limits, its numerical value and graphical bar 
representation would turn from green to red An alarm message was 
also printed out.
The computer package also had facility to control pH and dissolved 
oxygen (DO) levels, overriding the controllers on the Biostat MC 
unit This function was not employed for the bioreactor work 
described m  this thesis because the 'dead-band' of the controller 
could not be varied This had dramatic effects on the DO levels 
which varied by 20-30% The dead-band on the Biostat MC unit could 
be reduced to ± 5%.
2.7.2 Vessel preparation
Careful vessel preparation is essential for successful bioreactor 
cultures Each step outlined below must be adhered to.
1. The glass vessel was washed and rinsed as described before 
(2.2 1) The blades were removed from the impeller shaft and the 
aeration basket from the head plate and were washed and rinsed The 
metal parts of the oxygen and temperature probes were also cleaned
2 The glass vessel, the impeller blades, the aeration basket and 
the temperature probe were all siliconised (in theory cells should 
not adhere to the metal surfaces, but when these were not treated, 
some cells did grow on them)
3. Each blank plug and head-plate insert was removed and cleaned 
individually, paying careful attention to the thread area. Their 
o-nngs were examined for nicks or distortions and replaced if 
required. All o-rings were greased with silicone grease before each 
plug was fastened in place
4. The pH probe was inspected If the level of electrolyte was low 
(more than 1 cm below the blue hole), it was topped up. The
procedure for pH probe calibration was followed as described in the 
Braun Operating Manual with pH 7 and pH 10 standard buffers
(Lennox) If slope of the electrode was not between 56 5 to 59
mV/pH or the zero point displacement not within the range -0.5 to
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+0 5 pH, then maintenance action was taken (Section 2 7 3) or the 
electrolyte was removed and replaced with fresh 3M KCl electrolyte 
(Ingold AG), and the calibration procedure repeated
5. The response of the oxygen probe was checked The probe was 
polarised for at least 6 hours before the inspection started The 
inspection is made in three steps.
Step 1. Current Measurement With the 'RANGE' switch in TEST 
position, the value displayed was recorded At 20-25°C, the 
reading should be between 40-80
Step 2. Zero Current Measurement The electrode was placed 
carefully into a 50 mis syringe barrel connected to a nitrogen 
source The nitogen supply was turned on (less than 1 bar was 
sufficient) With the 'RANGE' switch in TEST position, the displayed 
value was recorded after 5 minutes This value must be less than 
1.5% of the current that was measured in air.
Step 3 Response Time The electrode was taken carefully out of 
the syringe barrel. 98% of the original current measurement must be 
displayed within 40-80 seconds If a malfunction in one of the 
parameters was discovered during inspection, then maintenance action 
was taken. In all doubtful cases it is suggested that the membrane 
body be replaced (Section 2 7 4)
5 The head plate was assembled according to the diagram below. 
Electrodes, inoculation tubes, sampling tubes, etc which extend 
to the bottom of the vessel must be accomodated in the outer ports, 
otherwise they will interfere with impeller rotation. The pH probe 
and the DO probe were inserted last.
5^0
1. Blank
2. 4-port connection
3. DO electrode
4. blank
5. Gas inlet
6. Reference thermometer
7. blank
8. gas outlet
9. inoculation port
10. pH electrode
11. exhaust cooler
12. 2-port sample loop connector
FIGURE 2.1 Assembly of head plate (Biostat MC)
One outlet of four-port connection piece was connected to a solution 
bottle containing 1 M sodium bicarbonate. The solution bottle had a
specially adapted lid with two outlets, one of which served as a
vent and was attached to a 0.22 pm autoclavable filter (Gelman, 
4464).
A second port on the 4-port connector was used to aerate the head 
space. It was connected via a forked connection to the gas inlet 
into the aeration basket and a 0.22 pm filter which was attached to 
the main gas supply.
The third and fourth ports were not used and were connected by a 
short loop of tubing to each other.
The sampling loop consisted of a loop of tubing connecting one
outlet of the 2-port connection to the other. A sampling device was 
inserted in the loop. This was made up of four parts: the
stainless steel bottom housing with outlets for the loop tubing; a
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rubber (self sealable septum) screwed in place via a metal o-ring 
with a stainless steel upper housing A sampling tube was attached 
to the inside of one of the outlets, while the second was left free
The septum was replaced before each run It was important to clean 
the device carefully before assembling it. This involved running 
water through it and through the tubing after soaking in RBS It was 
important that the treads were free from grease or dirt
The long piece of tubing (about 1 meter) was connected to the 
inoculation port A blue tip-fin was inserted in the free end with 
its narrow tip pointing out. The top 4-5 mm of the tip was cut off
7. The blades were attached onto the impeller shaft The blades 
were angled so that they are 90° to each other and 45° to the shaft
8. The air filters (Millex FG 50 Cat No SLFG05010) attached to the 
gas inlet, the gas outlet and the exhaust cooler were examined by 
forcing air through them with a syringe. If water bubbles could be 
observed inside the filter housing, then they may be water-logged 
They were replaced if necessary. Normally these filters were 
changed every 3-4 runs (about 8 autoclave cycles).
9. Silicone tubing was attached onto the aeration basket. It was 
observed that cells grew in between the rows of tubing when they 
were very close together Also cells attached and grew around the 
area of the sampling tube This possibly was due to insufficient 
medium agitation near the bottom of the aeration basket. These 
problems appeared to be solved by wrapping the tubing around every 
second rung on the metal basket This did not appear to be 
detrimental to the oxygen control
The tubing was then checked for holes or nicks This was done by 
forcing air through the tubing by syringe, while it was immersed in 
water, and looking for air bubbles Water must not enter the 
silicone tubing or it will wet the exhaust air filters If holes 
were present, the tubing was replaced.
The aeration basket was connected to the head plate (checking 
orientation of the gas inlet and outlets against the head plate gas 
inlet and outlets) and the gas tubes were attached to the head 
plate
10 The head-plate was assembled to the vessel and clamped shut 
with the quick locking strap The headplate was positioned on the 
vessel so that the bottom hose connection is on the left The 
fastening fittings should lie behind the hose connections as viewed 
from the top, and the buckle of the locking strap should be to the 
front
11 The completed culture vessel was mounted to the holding, 
fastened down with screws and the impeller coupled to the driving 
shaft The agitation was turned at a slow rate (about 10 rpm) to 
check that the blades are not obstructed All electrical leads, 
tubings and hoses should be attached to their appropriate 
connections, to check everything is in place
12 Before autoclaving about 1 litre of water was added to the 
vessel (enough to cover probes) and all inlet and outlet tubing 
(except the exhaust cooler) and the tubing to the sampling bottle 
were clamped to prevent the air filters becoming wet The open ends
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of the air filters were covered with tin foil The top of the 
impeller shaft, the top of the pH and DO probes and the electrical 
lead of the temperature probe were also covered well with tin foil. 
The vessel was now ready for sterilising The vessel was autoclaved 
for 20 minutes at 121°C/15 psi with the autoclave vent closed It 
is very important that the autoclave cools slowly (preferably 
overnight) since sudden pressure drops could damage the oxygen 
electrode
13 When cool, the autoclaved vessel was placed in the laminar flow 
cabinet and the water was pumped out via the inoculation tubing 
using a peristaltic pump (Braun FE411) in to a sterile roller 
bottle.
The tubing was connected (via the blue tip-fin) to a 1 litre Schott 
bottle containing 1 litre of medium without serum, L-glutamine or 
antibiotics, which was pumped into the culture vessel The 
inoculation tube was removed from the bottle tubing and was covered 
with IMS soaked cotton wool and wrapped in tin foil
The vessel was then assembled into the fermenter unit, and the 
impeller coupling connected and the connector hoses inserted in 
place The temperature is turned on and controlled at 37°C, and the
agitation rate is set at 40 rpm. The vessel is covered in tinfoil to
protect against light-inactivation of vitamins Incubation of the 
vessel in this manner for 2-3 days served as an added sterility
check
14. The oxygen probe was connected to its meter and switched on The 
probe must be on for a minimum of 6 hours, to polarise, before it 
can be calibrated. The oxygen probe was calibrated by first pumping 
nitrogen gas into the culture vessel and waiting for a steady 
reading The display was then set to zero with the ZERO 
potentiometer (RANGE switch set to 20%) The nitrogen was turned 
off Air was pumped into the vessel until a steady reading was
displayed. The RANGE switch was set to 100% and with the SLOPE 
potentiometer, and the display adjusted to 100%
2 7 3 Inoculation
Inoculation of the bioreactor was carried out in the laminar flow
cabinet For RPMI 2650 cultures, three 75 cm2 flasks (almost 
confluent) were sufficient to seed 1.8 litres of medium (1 8 x 108 
cells total) A single cell suspension of these cells was prepared 
m  90 mis of DHS and added to a sterile, siliconised Schott bottle. 
This was pumped very slowly into the vessel containing 1 litre of 
medium. L-glutamine (18 mis), Non-essential ammo acids (NEAA) (18 
mis) and p/s (18 mis) were added to the Schott bottle, swirled 
around, and pumped m  also Finally the remaining medium (650 mis
approximately) was pumped in The vessel was re-assembled into the 
bioreactor unit and all the meters and control modules switched on
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2 7.4 Collection of CM
CM was collected in serum free medium, so to remove the medium 
containing serum from the cells, the entire culture contents was 
centrifuged, while maintaining sterility This was achieved by 
pumping the cell suspension directly into 50 ml sterile universals 
(Sterilm Cat No 125 AP), centrifuging at 1000 rpm for 4 minutes, 
combining the pellets and resuspending them in a small volume m
medium without serum The cells could then be re-inoculated by
injection into the vessel containing 1.8 litres of fresh medium 
supplemented with L-glutamine, NEAA and p/s via the sample port, or 
as before through the inoculation port
2.7.5. Sampling
Samples were withdrawn by needle via the sample port. The sample 
loop tubing was connected to the 'ACID* pump on the main bioreactor
and with the CC>2 gas turned off, the acid pump was activated
Culture medium was circulated around the loop, drawn up from the 
sample tube inside the vessel, through the sampling port and back 
to the vessel via the head plate The lid of the sampling port was 
removed and filled with IMS Samples were withdrawn by inserting a 
sterile needle straight into the septum The lid was then snapped 
back in place and the direction of flow through the tubing changed, 
so that the tubing contents were pumped back into the vessel
2 7 6 pH electrode maintenance
The electrode was cleaned by soaking the membrane and diaphram areas 
alternatively in pepsin-hydrochloric solution and thiocarbamide 
solution for a few hours This removed protein and sulphur 
deposits. After soaking, the probes were rinsed well in distilled 
water and stored m  3M KCl
2 7.7 DO electrode maintenance
The maintenance of the DO electrode involved changing the 
electrolyte, replacing the membrane body and cleaning the anode.
The electrolyte was replaced after 2-3 runs (about six autoclaving 
cycles) carefully following the procedure detailed in the Braun 
manual. The membrane body was changed whenever there was a doubt as 
to its operational capability or when it was mechanically damaged.
2.8 PROCESSING OF CM
2.8 1 Ultrafiltration
Ultrafiltration was used in as a means of concentrating and 
fractionating the CM collected. The stirred cell method was used 
(Amicon No 8499 - 400 ml capacity chamber), with a variety of
molecular-weight cut-off membranes (Amicon)
YM 30 30,000 MW cut-off R30 + F30
YM 10 10,000 MW cut-off R10 + F10
YM 5 5,000 MW eut-off R5 + F5
YM 2 1,000 MW cut-off R1 + FI
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In general CM was concentrated m  the range 5-20x by
ultrafiltration
CM could be fractionated by concentrating filtrate from one
ultrafiltration membrane on a smaller one For example the Rl-30 
fraction was obtained by concentrating F30 on the YM 2 membrane
2 8 2 Diafiltration
Diafiltration was used as a means to desalt fractions following 
elution at high salt concentrations from heparin sepharose columns 
A 10 ml sample to be diafiltered was diluted with 100 mis of medium 
and concentrated by ultrafiltration to its original volume (10 mis) 
This was repeated Thus the salt in the sample had been effectively 
diluted 1/121 with medium
2.8.3 Dialysis
Concentrated CM samples and column fractions were dialysed against 
50 volumes of PBS and 25 volumes of medium using a low molecular 
weight, benzoylated, 1,200 cut-off tubing (Sigma D7884)
Before use the required length of tubing was boiled for 5 minutes in 
10 mM EDTA This was then washed well in distilled water and finally 
rinsed in ultrapure water. Dialysis was carried out at 4°C, with 
the buffer changed twice daily for 2 days
2.8 4 Lyophilisation
Lyophilisation of CM was carried out using a 4 5 L Consol Freeze 
Dryer (Virtis) Samples were frozen to -30°C overnight The freeze 
drying cycle was started and usually lasted for 36 hours or until 
the samples were dry
2 9 SOFT AGAR ASSAYS
Conditioned media samples were assayed for growth factor activity 
using three different soft agar assay systems, the basic protocols 
of which are similar A 2 ml test sample is required for assay in 
triplicate. The assays vary with regards to basal medium, indicator 
cell line and indicator cell concentration as indicated below.
TABLE 2 5 Soft Agar Assays
Assay Type Autocrine TGF-a-like TGF-fi-like
Cell line 
Cells/35 mm dish 
Basal Medium
RPMI 2650 
3 x 104 
MEM
NRK 
6 x 103 
DME
NRK-49F 
1 95 x 104 
DME
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Cells were trypsinised three days prior to assay and fed at least 
three hours before trypsinisation.
It is advisable that the passage number of NRK cells be kept between 
passage 19-21.
2.9.1 Cell pretreatment
2.9.2 Assay Protocol
The following protocol was followed for each assay.
1. Weigh out 1.548 g agar (Bacto Difco) and dissove in 100 mis of
ultrapure water. Autoclave. Incubate at 44°C immediately.
2. Calculate volume of agar medium (AgM) required by multiplying the 
number of samples by 7. Divide this figure by 2.58 to find the 
volume of MEM2x or DME2x required. Prepare the AgM in the following 
ratio:
MEM2x/DME2x 50 mis
HEPES (ImM) 2 mis
NaHC03 (7.5%) 1 ml
P/S 1 ml
Growth Medium (-FCS) 14 mis
Equilibrate to 44°C.
MEM2x/DME2x was prepared as follows:
MEM/DME lOx 20 mis
Ultrapure water 76 mis
HEPES (ImM) 4 mis
NaHC03 (7.5%) 2.2 mis
adjust to pH 7.4 with 1 M NaOH
3. Place 35 mm plates (Greiner, 627160) on trays and label
appropriately. Each sample is assayed in triplicate.
4. Add the thermo-labile components to the AgM at the following 
concentrations:
L-glutamine 1 ml
FCS 10 mis
5. Add agar to the AgM in the same volume as MEM2x or DME2x (i.e. in 
this case 50 mis). Mix well and quickly dispense 1.5 mis onto each 
35 mm dish. The remaining AgM is returned to the water bath and the 
temperature reduced to 41°C. The plates are allowed to set at room 
temperature.
5. Trypsinise cells and prepare a single cell suspension in medium 
without serum. The required concentration per ml to give the final 
concentration per dish is as follows:
RPMI 2650 
NRK
NRK-49F
2 x 105 cells/ml 
4 x 104 cells/ml
1.3 x 105 cells/ml
6. Add 0.5 mis of each cell suspension to each 2 ml test sample and 
unconditioned medium control samples.
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7 Add 2 5 mis AgM (41°C) to each sample (containing cells) and 
immediately dispense out 1 5 mis per plate (x3) After every five 
samples (maximum), re-equilibrate the AgM to 41°C
8 Cover trays m  tin foil and incubate at 37° C f 5% CC>2 for 10 days 
2 9 3 Colony counting
PLATE 2 Anchorage-independent growth of RPMI 2650 cells in soft
agar Phase 1 (150X) magnification
Colonies were counted on an inverted microscope (CK Olumpus, Tokyo) 
at 40x All colonies greater than 50pm m  diameter after 10 days in 
culture were counted An eye-piece graticule was graduated using a 
stage micrometer and was used to size colonies
All agar plates were viewed, superimposed on a transparent gndded 
disc with 4 mm2 grids 25 grids were viewed for each 35 mm dish
The average total number of colonies per plate was then estimated 
and the percentage colony forming efficiency {% CFE) determined
Number of colonies per plate
% CFE =   X 100
Number of cells plated
Each sample was set up m  triplicate and a mean % CFE was determined 
for each sample and the standard error of the mean calculated by the 
following formula
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SEM =
S x 2  - ( S x ) a / n  
n - 1
r r
Where n = number of replicates per sample 
x = CFE of each replicate 
2 = sum of the samples from 1 to n
2.10 PURIFICATION OF CM
2.10 1 Ion exchange chromatography
A preliminary experiment was set up to test the affinity of the 
autocrine activity for cation and anion exchangers. The gels used 
were Cellex-CM, a weak cation exchanger, (Bio-Rad, Cat No 
7481530), and Cellex-D, standard capacity (Bio-Rad, Cat No 
7480530) The gels (0 25 g/test tube) were pre-equilibrated in lOx 
buffers (25 mis) and adjusted to the pH values required with the 
acidic or basic component of the buffer The buffers used for each 
pH are listed in Table 2 6. The buffers were made up to 0 5M (10x) 
and 0 05 M (lx), for the equilibration and separation steps 
respectively
TABLE 2 6 Ion-exchange chromatography buffers
Cellex-CM Cellex-D
pH Buffer pH Buffer
4 0 Sodium Acetate 5 0 Sodium Acetate
4 8 Sodium Acetate 5 6 Sodium Acetate
5 2 Sodium Acetate 6 0 Potassium phosphate
5 6 Sodium Acetate 6 4 Potassium phosphate
6 0 Potassium phosphate 6 8 Potassium phosphate
6 4 Potassium phosphate 7 1 Tris HC1
6.8 Potassium phosphate 7.4 Tris HC1
7 2 Potassium phosphate 7 8 Tris HC1
7 9 Potassium phosphate 8.2 Tris HC1
8.0 Potassium phosphate 8 6 Tris HC1
8 9 Tris HC1
The conductivity was then reduced with seven washes of 25 mis of 
diluted buffer (lx) As much buffer as possible was removed by 
pasteur pippette 2 mis of buffer was added (lx)
RPMI 2650 CM concentrated 14x by ultrafiltration was dialysed 
against ultrapure water to reduce salt concentrations 2 mis of this 
CM was added to each tube of equilibrated gel The tubes were mixed 
for one hour with gentle inversion. The gel was allowed to settle 
and the supernatnant removed (4 mis approximately). Each sample was 
dialyaed against digtilled water for 24 hours and against 
unconditioned medium for 48 hours
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Each sample was then filter sterilised and assayed in the RPMI 2650 
autocrine assay
2 10 2 Hydrophobic Interaction chromatography
A 4 ml phenyl sepharose CL4B (Pharmacia, Cat No 17-0810-02) column
was equilibrated for 1 hour with MEM ultrafiltered to 5x with a
1,000 MW cut-off membrane 10 mis of a Rl(10x) samples was applied 
and then eluted with 50% glycerol. 4 ml fractions were collected 
Each fraction was dialysed against PBS for 24 hours and MEM for 12 
hours.
2.10.3 Heparin sepharose chromatography
CM was fractionated by heparin sepharose chromatography using 
Heparin Sepharose CL-6B (Pharmacia, Cat No 17-0467-01) which is 
stored m  a dry powdered form which must be swollen in buffer before 
use 1 g of dry powder gives approximately 4 mis of gel The gel 
must be extensively washed in buffer before the sample is applied to 
remove all preservatives It is recommended that the 1 g of powder 
is washed with 250 mis of buffer
2.10 3.1 Step elution
Step elution from heparin sepharose columns proved to be a 
successful method of CM fractionation.
100 mis of untreated CM was incubated at 4°C with 4 mis of heparin 
sepharose gel with constant stirring overnight The supernatant was 
removed by allowing the gel to settle and the gel was washed with 60 
mis of 0 01 M potassium phosphate buffer before being loaded into a 
10 ml column The column was rinsed through with a further 30 mis of 
buffer This 180 mis (approximately), 'UNBOUND' fraction, was 
ultrafiltered using a 1,000 MW cut-off membrane down to 10 mis (lOx 
of its original concentration).
A NaCl solution (3M) was prepared in 0 01 M potassium phosphate 
buffer and diluted appropriately with buffer The bound activity 
was then eluted with increasing salt concentration
0 0, 0 25, 0 5, 0.8, 1 0, 1 2, 1 5, 2 and 3 M NaCl 
Fractions were collected (4 mis) and absorbance (280nm) was read
2.10.3 2 Gradient Elution
The operation of the 10 ml heparin sepharose column was controlled 
by the 'BIOPILOT system' (Pharmacia) The control unit consists of a 
programmable controller linked to a series of pumps and valves and 
two monitors (UV, conductivity) and a chart recorder The
programmable controller directs the flow of liquid through the 
system It also controls product stream monitoring
A program was set up so that a concentrated CM sample (10 mis of a 
Rl(14x) sample) was applied to a 10 ml heparin sepharose column, 
pre-equilibrated in 0.01 M potassium phosphate buffer, pH 7 4 
(Buffer A). The column was then washed with 70 mis of buffer A A
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salt gradient was set up, such that the NaCl concentration is 
increased from 0 M to 3 M NaCl over 100 mis at a rate of 1 ml/mm 
The column is washed with a further 50 mis of 3 M NaCl in 0 01 
phosphate buffer, pH 7 4 (Buffer B)
Fractions (6 mis) were collected and filter sterilised before assay
2 11 STABILITY OF CM
2.11 1 Temperature Stability
Conditioned medium (10 mis), concentrated five fold by 
ultrafiltration, was dispensed into clean glass universale (30 mis) 
and placed In a covered waterbath set at 65°C for the required 
lenght of time (1 hour) Samples for boiling were placed in a beaker 
of boiling water over a flame, with lids slightly loosened When the 
temperature of the CM reached 98°C, the boiling was monitored for 3, 
6 and 20 minutes Each sample was then centrifuged at 3,000 rpm/15 
minutes to removed insoluble precipitates, and filter sterilised 
before assay
2.11 2 pH stability
Conditioned medium samples (5 mis) were dispensed out into 
universals. The pH of each sample was adjusted with different 
volumes of 5 M HCl and 5 M NaOH (see Table 3 5 8) and the samples 
were incubated at 4°C for two hours before the pH was re-adjusted 
Osmolanty was measured on the Osmomat 030 (Gonotec). Each sample 
was filter sterilised before assay
2 11*3 Protease stability
A concentrated CM sample was incubated for two hours at 37°C with 
10/jg/ml trypsin (Gibco) The reaction was stopped with 20pg/ml 
soyabean trypsin inhibitor (Sigma)
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2 12 PURE GROWTH FACTORS
2.12 1 Source
A range of growth factors from commencal sources were assayed in 
the soft agar assay. The growth factors, their suppliers and sources 
are given m  Table 2 7
TGF-a was a kind gift form Marjorie Winkler, Genentech 
TABLE 2.7 Growth Factors used in course of project
Growth Source
Factor
Insulin Sigma, Cat No. 1-1882 
Bovine pancreas
igf-i-p Promega, Cat No G5111
Human recombinant protein from S.cerevisiae
IGF-I-B Boehnnger Mannheim, Cat No BCL 1048-066 
Human recombinant protein from E. c o I j l
IGF-II Sigma, Cat No. M-9145 
BRL-3A cell CM
aFGF Sigma, Cat No F-5267 
Bovine brain
bFGF Sigma, Cat No F-5392
Bovine pituitary glands
TGF-13 Peninsula Lab Europe Ltd., Cat No IP-1085 
Purifed from human platelets
TGF-a Genentech, Cat No PD-1 
Human recombinant
EGF Sigma, Cat No E 4127 
Mouse
IL-la British Biotechnology Ltd , Cat No BDP-15 
Human recombinant protein from E coli
IL-1J3 British Biotechnology Ltd , Cat No. BDP-17 
Human recombinant protein from E. colx
PDGF
0
Peninsula Labs Cat No IP-1080
2.12.2 Preparation
The growth factors were supplied in lyophilised form and required 
reconstitution in appropriate buffers (each containing 1 mg/ml BSA) 
before use After reconsitution, the factors were diluted m  ATCC 
medium containing 1 mg/ml BSA Fraction V (Sigma, Cat No A9418) to 
give the indicated growth factor concentrations per ml of agar
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TABLE 2 8 Reconstitution of Growth Factors
Growth Quantity Reconstitution Final
Factor Buffer Concentrations
(+ lmg/ml BSA) (/ml agar)
Insulin lOOmg 0 5 ml 0 1M Acetic acid 50,5,1 ng
IGF-I-P 25/jg 0 5 ml 0 1M Acetic acid 50,10,5,1 ng
IGF-I-B 50/jg 0 5 ml lOmM HCl 50,10,5,1 ng
IGF-II 10/ug 0 5 ml lOmM HCl 50,10,5,1 ng
aFGF lpg 1 0 ml ATCC 50,10,5,0.5 ng
bFGF 1/ug 1 0 ml ATCC 50,10,5,0 5 ng
TGF-fl Svg 0 5 ml 0 1M Acetic acid Various
TGF-a 100/jg 1 0 ml PBS 50,10,5,1,0 5 ng
EGF lpg 1 0 ml ATCC 50,10,5,1,0 5 ng
IL-la 5(jg 1 0 ml PBS 10,1,0 1 units
IL-1B lOpg 1 0 ml PBS 10,1,0 1 units
PDGF 100U 4 0 mis 0 15M NaCl 2, 1 0 5 units
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3 0 RESULTS
3 1 DEVELOPMENT OF THE SOFT AGAR ASSAY
In order to reduce variability betweeen experiments a number of 
factors involved m  the autocrine assay were examined 
the number of cells present in each dish, 
the indicator cell pretreatment before the assay, and 
the performance of different batches of serum 
In these assays a common batch of conditioned media was tested 
This had been concentrated ten fold with a 1,000 molecular weight 
cut-off ultrafiltration membrane (Rl) Unconditioned medium (MEM) 
was also assayed, serving as a negative control
3.1 1 Effect of cell loading
The aim of this experiment was to determine an optimum cell 
concentration per plate in the RPMI 2650 autocrine assay The cell 
concentration per well was varied from 103 cells to 105 cells per 
plate The results are presented as the average number of colonies 
per plate and the calculated percentage colony forming efficiency 
(%CFE) based on the number of indicator cells plated
TABLE 3 1 1  Effect of indicator cell loading in the RPMI 
2650 autocrine assay
RPMI 2 650 
cells 
per 
dish
Rl (lOx) MEM
CountiSEM 
per dish
CFE+SEM
(%>
CounttSEM 
per dish
CFE±SEM
(%)
103 4 0± 1 0 0 40±0 10 0 3± 0 58 0 03±0 06
5xl03 10 0± 2 7 0 20±0 05 1 7± 0 58 0 03±0 01
3xl04 85 8± 10 2 0 29±0 03 3 3± 0 57 0 01±0 01
5xl04 220 5± 47 0 0 44±0 10 12 0± 4 00 0 02±0 01
lxlO5 508 0±104 0 0 51±0 10 29 7± 1 55 Q,.03+0 01
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The number of colonies formed per plate increased with the number of 
cells plated At lower cell loading densities the difference 
between stimulation and control levels depends on less than ten 
colonies which would make assessment of activity problematic Such
Acell loadings (less than 10 cell per dish) make statistically 
significant assessment difficult
As more cells are present, more colonies are formed The errors are 
quite high here due to inaccuracies arising from the counting of 
such large numbers of cells per plate As the cell loading was 
increased colonies grew closer together making it difficult to count 
and size individual colonies At higher cell loading levels it is 
necessary to be aware of the danger of saturating the plates,
resulting m  nutrient limitation occunng before the assay is read.
While varying the number of indicator cells loaded increased colony 
stimulation, it did not greatly affect the colony forming efficiency 
for the range examined
The optimum cell loading in the autocrine assay was chosen to be m
4between these two extremes at 3x10 cells per plate
3 1 2  Effect of indicator cell pretreatment
The condition of the cells used is known to affect the
reproducibility of the assay (Dooley, 1987, PhD Thesis) An
experiment was designed to analyse the effect of cell pretreatments
of a number of different flasks of cells
Four flasks of RPMI 2650 cells (passage 59), were set up on day 1, 
two at 2 x 104 (Flasks A and B) and two at 6 x 10^ (Flasks C and D).
Flasks A and C were fed on day 3, 24 hours before the assay All
four flasks were trypsimsed on day 4 and the cells were used to 
detect autocrine activity in a sample of Rl(10x) (i e conditioned 
medium concentrated 10 fold by ultrafiltration using a YM2
ultraflltration membrane (1,000 MW cut-off)) and a medium (MEM)
control The results are presented in Table 3 1 2 in the form of %
colony forming efficiency of the Rl(10x) and MEM samples and the 
fold stimulation of the Rl(10x) compared with the control
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TABLE 3 1 2  Effect of indicator cell pretreatment in the RPMI 2650 
autocrine assay represented as (%)CFE+SEM and the 
average fold stimulation above that of the MEM control.
Indicator cell 
Pretreatment
(%)CFE ± SEM
Fold
Stimulation
Rl(10x) MEM
A Sub-confluent, fed 0 06±0 04 0 03±0 01 2 0
B Sub-confluent, not fed 0 18±0 02 0 Q7±0 01 2 6
C Confluent, fed 1 28±0 17 0 22±0 07 5 8
D Confluent, not fed 0 49±0 02 0 18±0 02 2 7
The confluency of the indicator cell appears to be a crucial factor 
m  the stimulation observed in the assay Flasks C, m  particular, 
was more responsive to the autocrine activity The two subconfluent 
flasks, A and B, were not as responsive, although stimulation of 
more than 2 0 fold was present
This experiment highlights the importance of the condition of the 
cells m  the design of the autocrine assay Variability will be 
reduced somewhat if the pretreatment of the indicator cells is kept 
constant for every assay, although obviously other factors also play 
a role
3.1 3 Different serum batches
This experiment examined the behaviour of a range of sera from 
various animal sources A sample of conditioned media (Rl(10x))
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known to be active was included as a positive control, MEM as a 
negative control and MEM + 5% of the appropriate sera an internal 
control
A suitable serum for the autocrine assay is defined here as a batch 
that shows increased stimulation for the Rl(10x) sample above that 
of the MEM control without high stimulation in the MEM + 5% serum
sample
TABLE 3 1 3  Effect of sera from various sources in the RPMI 2650 
autocrine assay
Serum Batch* Rl(10x) MEM MEM+5% FCS
1 FCS 1 14±0 15 0 03±0 02 0 28±0 08
2 FCS 0 47±0 07 0 04±0 01 0 13±0 01
3 FCS 1 29±0 11 0 32±0 07 1 15±0 23
4 FCS 1 61±0 29 0 37±0 10 0 83±0 03
5 FCS 2 62+0 27 0 28 + 0 04 1 59±0 08
6 NC 0 35±0 09 0 03±0 02 0 10±0 03
7 DH 2 21+0 15 0 06±0 02 0 50±0 08
8 FCS 0 03±0 14 0 02+0 02 0 28±0 15
9 FCS 0 65±0 10 0 08±0 01 0 44+0 04
*FCS = Foetal Calf Serum 
NC = Newborn Calf Serum 
DHS - Donor Horse Serum
In this experiment it was found that the sera could be put into the 
following categories
Good Batches 1,7
Fair Batches 2,5
Bad Batches 3, 6, 8, 9
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The performance of this particular batch of donor horse serum 
(sample 7) was comparable with the best batch of foetal calf serum 
but due to availability, it was decided to use batch 1 FCS in 
subsequent autocrine assays
3 1 4  Reasons for improvements in assay reliability
The general conclusions that can be drawn from this set of 
experiments are limited The reliability of the assay was improved, 
however due to a number of technical changes with the assay 
procedure itself The main changes are listed below
1 MEM(2x) was made up on the day of assay as required using
freshly autoclaved ultrapure water This eliminated the
formation of precipitates that was frequently apparent in 
MEM(2x) stocks following storage at 4°C
2 Foetal calf serum and 1-glutamine were not added to the agar 
medium until just before the agar was added This reduced the 
time that these heat sensitive components would have to be 
exposed to 44°C
3 Indicator cells were set up in new flasks for each assay This 
ensured that the cells were evenly spread m  the flask and were 
more likely to be at the same stage of confluency Cells 
pretreated in this way were also easier to trypsinise
4 In order to avoid the possibility of evaporation if pre­
dispensed water was autoclaved, it was decided to autoclave 
excess water for preparation of agar medium and to dispense out 
76mls of water from it
3 2 STIMULATION OF RPMI 2650 CELLS IN SOFT AGAR BY PURE GROWTH 
FACTORS
The aim of this set of experiments was to see what classes and types 
of pure growth factors were capable of stimulating RPMI 2650 colony 
formation in the autocrine assay system Because of size limitations 
this experiment was split into a number of smaller, more manageable 
assays
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The purified growth factors were dissolved in appropriate buffers as 
described in Materials and Methods and then diluted m  ATCC medium 
supplemented with BSA The effect of BSA in the assay was compared 
to controls of ATCC without BSA to investigate whether a control of 
ATCC with lmg/ml BSA was required in the assays
TABLE 3 2 1 Effect of BSA on colony forming efficiency of RPMI 2650 
cells in soft agar
3,2 1 Effect of bovxne serum albumin (BSA) m  the RPMI 2650 soft
agar assay
Assay
% CFE i: SEM
Fold
stimulation
ATCC ATCC +
1 mg/ml BSA
1 0 21±0 04 0 33±0 04 1 6
2 0 13+0 04 0 88±0 09 6 8
3 0 10±0 03 0 14±0 02 1 4
Table 3 2 1 illustrates that BSA does effect the growth of RPMI 2650 
cells in soft agar The presence of BSA results m  increased growth 
over a medium control Subsequent assays with purified growth 
factors must therefore include a ATTC supplemented with lmg/ml BSA.
This set of experiments again illustrates the vanablity between 
individual assays In each of these assays, cell pretreatment waa 
identical, the agar medium employed the same batch of FCS and ATCC 
medium, and the BSA was prepared from a common stock solution
3 2.2 Insulin, Insulin-like growth factors I and II
In this experiment insulin-like growth factor I from two separate 
sources were compared IGF-IB (source=Boehnnger Mannheim, derived 
from E  c o l j . ) and IGF-IP (source=Promega, derived from S  
c o r e v i s a e ) IGF-II (Sigma) and insulin (Sigma) were also assayed at
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the concentrations indicated Dilutions of the growth factors were 
made m  ATCC medium supplemented with 1 mg/ml BSA as described in 
the Materials and Methods The results are presented in Table 3 2 2
TABLE 3 2 2 Effect of insulin-like growth factors I and II and 
insulin on colony forming efficiency m  the RPMI 2650 
autocrine assay The fold stimulation above the control 
is presented in brackets {sample/control}
Concentration per ml of agar medium
Growth
Factor 50ng lOng 5ng Ing
IGF-IB 0 57±Q 05 0 31±0 09 0 29±0 03 0 26±0 08
{1 7} {0 9} {0 9} {0 8>
IGF-1P 0 70±0 10 0 38±0 08 0 34±0 02 0 20±0 06
{2 1} {1 2} {1 0} {0 6}
IGF II 0 40±0 02 0 30±0 03 0 27±0 06 0 22±0 04
{1 2} {0 9 > {0 8} {0 6}
Insulin 0 38±0 05 N D 0 24±0 02 0 26±0 04
{1 2) {0 7} {0 8}
ATCC/BSA 0 33±0 04
*■N D = not determined
The two sources of IGF-I examined in this assay had comparable 
stimulatory activity and this activity was dilutable IGF-II and 
insulin were slightly stimulatory at 50 ng/ml but showed no 
significant activity at lower concentrations
These results were reproducible over 3 separate experiments There 
was some vanablity between the assays, as illustrated in the table 
below, but the general trend of each individual assay was similar
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TABLE 3 2 3 Illustration of the variability of three different 
assays calculated fold stimulation of 50 ng/ml of 
IGF-IB over the ATCC/BSA control
Assay
% CFE ± SEM
Fold
stimulation
50 ng/ml 
IGF-IB
ATCC +
1 mg/ml BSA
1 1 17±0 17 0 88±0 09 1 3
2 0 57±0 05 0 33±0 04 1 7
3 0 33±0 09 0 14±0 02 2 3
3 2 3 Acidic and basic fibroblastic growth factors (aFGF and bFGF)
In this set of experiments dilutions of acidic and basic fibroblast 
growth factors were made up m  ATCC medium supplemented with BSA (1 
mg/ml) and assayed in the RPMI 2650 autocrine assay at the 
concentrations indicated The acidic FGF samples were supplemented 
with 10 ng/ml heparin Controls of ATCC + 1 mg/ml BSA and ATCC + 
lmg/ml BSA supplemented with heparin were included
70
TABLE 3 2 3 Effect of acidic and basic fibroblast growth factors 
(aFGF and bFGF) in the RPMI 2650 autocrine assay The
results are presented in CFE(%)±SEM The fold
stimulation over the control is also shown 
in brackets {sample/control}
Concentration per ml of agar medium
Growth
Factor
50ng lOng 5ng 0 5ng
aFGF+hepann 
(lOng/ml)
2 53±0
{4
73
7}
1 40±0 42 
<2 6}
1 05±0 19 
{1 9}
0 66±0 07 
{1 2}
bFGF 1 46±0
(2
53
6}
1 09±0 13 
{2 0}
0 45±0 13 
{0 8}
0 42±0 17 
{0 8>
5ng/ml aFGF 
-heparin
0 65±0
{1
33
2}
Heparin 
(lOng/ml)
0 54±0 22
ATCC+lmg/ml
BSA 0 56±0 11
Both acidic and basic FGF were stimulatory above the ATCC/BSA 
control Acidic FGF retained activity at 5 ng/ml while basic FGF was 
not active below 10 ng/ml The aFGF activity was not augmented by 
the presence of heparin
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3 2 4 Transforming growth factor beta (TGF-13)
The effect of TGF-J3 was variable in a number of assays The 
variability m  response to TGF-fl is illustrated in Tables 3 2 4-6 
for 7 separate experiments with similiar indicator cell pretreatment 
looking at 3 different concentration ranges of TGF-/3
TABLE 3 2 4 Illustration of variability of response to TGF beta in 
three similar RPMI 2650 autocrine assays 
(range 0 002-0 2 ng/ml)
TGF-G
(ng/ml)
Assay 1 Assay 2 Assay 3
0 002 0 58±0 06 0 28±0 06 0 16±0 02
0 01 0 64±0 08 0 40±0 08 0 24±0 01
0 02 1 20±0 27 0 21+0 02 0 19±0 06
0 1 0 97±0 18 0 46±0 14 0 17±0 04
CMO 0 74±0 18 0 36+0 05 0 30±0 13
ATCC/BSA 0 88±0 09 0 33+0 04 
>
0 14±0 02
The concentration of TGF-ft was increased in subsequent experiments 
and the counts per dish are presented below
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TABLE 3 2 5 Illustration of variability of response to TGF beta in 
three similar RPMI 2650 autocrine assays 
(range 0 01-2 0 ng/ml)
TGF-J3
(ng/ml)
Assay 1 Assay 2
0 01 0 12±0 01 0 06±0 01
0 02 0 06±0 02 0 03±0 01
0 10 0 04±0 01 0 05±0 02
0 20 0 04±0 01 0 03±0 01
0 50 0 06±0 02 0 02±0 01
1 00 0 03±0 01 0 03±0 01
1 50 0 02 ±0 00 0 02±0 00
2 00 0 06±0 01 0 04±0 01
ATCC/BSA 0 06±0 01 0 04±0 01
TABLE 3 2 6 Illustration of variability of response to TGF beta in 
three similar RPMI 2650 autocrine assays 
(range 0 5-50 0 ng/ml)
TGF-B
(ng/ml)
Assay 1 Assay 2
0 5 0 42±0 05 0 88±0 09
1 0 0 93±0 17 1 03±0 14
5 0 0 58±0 08 1 39±0 24
10 0 0 75±0 05 1 35±0 23
50 0 0 73±0 14 1 43+0 21
ATCC/BSA 0 64±0 04 0 97±0 07
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As can be seen from the tables above, RPMI 2650 cells do not respond 
significantly to TGF-fl m  a predictable manner over a range of 
concentrations Even at high levels of TGF-J3 only control levels (or 
slightly above) were observed In some cases slight inhibition was 
detected
3 2 5 Interleukin 1-alpha and beta (IL-la and IL-1J3)
In this set of experiments dilutions of IL-la and IL-IB were made up 
in ATCC medium supplemented with BSA (1 mg/ml) and assayed in the 
RPMI 2650 autocrine assay at the concentrations indicated
TABLE 3 2 7 Effect of IL-la and IL-lfl on RPMI 2650 colony forming 
efficiency m  soft agar The fold stimulation above the 
control is shown in brackets
Concentration per ml of agar medium
Growth
Factor 10 Units 1 Unit 0 1 Unit
IL-la 0 07±0 04 1 38±0 24 1 16±0 23
< 04} {0 72} {0 60}
IL-1J3 0 10±0 03 0 26±0 10 0 38±0 08
{0 1} {0 4} {0 6}
ATCC/BSA 1 92±0 25
The interleukins exhibited dilutable inhibition at the 
concentrations examined The experiment was repeated with similar 
trends
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3 2 6 Epidermal growth factor (EGF) and transforming growth factor 
alpha (TGF-a)
EGF and TGF-a were made up in medium containing ATTC + lmg/ml BSA 
and assayed in the RPMI 2650 autocrine assay The results are
presented m  Table 3 2 8
TABLE 3 2 8 Effect of EGF and TGF-a on RPMI 2650 colony forming 
efficiency in soft agar The fold stimulation above 
control level is shown m  parenthesis
Concentration per ml of agar medium
Growth
Factor 50ng lOng 5ng lng 0. 5ng
EGF
TGF-a
0 94±0 03 
{1 0}
0 96+0 11 
{1 0}
0 87±0 33 
{0 9>
0 7 6±0 19 
{0 8}
0 67+0 16
{0 7}
1 19±0 19
{1 2 >
0 59±0 03 
{0 6}
0 85±0 11 
{0 9}
1 13±0 07 
{1 2}
1 11±0 32 
{1 1>
ATCC/BSA 0 97±0 07
Neither EGF or TGF-a significantly increased colony forming
efficiency for the concentrations examined The results indicated
inhibition by intermediate concentrations of TGF-a and EGF, with
slight stimulation at lower concentrations and no effect at 50
ng/ml This experiment was repeated with similar results
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3 2 7 Platelet-derived growth factor (PDGF)
PDGF was made up in ATCC medium containing lmg/ml BSA m  the RPMI 
2650 soft agar assay at the concentrations indicated The results 
of two independent experiments are presented in the table below
TABLE 3 2 9 Effect of PDGF on colony forming efficiency of RPMI 2650 
cells in soft agar The fold stimulation is presented 
m  brackets
Concentration per ml of agar medium
Control
0 5 units 1 0 unit 2 0 units
Assay 1 
Assay 2
1 16±0 08 
{5 3}
N D
1 08±0 13 
{4 9}
N D
0 98±0 11 
{4 5}
5 61±1 20 
(1 5}
0 22±0 06 
3 64±0 94
Although some PDGF can elicit some stimulation, the stimulation does 
not appear to be dilutable This would indicate that a wider range 
of concentrations should be examined
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3 3 PRESENCE OF GROWTH FACTORS IN THE RPMI 2650 CONDITIONED MEDIA
3 3.1 Standard curve of TGF-a activity in the NRK soft agar assay
The presence of TGF-a-like activity in the RPMI 2650 CM was 
determined by comparing two fractions of CM to a standard curve of 
TGF-a m  the NRK soft agar growth assay {see Section 3 3 3 1, 
below) CM from another cell line (HEP-2) was also assayed
A standard curve of TGF-a activity was set up as follows TGF-a 
(Genentech) was dissolved in PBS + lmg/ml BSA and diluted in 
ATCC/BSA as before From a stock concentration of 10jug/ml of TGF-a, 
a range of dilutions was prepared to give the final concentrations 
of test sample indicated (per ml) A control containing ATCC 
supplemented with 1 mg/ml BSA was assayed along with the prepared 
TGF-a standards
RPMI 2650 conditioned medium was concentrated lOx using a 1,000 MW 
cut-off ultrafiltration membrane (Rl) and diluted back to lx with 
MEM
Conditioned medium from the cell line HEP-2, collected in Ham's 
F12, was included in the assay This CM was concentrated lOx using a
30,000 MW cut-off membrane (R30) The filtrate was concentrated 10 
fold with a 10,000 MW cut-off (R10-30) These samples were assayed 
along with neat CM and an unconditioned medium control
The results are presented in Table 3 3 1 as % colony forming 
efficiency of NRK cells in soft agar The activity of the standards 
is graphed m  Figure 3 3 1 against their log(concentrâtion) 
Comparison of the activity of the samples against this standard 
curve gives an indication of the levels of TGF-a-like activity 
present
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TABLE 3 3 1 Standard curve of TGF-a activity in the NRJC soft agar
assay
TGF-a 
(ng/ml)
% CFE ± SEM I Conditioned
Medium
% CFE ± SEM
250 20 66±0 86
RPMI 2650
125 18 89±0 73 Rl(10x) 1 18±0 19
Rl(5x) 0 39±0 06
50 16 10±0 62 Rl(lx) 0 00±0 00
25 14 26±1 93 MEM 0 04±0 05
5 6 68±0 84
2 5 5 89±0 73 HEP-2
R10-30(lOx) 0 OOiO.OO
0 25 0 12±0 00 R30(lOx) 0 00±0.00
neat (lx) 0 04±0 05
HF 12 0 00±0 00
ATCC 0 04±0 05
TGFa(ng/ml)
FIGURE 3 3 1 Standard curve of TGF~a activity
The estimated TGF-a-like activity present in the CM samples was 
determined by comparison with the standard curve and are shown 
below in Table 3 3.2
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TABLE 3 3 2 Estimated levels of TGF-a in neat CM from different 
cell lines
Cell line TGF-a-like
activity
(ng/ml)
RPMI 2650
Rl(10x) 0 50
HEP-2
R30(10x) ooo
R10-30(lOx) o o o
Unconcentrated 0 00
3 3 2 Standard curve of TGF-fi activity in the NRK-49F soft agar 
assay
The presence of TGF-fl biological activity in the RPMI 2650 CM was
determined (using the NRK-49F bioassay, see Section 3 3 3 2, below)
by comparing two fractions of CM to a standard curve of TGF-J3 CM 
from other cell lines (BSC-1 and MSV-3T3) were also assayed A 
standard curve of TGF-fl activity was set up as follows TGF-Æ was 
dissolved in DME supplemented with 4 mmol HCl/1 mg/ml BSA Two
stock concentrations were made up (100 ng/ml and 10 ng/ml) with DME 
and from these Samples 1-4 and 5-7 (see Table 3 3 3) were prepared 
The appropriate controls containing HCl/BSA at the concentration of 
the stock solutions were assayed along with the prepared TGF-B
standards
RPMI 2650 conditioned medium was concentrated lOx using a 30,000 MW 
cut-off ultrafiltration membrane (R30) The filtrate was then 
concentrated lOx using a 5,000 MW cut-off membrane (R5-30) Both 
these concentrates were diluted back to lx with MEM Conditioned 
medium from the cell line BSC-1 (a known producer of TGF-fi), 
collected in MEM, was included as a positive control This CM was 
concentrated lOx using a 10,000 MW cut-off membrane and dilutions 
were made as indicated MSV-3T3 conditioned medium, collected in 
DME, and concentrated lOx using the 1,000 MW ultrafiltration 
membrane was also assayed
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Activity in the absence of EGF did not exceed control levels 
(0.02±0 02) for any sample and so is not included This assay was 
performed twice and the trends were comparable Table 3 3.3 shows 
the results obtained from a single assay
TABLE 3 3 3 Standard Curve of TGF-B activity m  the NRK-49F soft 
agar bioassay
Sample TGF-B
(ng/ml)
% CFE ± SEM Sample TGF-B
(ng/ml)
% CFE ± SEM
1 2 0 3 92±0 09 5 0 2ng 1 22±0 03
2 1 5 3 81±0 05 6 0 lng 0 88±0 03
3 1 0 4 02±0 08 7 0 05ng 0 50±0 02
4 0 5 3 06±0 06
i
Control 0 66±0 01 Control 0 36±0 02
TABLE 3 3 4 TGF-B activity of CM from three different cell lines
RPMI 2650 BSC-1 MSV-3T3
R30 R5-30 R10 R1
lOx 3 69±0 13 1 49±0 02 2 85±0 06 0 04±0.01
5x 2 47±0 03 0 94±0 01 N D 0 32±0 02
lx 1 65±0 01 0 21±0 01 0 43±0 01 0 13±0.01
Control 0 18±0 01 0 18±0 01 0 31+0 01
The relationship between the log(TGF-B) concentration and the 
colony forming efficiency of NRK-49F cells m  soft agar is shown m  
Figure 3 3 2, which illustrates its linearity Comparison of the 
activity of the different CM samples against this standard curve 
gives an indication of the TGF-B-like activity The calculated 
values are shown in Table 3 3 3, above
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r ~
TG F0(ng/m l)
FIGURE 3 3 2 Standard Curve of TGF-fi Activity in the NRK-49F soft 
agar bioassay m  the presence of EGF (2ng/ml)
TABLE 3 3 5 Calculated levels of TGF-B in CM from different cell 
lines
Conditioned
Media
jTGF-fl-like
activity
(ng/ml)
RPMI 2650
R30 0 91
R5-30 0 11
BSC-1 0 37
MSV 3T3 0 00
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3.3*3 Effect of pure growth factors in the transforming growth 
factor a and 13 soft agar assay systems
3*3 3 1 TGF-a Assay
Stxmulation of colony forming efficiency of NRK cell m  soft agar 
is a standard procedure for the measurement of TGF-like activity in 
conditioned media (Todaro and deLarco, 1978) As demonstrated in 
Table 3 3 2, the conditioned medium from RPMI 2650 cell exhibited 
this activity, but TGF-a did not cause stimulation in the autocrine 
assay system (see Table 3 2 8) The purpose of this experiment was 
to determine what other growth factors besides TGF-a can elicit a 
stimulatory response in the TGF-a bioassay
The pure growth factors were made up as described in Materials and 
Methods and assayed at the concentrations indicated Each
experiment was repeated and the results were comparable The data 
for each repeat experiment are presented m  Tables 3 3 6 and 3 3 7
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TABLE 3 3 6 Effect of EGF, TGF-a, Bombesin, IGF I and IGF II on
colony formation in the NRK soft agar assay
Growth Factor conc /dish
% CFE ± SEM
ASSAY 1 ASSAY 2
EGF 4 Ong 4 71±0 24 16 88±2 02
2 Ong 6 85±1 01 17 61±0 67
1 Ong 5 77±1 27 14 80±0 91
TGF-a 50 Ong 7 40±1 75 17 66±0 43
5 Ong 6 81±1 84 17 10+1 44
0 5ng 1 51±0 43 8 10±0 34
Bombesin 100 Ong 0 08±0 00 0 00±0 00
10 Ong 0 00±0 00 0 00±0 00
1 Ong 0 00±0 00 0 00±0.00
IGF I 100 Ong 0 16+0 00 0 47±0 17
50 Ong 0 08±0 08 0 10±0 09
10 Ong 0 00±0 00 0 00±0 00
1 Ong 0 00±0 00 0 00±0 00
IGF II 100 Ong 0 00±0 00 0 00±0 00
50 Ong 0 00±0 00 0 00±0 00
10 Ong 0 00±0 00 0 00±0 00
ATCC+lmg/ml BSA 0 00±0 00 0 05±0 09
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TABLE 3 3 7 Effect of EGF, TGF-fi, PDGF, aFGF, bFGF and Insulin on 
colony formation in the NRK soft agar assay for 
TGF-like activity
Growth Factor Conc/ml
%, CFE ± SEM
ASSAY 1 ASSAY 2
EGF 4 Ong 5 49±1 02 10 93±1 08
2 Ong 3 80±0 23 7 82±0 93
1 Ong 1 28±0 28 4 71±1 19
TGF-J3 2 Ong 0 03±0 03 0 03±0 03
0 2ng 0 03±0 03 0 03±0 03
0 02ng 0 00±0 00 0 03±0 03
PDGF 2 units 0 00±0 00 0 00±0 00
control 0 00±0 00 0 00 + 0 00
aFGF+hepann 50 Ong 0 00±0 00 0 00±0 00
5 Ong 0 00±0 00 0 00±0 00
0 5ng 0 00±0 00 0 00+0 00
bFGF 50 Ong 0 00±0 00 0 57 + 0 39
5 Ong 0 00±0 00 0 00±0 00
0 5ng 0 00±0 00t 0 00±0 00
Insulin 500 Ong 0 00±0 00 0 00±0 00
50 Ong 0 00±0 00 0 00±0 00
5 Ong 0 00±0 00 0 o+ioo 00
ATCC 0 00±0 00 0 00±0 00
ATCC+lmg/ml BSA 0 00±0 00 0 00+0 00
Heparin 0 00±0 00 0 00±0 00
As expected TGF-a and EGF stimulate NRK cells in agar IGF I was 
also stimulatory No other growth factor assayed could support NRK 
colony formation
3 3 3 2 TGF-ii assay
Conditioned medium from RPMI 2650 cells is capable of stimulating 
NRK-49F cells in the presence of EGF The assay procedure is 
standard for determination of the presence of TGF-fi It was shown 
in Table 3 3 5 that RPMI 2650 CM contains levels of TGF-ii-like 
activity The stimulation due to pure TGF-B m  the autocrine assay 
was variable (see Tables 3 2 4-6) The aim of these experiments 
was to determine other growth factors that may cause a similar 
stimulation to TGF-fl m  the NRK-49F bioassay
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The growth factors were made up as before and assayed in the 
NRK-49F soft agar assay with and without 2 ng/ml EGF The results 
are presented in Table 3 3 8
TABLE 3 3 8 Effect of EGF, TGF-a, bombesin, IGF I and II in the 
NRK-49F soft agar assay
Growth Factor conc /dish
% CFE ± SEM
+ EGF - EGF
EGF 4 Ong 1 o+»o00 67 1 72±0 72
2 Ong 1 50±0 21 1 o+i00iH 02
1 Ong 1 62 ±0 14 1 07±0 28
TGF-a 50 Ong 1 10±0 26 1 03±0 08
5 Ong 1 52 ±0 29 0 83±0 08
0 5ng 1 27±0 01 0 02±0 02
Bombesin 100 Ong 1 17 ±0 09 0 01±0 01
10 Ong 1 51±0 17 0 00±0 00
1 Ong 1 33±0 26 0 00±0 00
IGF I 100 Ong 4 81±0 55 0 47±0 17
50 Ong 3 33±0 62 0 10±0 09
10 Ong 2 28±0 55 0 00±0 00
1 Ong 1 99±0 38 0 00±0 00
IGF II 100 Ong 1 67±0 38 0 00±0 00
50 Ong 0 98±0 08 0 00±0 00
10 Ong 1 30±0 29 0 00±0 00
ATCC 0 71±0 26 0 00±0 00
ATCC+lmg/ml BSA 1 28±0 24 0 00±0 00
Control* 1 23±0 14 0 00±0 00
* Control for IGF I and 11=1/20 dilution (10 mmol HCl+1 mg/ml BSA) in
ATCC+1 mg/ml BSA
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TABLE 3 3 9 Effect of EGF, TGF-fi, PDGF, aFGF, bFGF and insulin m
the NRK-49F soft agar assay
Growth Factor conc /dish
% CFE i: SEM
+ EGF - EGF
EGF 4 Ong 0 03±0 00 0 01±0 01
2 Ong 0 00±0 00 0 00±0 00
1 Ong 0 02±0 02 0 00±0 00
TGF-J3 2 Ong 2 33±0 25 0 00±0 00
0 2ng 0 33±0 04 0 00±0 00
0 02ng 0 02±0 02 0 00±0 00
PDGF 2 units 1 28±0 20 0 01±0 01
control Contaminated 0 00±0 00
aFGF+heparm 50 Ong 0 00±0 00 0 00±0 00
{10ng/ml) 5 Ong 0 00±0 00 0 00±0 00
0 5ng 0 01±0 01 0 00±0 00
bFGF 50 Ong 0 02±0 02 0 57 + 0 39
5 Ong 0 00±0 00 0 00±0 00
0 5ng 0 00±0 00 0 00 + 0 00
Insulin 500 Ong 0 00±0 00 0 00±0 00
50 Ong 0 08±0 05 0 00±0 00
5 Ong 0 08±0 05 0 00±0 00
ATCC 0 00±0 00 0 00±0 00
ATCC+lmg/ml BSA 0 00±0 00 0 00±0 00
Heparin 0 00±0 00 0 00±0 00
Only TGF-J3 showed additional stimulation above the control in the 
presence of EGF The effect of IGF I was further examined with IGF 
from two separate sources (c f Section 3 3 2) The results are 
presented in Table 3 3 10
86
TABLE 3 3 10 Effect of IGF I (from 2 separate sources), IGF II,
insulin and TGF-ß in the NRK-49F soft agar assay.
IGF I-P=recombinant IGF from S c e r e v i s a e  (Promega)
IGF I-B=recombmant IGF from E coli (Boehringer Mannheim)
Growth Factor conc /dish
%, CFE ± SEM
+ EGF - EGF
IGF I-P 50 Ong 0 48±0 01 0 02±0 02
10 Ong 0 2 5±0 01 0 02±0 00
5 Ong 0 22 ±0 04 0 01±0 01
1 Ong 0 08±0 01 0 01±0 01
IGF I-B 50 Ong 0 17±0 06 0 01±0 01
10 Ong 0 12±0 04 0 00±0 00
5 Ong 0 14±0 04 0 00±0 00
1 Ong 0 04±0 04 0 00±0 00
IGF II 50 Ong 0 18±0 03 0 00±0 00
10 Ong 0 05±0 02 0 00+0 00
5 Ong 0 12±0 04 0 00±0 00
1 Ong 0 07±0 02 0 00±0 00
Insulin 50 Ong 0 07±0 00 0 00±0 00
5 Ong 0 10±0 03 0 00±0 00
1 Ong 0 07±0 02 0 00±0 00
TGF-B 0 2ng 0 19±0 13 0 00±0 00
0 lng 0 18 + 0 09 0 00±0 00
0 02ng 0 20 + 0 05 0 00±0 00
0 002ng 0 10±0 06 0 00±0 00
ATCC 0 00±0 00 0 00±0 00
ATCC+lmg/ml BSA 0 04 + 0 00 0 00 + 0 00
As in Table 3 3 8, IGF I appears to be stimulatory above the 
controls in the presence of EGF m  this experiment The TGF-J3 
samples were not particulary stimulatory due to the low 
concentration assayed, here
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3 4 STIMULATION OF RPMI 2650 CELLS IN SOFT AGAR BY CONDITIONED
MEDIA FROM VARIOUS CELL LINES
Conditioned media from cell lines that have been shown to possess 
autocrine activity were tested in the autocrine assay to investigate 
their effects on the stimulation of colony formation of the RPMI 2650 
cells in soft agar
The activity was compared with that obtained using a Rl(10x) fraction 
of RPMI 2650 CM CM from SCC9 and HEP2D cell lines were assayed neat 
and dilutions were made up with the appropriate media The results 
are presented in table 4 1
TABLE 4 1 Effect of conditioned media from different cell lines in 
the RPMI 2650 autocrine assay
RPMI 2650 SCC 9 HEP2D
Rl(10x) 4 46±1 13 
Rl(5x) 4 15±0 50 
MEM 2 13±0 57
Neat 1 81±0 11 
h 2 20±0 35 
ATCC 3 24±0 43
Neat 3 10±0 77 
h 2 29±0 63 
DME 2 05±0.35
RPMI 2650 conditioned media stimulated the soft agar growth by more 
than two fold above the medium control Neat CM from SCC 9 cells was 
inhibitory in the assay and this inhibition was dilutable CM from 
HEP2D cells exhibited some stimulation and again this effect was 
dilutable
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3 5 CHARACTERISATION OF THE RPMI 2650 AUTOCRINE STIMULATORY 
ACTIVITY
3 5 1 Concentration of the autocrine activity
Neat conditioned medium (CM) was sometimes active in the autocrine 
assay but the level of stimulation was normally quite low and made 
determination of activity and losses in activity particularly 
difficult to determine This is illustrated in Table 3 5 1, where 
the percentage colony forming efficiency of neat and concentrated 
CM are compared for four independent assays with different batches 
of CM The CM was concentrated by ultrafiltration with a YM2 
membrane (1,000 MW cut-off) to one tenth of its original volume 
(Rl(10x))
TABLE 3 5 1 Comparison of autocrine activity between neat 
unconcentrated and concentrated conditioned 
media Fold stimulation is shown in parenthesis
MEM control Neat CM Rl(10x)
CM A 0 05±0 12 0 37±0 01 1 48±0 48
{7 4} {29 6}
CM B 0 04±0 01 0 33±0 07 0 92±0 11
{8 3} {23 0}
CM C 0 01±0 01 0 12±0 03 0 73±0 06
{12 0} {73 0}
CM D 0 16±0 04 0 23±0 11 1 45±0 31
{1 4} {9 1}
Table 3 5 1 illustrates how concentrating the CM can significantly 
increase the percentage stimulation of the RPMI 2650 cells in soft 
agar
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This table also gives an indication of the variability of both the 
assay system and the activity levels of the CM over a random 
number of assays and batches of CM
The backround level varied from minimal growth (CM C) to quite
high levels (CM D) This may be indicative of variation in the
cells used for the assay, since all other parameters were held
constant For each of these assays the cells were pretreated in a 
similar manner and fed with the same medium type supplemented with 
the same batch of FCS The passage numbers of the cells were also 
similar and only varied from passage 39 to 42
The following table illustrates the relationship of concentration 
of CM to autocrine activity Conditioned medium (CM) was
concentrated to the indicated concentrations through a 1,000 MW 
cut-off ultraflltration membrane (Rl) to 10 times its original 
concentration (10x) This CM was diluted with medium, as 
indicated, to show the linearity of autocrine activity in this
batch of CM before stability studies were carried out The results 
are shown in Table 3 5 2 i n % C F E ±  S E M  and the fold
stimulation of each sample above the MEM control is also
presented
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TABLE 3 5 2 Activity curve of conditioned medium Fold
stimulation is calculated by dividing by the % CFE 
of medium (MEM)
% CFE ± SEM
Fold
Stimulation
lOx 4 117±0 405 32
8x 3 627±0 865 28
6x 1 941±0 676 15
4x 1 697±0 514 13
2x 0 821±0 257 6
lx 0 459±0 074 4
0 lx 0 181±0 018 1
MEM 0 128±0 064
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FIGURE 3 5 1 Linearity of conditioned medium activity with 
concentration
This CM was a very active batch where a 1/10 dilution of CM still 
retained activity The CM could be diluted down to 7-5x without 
reducing its activity below 10 fold of the MEM control This CM 
was used for subsequent stability work
3 5 2 Collection of conditioned medium
The following experiment was set up to determine the optimum 
collection method of medium conditioned by RPMI 2650 cells
A number of 75cm2 flasks were set up with 4 x 106 cells on day 1 
and fed on day 4 On Day 6 the flasks were rinsed well with PBS 
and fed with medium without serum The flasks were divided into 
two sets, Set A and Set B
Set A - 24-hour collection for one week.
The conditioned medium was removed and replaced with fresh 
serum-free medium on a daily basis for seven days (CM1-7) At 
each collection one flask of cells was trypsinised and counted 
The viability of the cells was determined by trypan blue 
exclusion
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Set B - Collection at 24, 48, 72 and 96 hours
The medium was left conditioning for increasing periods of time 
48, 72 and 92 hours At each collection (CM 48 hrs-92 hrs) one 
flask of cells were counted and viability was estimated by trypan 
blue exclusion
The pH of each lot of CM was measured and the CM was concentrated 
by ultrafiltration using a CX-10 immersible unit (with a molecular 
weight cut-off of 10,000) to a concentration of 5x The results 
are presented m  the table below (Table 3 5 3)
TABLE 3 5 3 Comparison of different protocols for collecting CM
pH Total 
Count 
(x 107)
%
viability
% CFE+SEM Fold
Stimulation
Set A
CM 1 7 38 1 81 97 1 28±0 32 12 8
CM 2 7 26 0 91 97 2 36±0 44 23 6
CM 3 7 21 1 48 98 0 97±0 21 9 7
CM 4 6 83 2 76 96 2 08±0 47 20 8
CM 5 6 99 1 83 98 1 88±0 11 18 8
CM 6 7 12 1 67 93 1 31±0 15 13 1
CM 7 6 99 2 31 92 1 27±0 63 12 7
Set B
CM 48 hrs 7 07 1 17 95 1 85±0 48 18 5
CM 72 hrs 7 03 2 75 96 1 95±0 63 19 5
CM 96 hrs 6 95 1 64 96 0 67±0 24 6 7
MEM 0 10±0 02
The activities of the CM collected at different times do not 
appear to vary significantly over a seven day period of
collection After the first day of collection, the pH drops below
7 3 while the cell numbers per flask and their viabilities change 
remain fairly constant The viability of the cultures do not drop
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below 92% which is high for cells growing in serum free medium for 
one week, which presumably is a result of conditioning factors 
being released by the cells
The reduced activity m  CM 96 hrs may be due to protease activity. 
The concentration of secreted proteases increases the longer the 
cells are m  culture Many proteases may be released from dying 
cells as they lyse These proteases could act on proteins, 
including the autocrine factor(s), inactivating them
The pH of the conditioned medium drops below 7 0 in a number of 
samples, which may destroy acid sensitive autocrine growth 
factors in the CM (investigated in Section 3 5 4), and result in 
reduced activity
3 5 3 Temperature Stability
Conditioned medium, concentrated five fold by ultrafiltration 
using a 1,000 MW cut-off membrane (Rl(5x)), was dispensed into 
glass universals and exposed to the indicated temperatures for the 
lengths of time shown The samples were then centrifuged, filter 
sterilised and assayed by the RPMI 2650 autocrine bioassay The 
results are presented in Table 3 5 4
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TABLE 3 5 4 Temperature stability of the autocrine activity
Treatment % CFE ± SEM
Average activity 
remaining (%)
•P
» o O 1 230±0 250 100
65 °C/1 hour 0 384±0 110 29
100°C/3 mins 0 530±0 280 41
100°C/6 mins 0 256±0 064 18
100°C/20 mins 0 352±0 160 26
MEM 0 043±0 015
This experiment was repeated on 5 different occasions, each with 
similiar results Table 3 5 5 shows the average activity retained 
following heat treatment for the 5 sets of results It shows that 
65% of the activity is lost after boiling for 6 minutes
TABLE 3 5 5 Average autocrine activity remaining following 
temperature treatment
Treatment
Average 
% Activity 
Remaining
37 °C/1 hour 100
65 °C/1 hour 62
100°C/3 mms 61
100°C/6 mins 35
Calculated by R1(treated) - MEM(treated)
Rl(control) - MEM(control)
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These results demonstrate that the autocrine activity is sensitive 
to heat treatment and that prolonged exposure to high temperatures 
can further reduce the activity Boiling for 20 minutes does not 
completely eliminate the activity, indicating that there is a 
heat stable component in the CM
Temperature stability of the TGF-a-like activity in the CM was 
also assessed The samples from one set of experiments were 
assayed in the NRK bioassay for TGF-a-like activity The results 
are presented in Table 3 5 6 as percentage colony forming 
efficiency of NRK cells in soft agar
TABLE 3 5 6 Temperature stability of the TGF-a-like activity in 
conditioned medium using the NRK soft agar assay
Treatment % CFE ± SEM
Average 
activity 
remaining(%)
37 °C/1 hour 4 11 t o 34 100
65 °C/1 hour 2 52 ±0 24 53
100°C/3 mins 2 41±0 31 51
100°C/6 mms 2 16±0 65 45
MEM 0 00±0 00
It appears from this experiment that TGF-like activity is more 
heat stable than the autocrine activity Some TGF activity is 
lost in the R1 fraction on boiling, but not to the same extent as 
the autocrine activity
These results indicate that the activity remaining following heat 
treatment may be due to the presence of TGF-like molecules
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A R1 sample (concentrated as described previously througha 1,000 
MW cut-off membrane to a concentration of 7x) was exposed to pH 3 
and pH 9 for 1 hour at 4°C and then readjusted back to pH 7 4. 
Each sample was freeze-dried and reconstituted to the same volume 
m  water An untreated sample was also freeze-dried and 
reconstituted as a control The results are presented in Table 
3 5 7
TABLE 3 5 7 PH stability of RPMI 2650 autocrine activity
3 5 4. pH stability
% CFE i
-------- .---
: SEM
R1 (7x) MEM
Untreated 2 04±0 15 0 18±0 05
Freeze-dried 2 42±0 58 0 31±0 05
Acid treated 0 33±0 05 0 07±0 03
Base treated 0 52±0 12 0 07±0 04
This initial experiment indicated that the autocrine activity was 
somewhat acid and base sensitive, although residual activity 
remained following incubation at pH 3 and 9
The pH stability was then examined more closely by exposing 
concentrated CM (Rl(5x)) to a range of pH levels from 2 8 to 12 2 
5mls of the Rl(5x) conditioned media were dispensed out and 
treated with 5M NaOH and 5M HCl (volumes indicated in Table 
3 5 8) The pH of each sample was measured The samples were 
incubated at 4°C for 2 hours before the pH was readjusted to pH 
7 4-7 7 Osmolanty (Osm/kg) was also measured The treatments 
are summarised m  Table 3 5 8
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TABLE 3 5 8 PH stability of RPMI 2650 conditioned medium* 
Treatment with different volumes of 5M HCl and 5M 
NaOH
Sample Volume
added
Te
pH
St Volume
added
Final
PH
Osm/kg
1 50^1 HCl 2 8 SOf j l NaOH 7 6 0 325
2 20^1 HCl 4 3 I S f J Ï NaOH 7 7 0 291
3 l O f j l HCl 6 8 I Q f j l NaOH 7 5 0 276
4 5jul HCl 7 1 S f j l NaOH 7 5 0 288
5 no addition 7 2 no addition 7 2 0 298
6 S/j I NaOH 7 6 S j j l HCl 7 5 0 294
7 l O f j l NaOH 8 5 9/jl HCl 7 6 0 295
8 20/jI NaOH 8 8 1 2 f j l HCl 7 6 0 287
9 35^1 NaOH 11 0 30f u i HCl 7 6 0 325
10 50^1 NaOH 12 2 45^1 HCl 7 5 0 460
The osmolanty only reached excessively high levels for sample 
number 10 due to overshooting pH 7 5 when re-adjusting the pH
Each of the samples was filter sterilised and assayed in the RPMI 
2650 autocrine assay The resulting colony forming efficiency (%) 
and the percentage of activity remaining is presented in Figure 
3 5 2 and Table 3 5 9
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FIGURE 3 5 2 PH stability profile of autocrine activity
TABLE 3 5 9 Percentage of autocrine activity remaining following 
incubation for 2 hours at different pH levels. The percentage 
is calculated on the basis of sample 5 (untreated)
_  .. 
Sample pH
Activity 
remaining (%)
1 2 78 32
2 4.32 34
3 6.79 42
4 7 13 63
5 7 24 100
6 7 75 105
7 8 47 85
8 8 79 56
9 10.97 62
10 12 24 19
These results show that residual activity is still present in the 
conditioned media exposed to extreme pH levels Acid treatment
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resulted in a residual activity of 32% (based on the untreated 
sample, number 5), whereas slightly more activity remains 
following base treatment
The band, within which the autocrine activity is retained at high 
levels, is quite narrow, (between pH 7 24 and 8 24). This 
indicates that a proportion of the autocrine activity is 
particularly sensitive to extremes of pH. The high osmolanty 
levels in sample 10 may have contributed to its low activity (see 
Table 3 5 8)
3 5 5 PH stability of the heat stable activity
Conditioned medium was treated as m  Section 3 5 3 Each of the 
boiled samples were exposed to high (pH 12 2) and low (pH 2 8) 
extremes pf pH for 2 hours (as described m  Section 3 5 4) by 
addition of 30 pi of 5M NaOH or HCl The pH was re-adjusted to pH 
7 24-8 24 and the samples were filter sterilised The results are 
presented in Figure 3 5 3 and in Table 3 5 10 as percentage of 
remaining activity following treatment
FIGURE 3 5 3 pH stability of the heat stable activity m  RPMI 
2650 CM (R1(5x))
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TABLE 3 5 10 pH Stability of heat treated RPMI 2650 conditioned 
medium (Rl(5x)) (% activity remaining following treatment 
calculated as a percentage of untreated activity, based 
on the average % CFE for each sample)
Average % activity remaining
Sample Untreated Acid
treated
Base
treated
o O 100 40 65
100°C/3 mins 49 21 2
100°C/6 mins 18 3 3
100°C/20 mins 26 6 1
It can be seen from these results that exposure of the heat 
treated samples to extremes of pH eliminates the autocrine 
activity, reducing its activity down to control levels The 
experiment was repeated with comparable results
3 5 6 Heat stability of the acid- and base- stable activities
Samples 1, 2 and 3 (acid treated) and 8, 9 and 10 (base treated) 
(from Table 3 5 8) were pooled, boiled for 6 minutes, filter 
sterilised and assayed in the RPMI 2650 autocrine assay. The 
resulting % CFE ± SEM and the percentage of remaining activity are 
shown in Table 3 5 11
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TABLE 3 5 11 Heat stability of the autocrine activity in the acid 
and base treated RPMI 2650 CM (Rl(5x)) (% 
colony forming efficiency ± SEM, % activity 
remaining following treatment)
% CFE ± SEM % Activity Remaining
Sample Untreated 100°C
/6 mins
Untreated 100°C
/6 mins
4 °C
Acid (Ave) 
Base (Ave)
1 23±0 25 0 26±0 06 
0 44±0 28 0 25±0 05 
0 55±0 36 0 28±0 08
100 18 
38 18 
27 24
MEM 0 04±0 01
The results in Table 3 5 11 indicate that the acid- and base- 
stable activities are heat stable, as boiling for six minutes does 
not significantly reduce the activity further
The errors m  this experiment were quite large with nearly 50%
error This was due to the design of the experiment The values
for acid (average) and base (average) samples (untreated) were 
calculated from the values from samples 1-3 and 8-12 in Figure
A
3 5 9 These samples had been exposed to a range of pH levels from 
6 8-2 8 and 8 8-12 2, respectively Acid and base sensitive 
factors in the CM may not be inactivated completely by exposure to 
pH 6 8 or 8 8, and so this experiment was not a true indication of 
the heat stability of the acid and base stable factors
A second experiment was set up in which the CM was exposed to two 
extremes of pH before the boiling step
The same batch of Rl(10x) was brought to pH 12 2 and 3 4 with 5M
NaOH and HCl The samples were incubated for 2 hours at 4°C before
being readjusted to physiological levels as before The pH
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treated samples were then boiled for 6 minutes The results of 
the unboiled acid and base treated samples and the boiled samples 
are presented in the table and figure below
TABLE 3 5 12 Heat stability of the acid and base treated RFMI 2650 
CM (Rl(5x>) (% activity remaining following
treatment)
% Activity Remaining
Sample Untreated 100°C 
/6 mins
•£> o o 100 43
Acid treated 54 -1
Base treated 54 23
FIGURE 3 5 4 Heat stability of the acid and base stable activities 
in RPMI 2650 CM (Rl(5x))
These results illustrate that the acid- and base- stable entities
are sensitive to high temperatures. In both experiments, however, 
base treated CM is still partially heat stable
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The results above also indicate that molecules which retain 
activity at pH 6 8 are partially heat stable and on their removal 
{by acid treatment) the remaining activity in the CM can be 
eliminated by heat treatment
3 5 7 Protease stability of the autocrine activity
The stability of the autocrine effect following treatment by 
trypsin was examined Trypsin is a specific protease, acting on 
polypeptide chains by catalysing the hydrolysis of peptide bonds 
at either lysine or arginine residues
Rl(7x) and MEM were exposed to 10 ^g/ml trypsin for 2 hours at 
37°c before addition of 20 ^g/ml trypsin inhibitor Controls for 
this experiment were a R1 sample incubated with trypsin plus 
trypsin inhibitor for 2 hours {T + TI) and a R1 sample incubated 
only with trypsin inhibitor (TI) for 2 hours The results are 
presented m  % CFE ± SEM in Figure 3 5 5 and as the % of activity 
remaining following treatments in Table 3 5 15
3 0-r
2 5-
w
in 2 0-
+1 1 5-
O 1 0-
^ ^
0 5-
0 0
U ntreated T+TI TI
FIGURE 3 5 5 Protease stability of autocrine activity 
T = Trypsin (lOfjg/ml)
TI = Soyabean trypsin inhibitor
(see text for details of controls)
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TABLE 3 5 15 Protease stability of autocrine activity
Treatment % Activity remaining
37°C/2 hours 100
T + TI 76
TI 137
Trypsin 30
In an average of 4 similar experiments the activity lost by 
exposure to trypsin amounted to 57% of the controls and so it can 
be considered that the active fraction is at least partially due 
to protein material
105
3 6 ULTRAFILTRATION OF THE CONDITIONED MEDIUM
3 6 1 Fractionation of the autocrine activity by ultrafiltration
As shown previously (Section 3 5 1) the autocrine activity can be 
concentrated using ultrafiltration with a 1,000 MW cut-off 
membrane Initial size determinations were carried out on 
conditioned media using different molecular weight cut-off 
ultrafiltration membranes The conditioned medium was concentrated 
ten fold and diluted down to 7x, 5x, 3x, and lx with unconditioned 
medium (MEM) The results are presented in Table 3 6 1
Notation used
RI, R30 concentrated CM using the 1,000 and 30,000 MW
cut-off membranes 
FI, F30 filtrates from ultrafiltration of CM through the
1,000 and 30,000 MW cut-off membranes 
Rl-30 filtrate from the 30,000 MW membrane concentrated
through the 1,000 MW membrane (i e concentrated 
molecules between 1,000 and 30,000 MW)
TABLE 3 6 1 RPMI 2650 autocrine activity in conditioned medium 
following ultrafiltration through 1,000 and 30,000 
MW cut-off membranes
Sample lOx 7 x 5x 3x lx
R1
Rl-30
R30
1 25±0 14
0 25±0 07
1 02+0 22
0 77±0 09 
0 19±0 05 
0 52±0 09
0 48±0 07 
0 07+0 02 
0 26±0 03
0 22±0 05 
0 07±0 02 
0 15±0 02
0 10±0 05 
0 05±0.02 
0.03±0.03
FI
F30
0 05±0 02 
0 01±0 02
MEM 0 02±0 02
Autocrine activity is present in each of the fractions analysed. 
R1 and R30 concentrates have comparable activities, whilG the 
Rl-30 fraction in this particular assay has a lower activity The
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relative activities of the R30 and Rl-30 fractions seem to be a 
function of the batch of conditioned medium itself (see also 
Figures 3 6 1 and 3 8 3)
The Rl-30 fraction could be further fractionated into molecules 
between 1,000 and 10,000, and 10,000 and 30,000 using an 
ultrafiltration membrane with a 10,000 MW cut-off The results are 
presented m  Table 3 6 2, below
TABLE 3 6 2 RPMI 2650 autocrine activity in conditioned medium 
following ultrafiltration through 1,000, 10,000
and 30,000 MW cut-off membranes
Sample lOx 7x 5x 3x
R1
Rl-10
R10-30
0 41±0 11 
0 47+0 13 
0 38+0 09
0 62±0 18 
0 36±0 04 
0 30±0 08
0 41±0 03 
0 14±0 05 
0 13±0 05
0 47±0 09 
0 02±0 02 
0 09±0 05
MEM 0 04±0 02
It appears from these results that activity is derived from 3 sets 
of molecules, One set greater than 30,000 MW, a second set between
10,000 and 30,000 MW and a third set between 1,000 and 10,000 MW 
The R1 fraction would therefore contain a concentration of each of 
these entities The previous stability work, therefore, examined 
physiochemical properties of the bulk conditioned medium
In this section the properties of fractionated CM is investigated. 
To simplify the problem only two fractions were examined* R30 
(containing concentrated molecules over 30,000 MW) and Rl-30 
(containing concentrated molecules in the range 1-30,000 MW 
approximately)
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3 6 2 Temperature stability of fractionated CM
A batch of conditioned medium was ultrafiltered through a 30,000 
MW cut-off membrane down to a concentration of 7x (R30) The 
filtrate from this ultrafiltration step was then concentrated with 
a 1,000 MW membrane to 7x (Rl-30) This fraction contains 
molecules between 1,000 and 30,000 MW The same batch of CM was 
ultrafiltrated with a 1,000 molecular weight cut-off membrane 
(Rl) This concentrated all the molecules greater than 1,000 MW 
seven fold
Each of these fractions was exposed to a temperature of 100°C for 
3 minutes and 20 minutes The samples were then filter sterilised 
and assayed in the RPMI 2650 autocrine assay The results are 
presented in Figure 3 6 1 in the form of % CFE ± SEM and in Table 
3 6 3 in the form of percentage of activity remaining following 
the described treatments
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FIGURE 3 6 1 Heat stability of conditioned medium fractionated 
by ultrafiltration into molecules greater than 30,000 
MW (R30), molecules between 1,000 and 30,000 MW (Rl-30) 
and molecules greater than 1,000 MW The results are 
presented in the form of % colony forming efficiency
Boiling the Rl and Rl-30 retentâtes for 3 minutes resulted m  the 
loss of about half of the activity compared with the untreated 
samples Prolonged boiling (20 minutes) reduced the remaining 
activity further in both of these samples
The physiochemical profile for R30 was different Boiling for 3 
minutes did not significantly reduce the activity below the 
untreated sample Further boiling resulted m  stimulation of 
growth, more than doubling the activity found with the untreated 
control (although the % error in this sample was quite large) In 
repeat experiments autocrine activity of boiled R30 samples were 
also higher than control activities
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TABLE 3 6 3 Heat Stability of conditioned medium fractionated to 
7x by ultrafiltration into molecules greater than 30,000 MW 
(R30), molecules between 1,000 and 30,000 MW (Rl-30) and 
molecules greater than 1,000 MW (% remaining activity)
Sample
% activity remaining
Rl Rl-30 R30
4 °C 100 100 100
100°C/3 mins 50 45 91
100°C/20 mins 23 -46 364
3 6 3 Acid and base stabilities of the fractionated CM
A similar batch of CM was fractionated into Rl-30 and R30 
fractions as before Each sample, along with a Rl concentrate, 
were acid and base treated as m  Section 3 5 4 The treated 
samples were filter-stenlised and assayed in the RPMI 2650 soft 
agar assay The results are presented m  Figure 3 6 2 and in 
Table 3 6 4
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FIGURE 3 6 2 pH stability of conditioned medium fractionated to
7x by ultrafiltration into molecules greater than
30,000 MW (R30), molecules between 1,000 and 30,000 
MW (Rl-30) and molecules greater than 1,000 MW 
The results are presented m  the form of % 
colony forming efficiency
TABLE 3 6 4 pH Stability of conditioned medium fractionated 7x 
7x by ultrafiltration into molecules greater than 
30,000 MW (R30), molecules between 1,000 and 30,000 
MW (Rl-30) and molecules greater than 1,000 MW 
(% remaining activity)
Sample
% activity remaining
R1 Rl-30 R30
Untreated 100 100 100
Acid Treated 9 0 91
Base Treated 23 -9 164
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Acid and base treatment significantly reduced activity m  the R1
fraction and eliminated the autocrine activity in the Rl-30
sample While acid treatment had no significant effect on the R30
fraction, base treatment appeared to enhance it slightly
3 6 4 Boiling R30 fraction at low pH
Samples of R30(7x) and unconditioned medium (MEM) were acid 
treated (pH 3) and heat treated (boiled for 20 minutes) as before. 
An identical sample was boiled at pH 3 before being readjusted 
back to pH 7 4 A fourth sample was acid treated and then boiled
for 20 minutes The results are presented m  Table 3 6 5
TABLE 3 6 5 Stability of the autocrine effect to boiling under 
acidic conditions
Sample
% CFE i: SEM
R30 MEM
Untreated 0 38±0 03 0 02±0 02
Heat treated 0 33±0 03 0 02±0 03
Acid Treated 0 17±0 05 0 02±0 02
Heat treated
at pH 3 0 02±0 02 0 02±0 02
Acid treated,
heat treated 0 05±0 02 0 03±0 00
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following boiling for 20 minutes Acid treatment, here, however 
appears to reduce autocrine activity
Boiling the R30 fraction at low pH resulted in complete
elimination of activity in a one step procedure
The acid stable activity m  the R30 sample is destroyed by
boiling, this effect is similar to that observed in the bulk CM
(Section 3 5 6) suggesting that the stable activity in the R1 CM 
may be as a result of the acid stable entity in the R30 fraction
Again in this experiment, the autocrine activity is retained
3 6 5 Effect of boiling on the protease stability of the R30
fraction
The unusual heat stability profile of the CM was examined with
regard to protease stability Samples of R30 (untreated) and R30
(boiled for 20 minutes) were prepared as before Each sample,
along with a medium control (MEM) and medium boiled for 20
minutes, was subjected to the same treatments as described in
Section 3 5 7 The results are presented in Figure 3 6 3 and in
Table 3 6 6 as the average percentage of activity remaining
following treatment
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Untreated Boiled
L = = = = = = = = = = = = = = = = = = = = = = _ _ _ _ _ _ ______________________
FIGURE 3.6.3 Comparison of the protease stabilities of R30 
fractions before and after boiling for 20 minutes
TABLE 3.6.6 Comparison of the protease stabilities of R30 
fractions before and after boiling for 20 minutes
Treatment
% activity remaining
R30 R30 boiled
Untreated 100 100
Trypsin (T) 78 27
T + T inhibitor 90 96
T inhibitor 100 98
This experiment was repeated with comparable results.
114
No activation above the level of stimulation of the R30 sample was 
observed on boiling, but most of the activity was retained
Unboiled R30 is not particulary sensitive to trypsin, this might 
account for the residual 30 % activity on protease treatment of
the bulk R1 CM (Section 3 5 7)
Boiled R30 is trypsin sensitive, but not all its activity is 
removed Trypsin acts by hydrolysing the peptide bonds at either 
lysine or arginine This result would suggest that either boiling 
removes a binding moiety that blocks these residues leaving the 
molecule more susceptible to protease attack or boiling, results 
in loss of a conformatlonally stable form, exposing sites in the 
molecule where the trypsin can act
3 6 6 Diafiltration of the R30 and boiled R30 samples
The aim of this experiment was to investigate the hypothesis that 
a large binding molecule is removed from the R30 autocrine factor 
on boiling resulting in an active fraction with a lower molecular 
weight
In this experiment R30 and a boiled sample of R30 were diafiltered 
using a 30,000 MW cut-off membrane Their filtrates were 
concentrated with the 1,000 MW cut-off (Filt-Rl-30) In this way, 
if the R30 fraction is broken down into smaller active components 
the activity will be concentrated in Filt-Rl-30 fraction, rather 
than the R30 fraction The results are shown m  Table 3 6 7
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TABLE 3 6 7 Diafiltration of the R30 and boiled R30 fractions. 
All samples were concentrated to lOx
Treatment
% CFE ± SEM
R30 R30 boiled
Untreated 
diafiltered R30 
Filt-Rl-30
0 38±0 03 
0 14±0 04 
0 25±0 02
0 33±0 03 
0 11±0 05 
0 16±0 03
Control (MEM) 0 02±0 02
Again in this experiment, while no activation occurs, the results 
demontrates that the R30 activity is retained following extensive 
boiling
Diafiltration reduces the activity of both the boiled and unboiled 
R30 samples This may be due to the presence of molecules in the 
range 1,000-30,000 MW being removed from the R30 fraction by 
diafiltration where they are present at a Ix concentrations These 
molecules were then concentrated in the Filt-Rl-30 fraction, where 
their activity was detected
The boiled R30 fraction exhibited lower levels of activity in the 
Filt-Rl-30 concentrate This is due to the inactivation of the 
smaller (temperature sensitive) molecules by boiling for 20 
minutes
It does not appear from these results that boiling causes a large 
molecule to break down to smaller sized molecules (less than
30.000 MW), since the trend of the activity remains the same 
before and after boiling (except for the loss m  activity of the 
heat labile Rl-30 fraction) It is possible however that removal 
of a binding moiety may result m  active molecules greater than
30.000 MW which will not be revealed by this experiment
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It is unlikely, therefore, that boiling alters the R30 fraction in 
a way that would render the molecule similar to the Rl-30 
fraction It may be assumed therefore that at least two distinct 
entities are involved in the autocrine activity of the CM
3 6 7 Fractionation of the TGF-a-like activity
The samples from the fractionation experiment (Table 3 6 1) were 
also assayed in the NRK soft agar assay for the detection of 
TGF-a-like activity The results are presented in Table 3 6 8 as 
% colony forming efficiency of NRK cells
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TABLE 3 6 8 TGF-a-like activity in conditioned medium following 
ultrafiltration through 1,000 and 30,000 MW cut-off 
membranes
Sample lOx 7x 5x 3x lx
Rl
Rl-30
R30
N D 
0 08±0 08 
0 00+0 00
0 53±0 15 
0 00±0 00 
0 00±0 00
0 21±0 15 
0 00±0 00 
0 00±0 00
0 11±0 08 
0 00±0 00 
0 00±0 00
0 00±0 00 
0 00±0 00 
0 00±0 00
FI (lx) 
F30(lx)
0 00+0 00 
0 00±0 00
MEM 0 00±0 00
N D = Not Determined
Activity appears to manifest only m  the Rl fraction but it is 
lost when the Rl is fractionated into large and small molecules. 
This would make it seem that the activity is dependant on the 
presence of both fractions and so is a more complicated event than 
simply the presence of TGF-a-like molecules
3 6 8 Fractionation of the TGF-13-like activity
The samples from the fractionation experiment (Table 3 6 1) were 
also assayed in the NRK-49F soft agar assay for the detection of 
TGF-fi like activity The results are presented in Table 3 6 9 as 
% colony forming efficiency of NRK-49F cells in the absence of EGF 
and Table 3 6 10 in the presence of 2 ng/ml EGF
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TABLE 3 6 9 Stimulation of NRK-49F in soft agar without EGF 
by conditioned medium following ultrafiltration 
through 1,000 and 30,000 MW cut-off membranes
Sample lOx l x 5x 3x lx
R1
Rl-30
R30
0 13+0 05 
0 00±0 00 
0 00±0 00
0 00±0 00 
0 00+0 00 
0 00±0 00
0 00±0 00 
0 00±0 00 
0 00±0 00
0 00±0 00 
0 00+0 00 
0 00±0 00
0 00±0 00 
0 00+0 00 
0 00±0 00
FI (lx) 
F30(lx)
0 00±0 00 
0 00+0 00
MEM 0 00±0 00
N D = Not Determined
TABLE 3 6 10 Stimulation of NRK-49F in soft agar with 2 ng/ml EGF 
by conditioned medium following ultrafiltration 
through 1,000 and 30,000 MW cut-off membranes.
Sample 7x 5x 3x lx
R1
Rl-30
R30
47 92±9 34 
0 00±0 00 
25 38+2 49
39 78±13 21 
0 00±0 00 
19 57±0 00
N D 
0 00±0 00 
14 02±3 09
7 03±1 69 
0 00+0 00 
2 91±0 29
FI (lx) 
F30(lx)
N D 
N D
MEM 0 00±0 00
N D = Not Determined
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TGF-/3 activity in the R1 fraction appears to be derived from 
molecules greater than 30,000 MW, and this activity is dilutable 
The reduction in activity between R1 and R30 however, maybe due to 
some synergy with factors in the Rl-30 fraction This result 
supports the results presented previously in Section 3 3 2
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3 7 PURIFICATION OF THE RPMI 2650 AUTOCRINE ACTIVITY
A number of strategies were employed to attempt to partially purify 
the RPMI 2650 autocrine activity Purification methods included ion 
exchange chromatography, hydrophobic interaction chromatography 
and heparin sepharose chromatography
3 7 1 Effect of dialysis on the autocrine activity
In the course of this part of the thesis a number of purification 
procedures were examined which required dialysis of concentrated 
conditioned media Comparison between the activity of dialysed and 
undialysed concentrated CM (to the indicated levels by 
ultrafiltration through a 1,000 MW cut-off membrane) is presented 
m  Table 3 7 1 for four independent assays
TABLE 3 7 1 Effect of dialysis on different batches of CM m  a 
number of different assays
Assay R1
% CFE ± SEM
% Activity 
Remaining 
after 
dialysisUndialysed Dialysed Control
1 14x 5 08±0 38 2 90±0 10 0 40±0 04 53%
2 lOx 2 17±0 35 0 36±0 07 0 13±0 06 11%
3 lOx 1 48±0 84 0 47±0 43 0 05±0 12 29%
4 7x 1 72±0 32 0 37+0 25 0 05+0 12 20%
As can be seen from these results, substantial loss in activity 
occurs on dialysis This may be due to a number of factors
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(a) Autocrine Activity may "stick" to the dialysis bags Following 
dialysis the tubing had adsorbed quite an visible amount of phenol 
red. It is possible that the autocrine activity may adsorb to the 
membrane m  a similar manner
(b) Inadaquate washing of dialysis tubing The dialysis tubing is 
stored at 4°C in benzoate preservative Before use, the tubing is 
boiled extensively m  lOmM EDTA and then rinsed well m  ultrapure 
water Insufficient rinsing of these compounds could perhaps result 
in reduced cell growth
(c) Removal of molecules less than the cut-off MW of the membrane. 
The MW cut-off of the tubing used was 1,200 daltons This should 
ensure that most of the active molecules greater than 2,000 MW will 
be contained m  the dialysis bags
3 7 2 Effect of dialysis on TGF-a activity
Dialysis is a common procedure in published purification protocols 
for TGFa To investigate if the failure to dialyse the autocrine 
activity may be due to either material or technical problems, TGF-a 
activity levels were detemined before and after dialysis for a 
similar sample of CM
CM concentrated to lOx by ultrafiltration with a 1,000 MW cut-off 
membrane was dialysed using the same dialysis tubing as in Section 
3 7 1 (1,200 MW cut-off) Dilutions of the dialysed and undialysed 
samples were assayed in the TGF-a soft agar bioassay to determine 
if dialysis would cause a reduction in activity The results are 
presented in Table 3 7 2
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TABLE 3 7 2 Dialysis of TGF-a activity in RPMI 2650 CM
Rl
% CFE i: SEM
Undialysed
.
Dialysed
lOx 2 85±0 71 2 77±0 00
5x 1 34±0 29 1 98±0 36
lx 0 04±0 05 0 00±0 00
MEM 0 00±0 00
This result shows that CM can be safely dialysed without loss of 
TGF-a activity This experiment was carried out independently from 
the assays in Table 3 7 1, with different batches of CM and 
dialysis tubing, the procedure, however, was identical This result 
suggests that the washing procedure of dialysis tubing is adequate, 
discounting possibility (b) m  Section 3 7 1, although it does not 
rule out the possibility that there may be a fault in the 
particular batch of dialysis tubing used for the autocrine assays
3 7 3 Ion-Exchange Chromatography
Conditioned media concentrated 14x by ultrafiltration with a 1,000 
MW membrane were incubated with anion exchange (Cellex-D) and 
cation exchange (Cellex-CM) gels Fractions were equilibrated with 
different pH buffers Each fraction was dialysed before being 
filter sterilised and assayed in the autocrine assay The results 
are presented in Table 3 7 3
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VTABLE 3 7 3 Autocrine activity following treatment with 
ion-exchange resins (% CFE ± SEM)
Controls
Anion exchanger 
(DEAE)
Cation Exchanger 
(CM)
pH % CFE±SEM PH % CFEiSEM
Rl(14x) 5 08±0 38 5 0 0 19±0 09 4 0 0 13±0 01
Rl(7x) 4 58±0 42 5 6 0 20±0 06 4 4 0 02±0 01
Rl(14x) 6 0 0 30±0 10 4 8 0 08±0 03
dialysed 2 90±0 10
6 4 0 22±0 03 5 2 0 09±0 02
MEM 0 40±0 04
6 8 0 21±0 07 5 6 0 05+0 03
7 1 0 10±0 02 6 0 0 02±0 01
7 4 1 91+0 40 6 4 0 04±0 03
7 8 0 11±0 03 6 8 0 03±0 01
8 2 0 06±0 04 7 2 0 07±0 06
8 6 0 03±0 01 7 9 0 06±0 02
8 9 0 04±0 02 8 0 0 04±0 03
The conditioned media used in this experiment was particularly 
active A 14x concentrate exhibited high autocrine activity (12 7 
fold above the control) Diluting this activity down to 7x showed 
comparable activity This apparently is the upper limit of the 
linearity of this CM sample
Dialysing the Rl(14x) concentrate in the same way as the samples 
from the ion exchange column resulted in a reduction of autocrine 
activity of (on average) 53% This is discussed m  Section 3 7 1.
Activity was below control levels for most of the samples assayed 
The one exception to this was the sample, DEAE(7 4), where 32% 
of the activity was eluted
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The inability of this procedure to concentrate activity may be due 
to a number of reasons Firstly the autocrine activity is 
particulary pH sensitive and exposure to the pH extremes used in 
the ion exchange chromatography, would undoubtedly eliminate the 
activity Although from the stability experiments it would be 
expected that the activity would be reduced by about 20% of the 
untreated sample In these samples from the ion-exchange column 
the activity is less than the MEM control This indicates that the 
loss m  activity in the CM is not due solely to the adverse pH 
conditions Secondly, each of the samples were dialysed It was 
shown m  section 3 7 1 that dialysis does have a detrimental effect 
on the autocrine activity A combination of these two effects may 
result m  complete inactivation
3 7 4 Hydrophobic Interaction Chromatography
A 4ml phenyl sepharose column was equilibrated for 1 hour with MEM 
that had been concentrated to 4x by ultrafiltration using a YM 2 
(1,000 MW cut-off) membrane 10 mis of Rl(10x) was applied and then 
eluted with 50% glycerol in 5x MEM 4ml fractions were collected 
Each fraction was dialysed against PBS for 24 hours and MEM for 12 
hours In some samples this resulted in a volume change The 
experimental details of the diaysis step and the optical densities 
measured at 280nm are shown in Table 3 7 4 The samples were then 
assayed in the RPMI 2650 soft agar autocrine assay The activities 
are presented in % CFE ± SEM in Table 3 7 5
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TABLE 3 7 4 Dialysis of fractions from hydrophobic interaction 
column and a CM control OD(280) are also presented.
Sample Initial Final OD
Volume Volume 280
Wash
1 3 7 3 7 0 939
Sample Breakthrough
2 4 0 3 7 0 804
3 3 9 3 5 0 879
4 3 8 3 5 0 736
Elution with 50% Glycerol
5 3 9 3 4 0 825
6 3 9 3 4 0 603
7 3 0 7 0 0 531
Control
R1 (lOx) dialysed 3 5 3 5 1 125
TABLE 3 7 5 Autocrine Activities (% CFE ± SEM) of fractions 1-7 
(see Table 3 7 4) from the hydrophobic 
interaction (phenyl sepharose) column
Controls % CFE ± SEM Sample % CFE ± SEM
R1 (lOx) 2 17 + 0 35 1 0 09±0 04
R1 <2x) 0 54±0 03 2 0 10+0 03
R1 (lOx) dialysed 0 36±0 07 3 0 11±0 02
R1 (2x) dialysed 0 34 + 0 08 4 0 05±0 04
5 0 14±0 05
MEM 0 13±0 06 6 0 08±0 04
MEM(4x) 0 18±0 02 7 0 20±0 05
The conditioned media used in this experiment was quite active 
giving on average a 12 fold stimulation above that of the MEM (4x) 
control Again following dialysis this activity is reduced to 
approximately 2 fold stimulation
126
It appears from this experiment that some activity has an affinity 
for the column and is retained after extensive washing, although 
the eluted activity is not as high as the CM controls This, 
however, may be due to the dialysis step
3 7 5 Heparin Sepharose Chromatography
3 7 5 1 Step Elution
100 mis of conditioned medium was incubated overnight with 4mls of 
heparin sepharose gel at 4°C (stirred) The heparin sepharose gel 
was allowed to settle for 30 minutes and the supernatant was 
removed (approximately 90 mis) The gel was washed with 60mls of
0.01M Potassium Phosphate buffer and loaded into a column The 
column was washed through with a further 30mls of buffer This 180 
mis (approximately) constituted the unbound sample and was 
ultrafiltered down to 10 mis with a 1,000 MW cut-off membrane to 
give a unbound fraction concentrated 10 fold from its original 
volume (100 mis)
Batches of 20mls of buffer containing 0, 0 25, 0 5, 0 8, 1 0, 1 2, 
1.5, 2 and 3M NaCl were passed sequentially through the column 4 
ml fractions were collected and OD(280) was read Each fraction was 
filter sterilised before assaying m  the RPMI 2650 autocrine assay. 
The results are presented m  Table 3 7 6 and Figure 3 7 1
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FIGURE 3 7 1 Heparin Sepharose Chromatography of RPMI 2650 CM by step
elution (bar= % CFE ± S E M ,  dotted line- NaCl ( M ) , Continous 
line = OD280) The optical density (280 Dm) for neat CM was equal 
to 0 858 and unbound fraction (lOx), 1 154)
TABLE 3 7 6 Autocrine activity of non-heparin binding autocrine 
activity (dilution curve), concentrated CM (Rl), 
unconcentrated CM (CM(neat)), and unconditioned 
medium (MEM) The bound activity was eluted stepwise 
and its activity is presented in Figure 3 7 1
Controls % CFE ± SEM Unbound % CFE ± SEM
Rl(7 5x) 1 429+0 454 (lOx) 0 288 + 0 045
Rl(2 5x) 0 192±0 032 (7 5x) 0 288 + 0 064
Rl(lx) 0 171 + 0 033 (5x) 0,>171+0 037
CM(neat) 0 139±0 018 (2 5x) 0 064+0 032
MEM 0 000±0 000 (lx) 0 032±0 032
Conditioned medium which had no affinity for heparin sepharose was 
found to exhibit autocrine stimulation when concentrated with a
1,000 MW cut-off membrane The level of stimulation was not as high 
as the conditioned medium that had been concentrated 7 5x by 
ultrafiltration , indicating the possiblility of some autocrine 
activity being retained on the column
Eluting the column with increasing salt concentration resulted in a 
number of activity peaks A small peak of autocrine activity was 
isolated at a salt concentration of 0 25M NaCl and a larger peak 
was eluted at 0 5M NaCl Above 1M NaCl little or no growth was 
observed Similar results were obtained over four repeat 
experiments
Control levels of growth in this assay was particularly low and so 
discriminating between inhibition and lack of stimulation was 
difficult
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3 7 5 2 Dxafiltration of fractions eluted from heparin sepharose
To see if any autocrine activity was eluted from the heparin 
sepharose gel at salt concentrations higher than 1M NaCl, but whose 
activity was obscured due to the high salt concentration, the 
following diafiltration experiment was undertaken
150mls of RPMI 2650 conditioned medium was incubated overnight at 
4°C (stirred) with 8mls of heparin sepharose gel The gel was 
allowed to settle and 150mls of supernatant was drawn off This 
was then concentrated by ultrafiltration to 15mls (10x) The 
remaining supernatant was removed and the gel washed well with 
buffer Two 15ml fractions were collected following elution with 
15 mis of 0 5M NaCl and 3M NaCl 150 mis of the same batch of 
conditioned medium was also concentrated down to 15 mis by 
ultrafiltration using a 1,000 MW cut-off membrane
10 mis of each of the above samples (Rl, Unbound, 0 5M and 3M 
eluants) were added to lOOmls of MEM and ultrafiltrated down to 10 
mis This was repeated resulting in a overall reduction in salt 
concentration of 1/121 Each sample was filter sterilised and 
assayed m  the RPMI 2650 autocrine bioassay The results are 
presented m  Table 3 7 7
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samples eluted from the heparin sepharose chromatography 
column Each sample is a lOx concentrate (see text)
TABLE 3 7 7 Effect of diafiltration on autocrine activity of
Sample
% CFE ± SEM
Untreated Diafiltrated
R1 5 55±0 93 5 27±0 41
Unbound 1 05±0 21 1 05±0 10
0 5M fraction 1 03+0 42 1 06+0 27
3M fraction 0 00+0 00 0 46±0 29
MEM 0 12±0 04
It can be seen from these results that the high salt concentration 
does effect the autocrine activity of the fraction eluted at 3M 
NaCl
The untreated 3M eluate showed considerable inhibition below the 
level of the control But diafiltrating this sample resulted in 
growth equivalent to control levels (when SEM is taken into 
account) This would suggest that little or no autocrine 
stimulation was eluted at salt concentrations higher than 0 5M 
NaCl Alternatively it might mean that the fraction tightly bound 
to the heparin requires some entity in either the 0 5M fraction or 
the unbound fraction to elicit an autocrine response
This experiment also shows that the autocrine activity can be 
safely diafiltered without loss m  activity In cases where 
desalting is essential, diafiltration may be considered a viable 
alternative to dialysis
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3.7 5 3 Gradient elution
Heparin sepharose chromatography of the CM was further examined by 
applying a similar sample (10 mis) of concentrated CM (Rl(14x)) to 
a 10 ml heparin column using the automated Biopilot System (FPLC) 
The column was pre-equilibrated in phosphate buffer (pH 7 4) as 
before A program was set up (described in detail in Material and 
Methods) so that, following extensive column washing, a gradient 
from 0 to 1 5 M NaCl in phosphate buffer eluted off bound activity 
6 ml fractions were collected and filter sterilised before assay
The column was run at room temperature so a CM control (Rl(14x)) 
was left at the same temperature for the duration of the run
The activity was low m  all the samples assayed Phenol red was 
eluted over 3 fractions m  a volume of approximately 18 mis, this 
is equivalent to a 1/1 8 dilution Presuming the unbound fraction
is diluted in a similar manner, it is possible that, at this
concentration level, its autocrine activity could not be detected
The bound fraction is eluted by a salt gradient, but no detectable 
autocrine activity was measured It is possible that either the 
activity was diluted out below detection level or else running the 
Biopilot at room temperature inactivated the labile component of 
the autocrine activity (see later)
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FIGURE 3 7 2 Heparin sepharose chromatography of RPMI 2650 CM eluted by 
gradient elution
3 8 FURTHER CHARACTERISATION OF HEPARIN BINDING AND NON-HEPARIN
BINDING FRACTIONS
3 8 1 Temperature stability of fractions eluted from heparin 
sepharose
Samples of unbound and 0 5M eluate were prepared by step elution 
These samples, along with conditioned medium concentrated by 
ultrafiltration with a 1,000 MW cut-off membrane (Rl(lOx)) were 
exposed to boiling for 3 and 20 minutes (as described in section 
3 5 3) Each fraction was then filter sterilised and assayed in 
the RPMI 2650 autocrine bioassay The results are presented in 
Figure 3 8 1 and Table 3 8 1
FIGURE 3 8 1 Heat stability of the fractions eluted from the
heparin sepharose column (presented in % CFE t SEM)•
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TABLE 3 8 1 Heat stability of the fractions eluted from the 
heparin sepharose column (presented as % 
activity (average) remaining)
Sample
% activity remaining
R1 unbound 0 5M Eluate
o o 100 100 100
100°C/3mins 50 -25 27
100°C/20mins 23 358 - 9
The results obtained for the Rl(7x) sample correlate with results
obtained previously for the stability of the autocrine activity
(see Section 3 5 3) Boiling for 20 minutes further reduces the
autocrine activity by about 50% of that observed when the same
fraction was boiled for 3 minutes
The bound fraction (0 5M eluate) also exhibits heat sensitivity. 
Boiling for 3 minutes reduces the autocrine activity while boiling 
for 20 minutes reduces it further (to control levels) This is 
similiar to the results obtained for the 1-30,000 MW 
ultrafiltration fraction (see Figure 3 6 1 and Table 3 6 3)
The results obtained from the unbound fraction were not as easy to 
interpret Boiling for 3 minutes actually eliminated the activity
of the unbound fraction, while prolonged boiling appeared to
activate it A similiar activation was also apparent when the R30
fraction from ultrafiltration was boiled for extended periods (see
Figure 3 6 1 and Table 3 6 3)
The loss of activity in the unbound fraction following boiling for 
three minutes is unexpected Due to time constraints, further 
investigation of this effect was not undertaken
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3 8 2 pH Stability of fractions eluted from heparin sepharo»©
Samples of unbound and 0 5M eluate were prepared (as for Section 
3 7 5 2) These samples, along with conditioned medium
concentrated by ultrafiltration with a 1,000 MW cut-off membrane 
(Rl(10x)) were exposed to pH 2.5-3 0 and 11 0-12 4 for two hours 
(as described m  section 3 5 4) Each fraction was then filter 
sterilised and assayed m  the RPMI 2650 autocrine bioassay. The 
results are presented in Figure 3 8 2 and Table 3 8 2
FIGURE 3 8 2 pH stability of the fractions eluted from the
heparin sepharose column (presented in % CFE ± SEM)•
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TABLE 3 8 2 pH stability of the fractions eluted from the 
heparin sepharose column (presented as % activity 
(average) remaining)
Sample
% activity remaining
R1 unbound 0 5M Eluant
Untreated 100 100 100
Acid treated 26 223 47
Base treated 23 1075 3
Again, the results for the R1 sample correlate with profiles 
obtained previously (Section 3 5 4) Both acid and base treatments 
eliminate over 70% of the autocrine activity
The bound fraction (0 5M eluate) is pH sensitive Acid treatment
results in a loss of more than 50% of the activity while base 
treatment eliminates the activity almost completely This again 
follows the trends of the results from the Rl-30 fraction where the 
autocrine activity was lost by both acid and base treatment
The unbound fraction is more pH stable than the bound fraction 
Acid treatment resulted in no reduction of activity (the acid 
treatment seems to be even somewhat stimulatory compared with the 
untreated control) From these results it can be seen that 
treatment with NaOH resulted in a quite definite stimulation in 
activity above the untreated control The R30 fraction from 
ultrafiltration experiments showed comparable trends (Figure 3 6.2 
and Table 3 6 4)
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3 8 3 Affinity of autocrine activity (fractionated by ultrafiltration) 
for heparin sepharose
The similarity in reponse to treatments between the Rl-30 and the 
bound fraction (0 5M eluate) and the R30 fraction and unbound 
fraction was further investigated in this experiment
Conditioned medium was fractionated into three fraction <R1, Rl-30
and R30) A sample of each concentrate was incubated overnight 
with heparin sepharose The unbound fraction was taken off and the 
bound fraction was eluted with 0 5M NaCl in phosphate buffer as 
before Each resulting fraction was a ten fold concentrate of the 
original CM (see Materials and Methods) Medium (MEM), also 
concentrated lOx by ultrafiltration, was incubated m  the same way 
with heparin sepharose and bound and unbound fractions collected as 
controls
The results in % CFE ± SEM are presented m  Figure 3 8.3 and in 
Table 3 8 3 as the distribution of autocrine activity between bound 
and unbound forms
FIGURE 3 8 3 Affinity of ultrafiltration fractions for heparin 
sepharose There was no growth in the Rl-30-Unbound sample
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TABLE 3 8 3 Affinity of ultrafiltration fractions for heparin 
sepharose (expressed as % of activity remaining 
following heparin sepharose chromatography)
% Activity
Sample R1 Rl-30 R30
lOx 100 100 100
Bound 16 81 7
Unbound 31 0 172
The results presented m  Figure 3 8 3 and Table 2 8 3 show that no 
activity was eluted in either the bound or the unbound fractions 
when unconditioned medium was incubated with heparin sepharose 
This indicates that all the eluted activity could be attributed to 
the CM only Since MEM was the applied to the heparin sepharose 
after the CM samples, this result shows that no activity is 
retained on the column which can be leeched off in subsequent runs.
The activity in the R1 sample divides between bound and unbound 
fractions in a similar manner to heparin sepharose chromatography 
of the bulk CM, but the ratio of bound unbound depends on the batch 
of CM (analogous to the ratio of Rl-30 R30, see Section 3 6 1).
It is clear from these results that the Rl-30 activity is heparin 
binding, while the R30 fraction is predominately non-binding
This experiment was repeated on three different occasions with 
comparable results
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3 B 4 Heparxn sepharose affinity of TGF-B activity fractionated by 
ultrafiltration
The samples assayed in Section 3 8 3 were also tested in the 
NRK-49F soft agar bioassay for detection of TGF-B-like activity. 
The results, in the form of % CFE (± SEM) of NRK-49F cells in the 
presence of 2ng/ml EGF, are presented in Figure 3 8 4 and Table 
3 8 4 Activity in the absence of EGF did not exceed control medium 
levels (0 02±0 02) and so are not presented
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FIGURE 3 8 4 Affinity of ultrafiltered TGF-fl activity for heparin 
sepharose.
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TABLE 3 8 4 TGF-fl activity remaining following heparin sepharose 
chromatography of conditioned medium fractionated by 
ultraflitration
% CFE ± SEM of NRK-49F cells
Sample Rl Rl-30 R30
Concentrate
Bound
Unbound
C
3 87±0 12 
0 71±0 01
0 13±0 02 
0 03±0 02 
0 00±0 00
21 83±0 92 
12 42±0 92 
2 42±0 15
MEM 0 02±0 02
C = Contaminated
These results support the results shown earlier (Table 3 6 7 and 
Section 3 3 2) where TGF-fl-like activity in the R1 concentrate is 
predominately found in the R30 fraction
These figures demonstrate that the TGF-fl activity m  both the R30 
and the Rl fractions is heparin binding, although substantial 
activity is lost in the R30 fraction when eluted from heparin 
sepharose This may suggest a synergistic interaction between the 
bound and unbound forms
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3 9 SCALE-UP OF GROWTH AND AUTOCRINE FACTOR PRODUCTION FROM RPMI
2650 CELLS
3 9 1 Growth of RPMI 2650 cells on different microcarrier bead 
types
Conditioned medium from RPMI 2650 cells was routinely collected 
from monolayer roller bottle cultures (as described in Materials 
and Methods) This set of experiments examined the suitability of 
using microcarner beads coated with different materials for 
growing RPMI 2650 cells and their suitability for collection of 
autocrine activity Two different bead types were studied 
Biospheres (Whatman) and Cytodex (Pharmacia)
3 9 1 1  Glass, plastic and collagen coated Biospheres
Three types of microcarner beads (Biospheres, Whatman) were 
compared in 100 ml spinner flasks containing 0 2 mg/100 mis of 
each of the beads and 4 x 10^ RPMI 2650 cells The cultures were 
incubated at 37°C for 6 days with feeding on day 4 The 
microcarriers have a central core of plastic and are coated with 
either glass, plastic or collagen (Flasks A, B and C 
respectively) At intervals samples were removed and the number of 
free and attached cells were counted The growth curve for the 
cells m  each flask is shown in Figure 3 9 1
The growth curves are similar for each of the bead types tested
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Days in Culture
FIGURE 3 9 1 Comparison of the growth of RPMI 2650 cells on three 
different types of microcarrier beads (Biospheres)
Not all the cells attached to the beads The number of free cells 
m  suspension was also monitored and the percentage of attached 
cells was calculated The results are presented in Figures 3 9 2. 
and 3 9 3
\
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FIGURE 3 9 2 Comparison of the growth of RPMI 2650 cells in 
suspension in three microcarrier cultures.
Days in Culture
FIGURE 3 9 3 Percentage of cells attached to each microcarrier 
bead (Biospheres).
These results show that while initially the cells attached quickly 
to the glass beads, more than 50% of the cells were in suspension 
in the plastic and collagen cultures after 3 days By the end of 
the experiment, however, most of the cells were attached in each
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of the systems The cells in suspension grew, but apparently not 
as the same rate as the attached cells This is the reason why 
the percentages of cell attachment were so high after 6 days
These beads, while providing a good substrate for the cells to 
grow, were not translucent and so did not allow adequate visual 
monitoring of the attached cells Because it was difficult to 
determine the physical state of the attached cells, no further 
work was done on this bead type
3.9.1 2 Cytodex 1, 2 and 3
The performance of three different dextran bead types were 
examined (Cytodex, Pharmacia) These beads are translucent and 
allow observation with standard microscopy techiques Cytodex 1 is 
a dextran bead with positively charged DEAE distributed throughout 
the matrix Cytodex 2 has a dextran core surrounded by a layer of 
positive charges (N,N,N-trimethy1-2-hydroxy-aminopropyl groups). 
Cytodex 3 is a dextran bead coated with collagen which is said to 
promote cell adhesion
Three spinner flasks were set up with 6 x 10^ RPMI 2650 cells per 
ml in lOOmls of MEM + 5% FCS and 0 3 g/100 mis of each
microcarrier bead type The cultures were monitored for 6 days, 
with complete feeding on day 4 Samples were taken after 42 
hours, 72 hours and 6 days (144 hours) according to the procedure 
for microcarrier sampling The number of attached and free cells 
were monitored The number of attached cells per ml of culture is 
given in the Figure below The percentage of cells attached at 
the various sample times is given in Table 3 9 1
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FIGURE 3 9 4 Growth of RPMI 2650 cells on different microcamer 
beads (Cytodex).
TABLE 3 9 1 Percentage of cells attached to the Cytodex 
microcarrier beads
Sample Cytodex 1 Cytodex 2 Cytodex 3
48 hrs 98% 51% 100%
72 hrs 100% 85% 100%
114 hrs 99% 99% 100%
The growth curves (in Figure 3 9 4) suggest that Cytodex 3 is the 
best microcarrier for the growth of cells The cells spread well 
on the beads with only minimal free cell growth. Cytodex 1 
allowed better cell attachment than Cytodex 2, although the cells 
did not grow as well after attachment The reduced growth may be 
due to the high charge density in the Cytodex 1 beads.
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The cells grown on Cytodex microcarrier beads in this experiments 
experiences a quite long lag phase, which was not seen in the 
cultures grown on Biospheres (Figure 3 9 1) This is not a 
characteristic of the bead-type, however, since a Cytodex 3 
culture which was set up at the same time as the Biosphere 
cultures, exhibited no observable lag phase (Figure 3 9 5)
Days in Culture
FIGURE 3 9 5 RPMI 2650 cells grown on Cytodex 3 Microcamere
3 9 1 3  Autocrine Activity m  CM collected from RPMI 2650 
microcarrier cultures
The culture flasks in the previous section (3 9 1 2) were set up 
on day 6 m  serum free medium Conditioned medium was collected 
after 3 days The CM was then ultrafiltered and concentrated ten 
fold through a 30,000 MW cut-off membrane (Rl(10x)) The filtrate 
was then passed through a 5,000 MW cut-off membrane (R5-30(10x)) 
Each sample was assayed m  the RPMI 2650 autocrine assay and the 
results are presented in Table 3 9 2
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TABLE 3 9 2 Autocrine activity of conditioned media collected on 
from cells grown different microcarrier beads.
Bead R30 R5-30
Cytodex 1 
Cytodex 2 
Cytodex 3
2 72±0 27 
2 43 + 0 13 
1 61±0 43
3 24±0 00 
3 92±0 00 
3 00±0 38
MEM 1 62±0 22
By dividing the stimulation above the control by the number of 
cells present, an "Autocrine Index" can be calculated This is a 
measure of the fold stimulation per producer cell for each of the 
conditioned media collected and is equal to
% CFE - Total number of cells 
1 62
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TABLE 3 9 3 Autocrine Index (see above) per cell {6 days growth)
Bead
Type
Autocrine Index 
(xlO6)
R30 R5-30
Cytodex 1 0 86 1 03
Cytodex 2 0 20 0 33
Cytodex 3 0 07 0 14
Calculation of the Autocrine Index allows better comparison 
between each production system Although the Cytodex 1 bead did 
not appear to provide an optimum substrate for cell attachment, 
the relative amount of growth factor produced was higher than the 
other systems
Alternatively, Cytodex 3 was the best microcarrier for cell 
growth, but the autocrine activity was very low with barely 
detectable levels in the R5-30 fraction Cytodex 3 is coated with 
denatured Type I collagen It is possible that the heparin-binding 
moiety is adsorbed into the collagen layer and so is not released 
freely into the CM
The results emphasise the difference between an optimum system for 
cell growth and an optimum for production
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3.9 2 Growth optimisation and autocrine activity production from 
RPMI cells 2650 in suspension cultures
3 9 2 1 Culture Medium
All the monolayer work with RPMI 2650 was carried out using MEM 
medium supplemented with a particular batch of FCS (No 48) The 
following experiment was set up to examine the performance of a 
modified MEM, MEMS (Flow) (See Appendix F) MEMS, designed 
especially for suspensions cultures has a low calcium content and 
is said to promote single cell suspensions
Two spinner flasks (lOOmls) were set up, one with MEM and one with 
MEMS Each flask was supplemented with 5% FCS Each flask was 
inoculated with 1 2xl05 RPMI 2650 cells per ml and was incubated 
at 37°C/30 rpm Samples were taken at regular intervals The 
growth curves are presented in Figure 3 9 6
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FIGURE 3 9 6 Comparison of the growth of RPMI 2650 cells in MEM 
and MEMS
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The physiology of growth was very different between the MEM and 
the MEMS media The cells grew in very large clumps m  MEM The 
cells were very tightly packed, perhaps resulting in decreased 
viability in the centre Because the clumps were so entrapped they 
were quite difficult to trypsinise so accurate counting was 
difficult
In the low calcium medium (MEMS), the clumps were much looser and 
could be trypsinised with less difficulty The viability was also 
improved
PLATE 3 RPMI 2650 cells grown in aggregate culture m  MEM medium 
supplemented with donor horse serum (5%) Phase 1 
(150X) magnification.
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PLATE 4 RPMI 2650 cells grown m  aggregate culture in MEMS medium 
supplemented with donor horse serum (5%) Phase 1 
(X50X) magnification
After 7 days culture the medium was removed and the cells were set 
up for CM collection CM was collected on a daily basis by 
removing 50mls of medium/ centrifuging out the cells and 
resuspending the pellet m  50mls of fresh medium without serum.-- 
This procedure was repeated for three days These conditioned 
media samples were then ultraflltered ten fold using a 10,000 MW 
cut-off immersible CX-10 filter (Millipore) The retentâtes were 
filter sterilised and assayed m  the RPMI 2650 autocrine assay 
The results are shown in Table 3 9 4
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TABLE 3 9 4 Autocrine activity of cultures grown in MEM and MEMS 
for one week before set up for daily CM collections
MEM MEMS
DAY 1 
DAY 2 
DAY 3
0 03±0 01 
0 21±0 08 
0 24±0 02
0 00±0 00
0 09±0 01
1 66±0 13
Control 0 09±0 05 0 09±0 05
This experiment demonstrated that RPMI 2650 cells produced 
auto-stimulatory activity in both types of media tested Very low 
levels of activity were detected in MEM after 2 days with no 
activity at all m  the MEMS culture On day 3, the autocrine 
activity in the MEM culture had not significantly changed but high 
amounts of activity was present in the MEMS CM
The autocrine activity profile from the suspension cultures 
appears to be different to that seen in monolayer cultures (see 
Section 3 5 2) Following this experiment it was decided to 
collect CM from suspension cultures after 3 days rather than on a 
daily basis as with roller bottles
3 9 2 2 Serum batch testing in suspension cultures
Since scaling up the RPMI 2650 CM production system involves 
increased usage of foetal calf serum, it was decided to test 
donor horse serum (DHS) as a less expensive alternative to FCS. In 
this experiment, three different batches of donor horse sera were 
compared to a standard batch of foetal calf serum
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Four spinner flasks were inoculated with 107 RPMI 2650 cells m  
100 mis of MEMS 5 mis of 4 different batches of serum were added 
as follows
Flask A MEMS + 5% No 48 FCS
Flask B MEMS + 5% No 87 DHS
Flask C MEMS + 5% No 62 DHS
Flask D MEMS + 5% No 32 DHS
The cultures were incubated at 37°c/30rpm The growth curves are 
presented in Figure 3 9 7
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A — A  DHS 62 
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FIGURE 3 9 7 Growth curves of RPMI 2650 cells grown in 100 ml
spinner flasks with different serum batches
Each of the batches tested performed quite well over the time 
period examined, with Flask D supporting the most growth From
these results it was decided to use this donor horse serum batch
for subsequent suspension work
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3 9 2 3 Effect of agitation on growth factor activity
In this experiment, the effect of agitation on the production 
of autocrine, TGF-a and TGF-fi activities was examined
Two spinner flasks of RPMI 2650 cells were grown under identical 
conditions (37°C/ 30 rpm) in MEMS supplemented with DHS Samples 
were collected and counted on a daily basis as described 
previously After 4 days the cultures were centrifuged and the 
cells re-set up in MEMS without serum Flask A was set up at 20 
rpm and flask B was set up at 60 rpm Samples continued to be 
taken for two more days after which the conditioned medium was 
collected
The growth curves for each flask is given in Figure 3 9 8
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FIGURE 6 9 8 Effect of different agitation rates on cell growth m  
serum free media 2 flasks of RPMI 2650 
cells were incubated at 37°C/30rpm in MEMS supplemented 
with DHS On day 4 the cells were set up for CM collection. 
Flask A was agitated at 20 rpm, Flask B at 60 rpm.
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Growing the cultures at the same initial agitation rate ensured 
that the cells in each flask were in a similar condition when they 
were set up m  serum-free media and the agitation rate changed 
This experiment, therefore, just looked at the effect of the 
agitation rate on growth factor production
Setting up the cultures for CM is m  itself quite a distructive 
procedure Centifuging the cells and resuspending the pellet in 
medium without serum invariably causes some cell death, with 
viability dropping to about 60% m  both flasks At high agitation 
rates the viable cells could not recover and after 2 days the 
viability had dropped to 8% At lower stirring speeds, however, 
recovery was possible and the viability had risen to 80% by the 
time the CM was collected
CM was collected on Day 3, as decided previously (Section 
3 9 11) This CM was concentrated ten fold using a 1,000 MW 
cut-off membrane and retentate was filter sterilised and assayed 
in the RPMI 2650 bioassay
TABLE 3 9 5 Growth factor activity in CM collected at different 
agitation rates
Flask A 
20 rpm
Flask B 
60 rpm
MEMS
Autocrine (5x) 
TGF-J3 (5x) 
TGF-a (lOx)
3 13±0 33 
0 94±0 21 
0 27±0 20
3 06±0 13 
0 73±0 08 
0 63+0 06
0 33±0 05 
0 02+0 00 
0 00±0 00
It would be expected that at such low levels of viability, a high 
number of dead cells lyse, releasing proteolytic enzymes These 
proteolytic enzymes would then act on the growth factors causing 
reduced activities This is not the case, however, in this 
system Comparable levels of autocrine and TGF-fl activities were 
measured in the CM collected from each flask, with increased 
levels of TGF-a-like activity at the higher agitation rate
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These results would suggest that possibly the TGF-a-like activity 
is intracellular and is released on cell lysis It also suggests 
that the TGF-B and autocrine activity may not be growth related 
and are produced consituitively
3 9 3 Scale-up of RPMI 2650 cell using a 2L Biostat MC
Three similar runs were set up on the Braun Biostat MC 2L 
bioreactor to examine the effect of dissolved oxygen levels on the 
growth factor activity of RPMI 2650 conditioned medium
The bioreactors were set up with 4 confluent 75cm2 flasks of RPMI 
2650 (passage 61-66) in 1 8L of MEMS supplemented with 5% DHS and 
1% p/s The pH was controlled at pH 7 3 Each run was set up so 
that the oxygen concentration would not drop below 40% for the 
duration of the growth phase An upper oxygen limit was not 
imposed (which allowed calculation of metabolic oxygen consumption 
rates) The dissolved oxygen (DO) levels were monitored
continuously and the measured readings (averaged every ten hours) 
are shown in Figure 5 9 9
i
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were grown under identical conditions for four days 
in serum supplemented medium, without oxygen control. 
On day 4 the cultures were set up in serum free medium 
and the oxygen levels were set to the indicated 
levels. The graph represents 10-hourly averages for 
each run.
The reduction in dissolved oxygen levels (up to day 4) is most 
probably due to the metabolic activity of the cells It is 
unlikely that mass transfer would account for the decrease since 
the probe was calibrated for 100% air saturation. Calculation of 
oxygen depletion rates shows slight differences between each run. 
The values estimated are presented in Table 3 5.6
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TABLE 3 9 6 Calculated oxygen consumption rates for each
bioreactor run (see Appendix F) (for approximately 10^ 
cells per ml in a 1 8L culture)
Oxygen Consumption Rate 
(mmol 0 2/hour)
Low Oxygen 0 0010
Mid Oxygen 0 0019
High Oxygen 0 0018
After four days the cell suspension was centrifuged and the cell 
pellet re-suspended in medium without serum The dissolved oxygen 
level was set to the appropriate value ±5% i e
Low oxygen = 20%,
Mid oxygen = 40%, and
High oxygen = 80%
The controllers maintained the oxygen levels at ±5% of the set 
point with nitrogen and oxygen Conditioned medium was collected 
after 3 days by centrifuging the culture at 3,500 rpm for 15 
minutes The conditioned media was stored at 4°C until further 
processed
Cell counts were taken daily The growth curves of the three runs
are shown in Figure 3 9 10
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FIGURE 3 9 10 Growth curves of RPMI 2650 cells grown in the 
Biostat MC. The cells were grown under 
identical conditions for four days in serum 
supplemented medium* On day 4 the cultures were 
set up m  serum free medium and the oxygen levels 
were set to the indicated levels.
Measurement of oxygen consumption rates is not necessarily a good 
marker for the growth of each culture. The cells in the "Low 
Oxygen“ run grew at a slighly lower rate than the "High Oxygen* 
culture, but the oxygen consumption rate was almost half While 
the "Mid Oxygen" run growth rate was high compared with the "High 
Oxygen” run, but their oxygen consumption rates were similar.
The viability of each of the bioreactor cultures remained at over 
95% for the duration of the growth phase. When the cells were set 
up in serum free medium and the oxygen level controlled, the 
viabilities dropped. The viabilities determined for the serum free 
samples in each of the runs are presented in Table 3.9 6
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TABLE 3 9 6 Viability of RPMI 2650 cells at different oxygen 
levels (see text for details)
Culture
Viability (%)
)
Day 5 Day 6 Day 7
Low Oxygen 90 69 50
Mid Oxygen 94 97 94
High Oxygen 93 82 83
The growth of cells was comparable for each run Although the
seeding innoculation for the "Mid-oxygen" run was lower than for
the others, after 4 days growth the cell densities was the same
for all three cultures
Cell numbers decreased dramatically due to experimental error when
the "Low-oxygen" run was set up in serum free medium The
viability of the remaining cells were initally high (90%) These 
cells maintained cell number but viability dropped to 50% after 
three days in serum free medium
Oxygen appears to have quite a dramatic effect at high levels on 
the growth and viability of the RPMI 2650 cells m  suspension The 
number of cells was reduced by one-third over the three day
collection period The viability also dropped, but only to 83% 
The loss in cell number must be attributed to cell lysis and
substantial amounts of cell debris were found in the samples
taken
These results suggest that an intermediate oxygen level is the 
best for serum free growth of RPMI 2650 cells
lOOmls of conditioned media from each run was ultrafiltered with a
1,000 MW cut-off membrane ten fold (Rl(10x)) lOOmls of each CM 
was also incubated with 4 mis of heparin sepharose and the bound
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and unbound fraction were collected (as described m  Materials and 
Methods) The resulting fractions were assayed in the RPMI 2650 
autocrine assay, the NRK soft agar for TGF-a-like activity and the 
NRK 49F soft agar bioassay for TGF-fl activity The results are 
presented m  Table 3 9 7
TABLE 3 9 7 Growth Factor activités in CM collected at different 
oxygen levels
% CFE ± SEM
Sample Autocrine TGF-a TGF-Î3
Low Oxygen
Rl 8 81± 1 45 1 06±0 12 1 06±0 08
Unbound 5 21±0 49 0 27±0 22 0 13±0 02
Bound 1 54±0 50 0 04±0 05 0 47±0 13
Mid Oxygen
Rl 7 62±0 36 N D 0 62±0 00
Unbound 5 27±0 19 N D 0 32±0 04
Bound 1 13±0 43 N D 0 30±0 02
High Oxygen
Rl 7 45±0 66 2 36±0 12 0 58±0 15
Unbound 3 53±0 51 0 16±0 06 0 05±0.02
Bound 2 92 ±0 59 0 06±0 06 0 58±0 10
MEMS 0 37±0 12 0 00±0 00 0 02±0 02
N D = Not Determined
Autocrine activity
These results indicate that dissolved oxygen levels do not effect 
the overall autocrine activity of the cells Each of the 
concentrated CM (Rl) gave equivalent activities These results 
were similar in four repeat assays
Most of the activity was non-hepann binding in the CM collected 
from low and mid oxygen While the CM collected at high oxygen 
levels demonstrated relatively less unbound activity, while the 
amount of heparin binding activity was higher than in the other 
runs
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The total cell count at high oxygen levels had dropped 
dramatically during growth in medium without serum It is 
possible that a high number of dead cells lysed and released 
intracellular components which may include intracellular growth 
factors (e g FGF)
It is unlikely that the differences in bound activities is due to 
inactivation over time at 4°C since the sequence of runs was 
"Low", followed by "High" and "Mid" oxygen levels, i e the 
conditioned medium from the ’Low" run was longest m  storage
TGF-a Activity
The results in Table 3 9 7 demonstrate an increase in TGF-a 
activity with increasing oxygen levels This activity was lost 
following heparin sepharose fractionation This correlates with 
previous results which showed that TGF-a activity was lost by 
ultrafiltration fractionation (Table 3 6 8)
Subsequently these samples were assayed with with a standard curve 
of pure TGF-a (see Figure 3 3 1) The calculated TGF-a-like 
activity present in the high and low oxygen CMs are presented in 
the table below The assay was repeated with similar results
163
TABLE 3 9 8 Equivalent TGF-a activity in conditioned media 
collected at high (80%) and low (20%) oxygen levels
Sample Equivalent TGF-a 
Activity (ng/ml)
High oxygen 
Low oxygen
7 74 
0 47
The results (as in Section 3 9 3 3) demonstrate a correlation 
between viability and TGF-a levels This again may be an 
indication of that either the TGF-a activity is intracellular or 
it may be activated by extreme conditions
TGF-B Activity
TGF-Æ activity increases to a small degree as the oxygen level is 
decreased This effect is not reflected, however, in the
activities of the bound and unbound fractions The assay was only
performed once so the conclusions that can be drawn are somewhat 
limited
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4 0 DISCUSSION
4.1 THE RPMI 2650 AUTOCRINE ASSAY SYSTEM
Transforming growth factors were originally identified by their 
ability to induce non-transformed cells to grow in semi-solid 
media, such as soft agar Growth in soft agar is generally 
considered to be the best in vitro correlate of tumorigenicity in 
vivo (Shin et al , 1975, Cinofe and Fidler, 1980) This is the 
system used to detect autocrine stimulatory factors m  RPMI 2650 
conditioned media (Dooley and Clynes, 1986).
In agar systems the number of cells forming colonies is low 
compared with agarose assay systems. One study comparing the 
growth of a range of different cell types in agar and agarose found 
that none of the 6 non-tumongenic cell lines grew in agar or 
agarose, 10 out of 13 tumorigenic cell lines grew equally well m  
both systems while the remaining 3 cell lines grew in agarose but 
not in agar (Neugut and Weinstein, 1979) Pretreating the agar to 
remove mucopolysaccharides resulted in increased colony formation 
indicating that colony formation in soft agar is limited by the 
presence of acid polysaccharides (Sanders and Smith, 1970) These 
studies suggest that growth in agar is a more stringent criterion 
J than growth in agarose and so may be indicative of a more advanced 
stage of transformation
The reason transformed cells can generally proliferate in 
semi-solid media, while non transformed cells can only do so after 
incubation with specific growth factors, is not well understood It 
has been suggested that proliferation in semi-solid media is 
dependent on either the interaction of cells with extracellular 
adhesion receptors (Allen-Hoffmann et al., 1990, Ignotz and
Massague, 1985) or the intracellular pH of the cells (Schwartz et
al , 1990, Van Zoelen and Tertoolen, 1991).
Soft agar assay systems have a number of advantages over 
conventional anchorage dependent monolayer growth factor assays 
where the end point is established by determining the percentage 
area covered by cells Such a system can be responsive to factors 
present in serum which promote attachment and spreading of the 
cells Lamimn, for example, has been found to be capable of 
promoting cell growth (Rizzino, 1984), while fibronectin was shown
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previously to aid attachment to glass (Bradshaw et al , 1983)
Such factors have been demonstrated to be unneccesary for growth of 
NRK cells in soft agar and their presence does not stimulate colony 
formation (Rizzino et al , 1984). Collagen, however, has been
shown to stimulate colony formation of both transformed and 
non-transformed BHK cells in soft agar (Sanders and Smith, 1970)
The incorporation of ^H-thymidine into acid insoluble materials has 
been widely used as a convenient method of assessing the 
stimulatory and inhibitory effects on the growth of many cell 
lines, including 3T3 cells However this technique not only 
measures effects on DNA synthesis, but can also reflect alterations 
in the transport of thymidine across the plasma membrane and m  the 
phosphorylation of this nucleoside by thymidine kinase, which 
occurs before it can be incorporated into DNA In some systems 
previously thought to have anti-proliferative activity, have 
subsequently been shown merely to inhibit thymidine transport 
(Rozengurt, E , 1981)*
The autocrine assay was set up in complete agar medium containing 
foetal calf serum It has been shown that serum contributes to the 
growth of the cells m  agar (Kaplan and Ozanne, 1983; Wilder and 
Rizzino, 1991) Peehl and Stambndge (1981) found that increasing 
the serum concentration above 10% resulted in increased spontaneous 
colony formation. Also van Zoelen et al (1985) found that
increasing FCS levels from 10% to 20% more than doubled the 
percentage of colonies formed in soft agar in the presence of 2 
ng/ml EGF.
The serum concentration m  this study (5 8%) supported a low
background level of soft agar growth compared with published 
systems. Wilder and Rizzino (1991) grew murine epithelial cells in 
soft agar with 9% FCS, which resulted in background colony 
efficiency of less than 2%. Rizzino and Ruff (1986) suggested that 
a good serum batch would support the formation of less than 50 
colonies in the presence of EGF and greater than 1,000 colonies in 
the presence of EGF plus TGF-J3 (in 24-well plates with a cell
loading of 2 5 x 10^ cells per well), which is equivalent to colony
forming efficiencies of 2% in the absence of EGF, and 40% in its 
presence
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Serum contains a range of polypeptide growth factors which have 
been shown to be capable of promoting anchorage independent growth 
It is generally recognised that anchorage independent growth is a 
function of the total concentration of growth factors in the medium 
to which these cells can respond (Kaplan and Ozanne, 1983) In 
most cases, response m  soft agar is due to a combination of a 
number of different factors
For example maximal growth is achieved in the NRK-49F system 
(employing foetal calf cerum) in the presence of TGF-B, EGF (or 
TGF-a) (Assoian et al., 1984), which are present in serum 
(Childs et al., 1982). Rizzino et al. (1986) have shown that in 
plasma supplemented media, PDGF can stimulate soft agar colony 
formation of NRK-49F cells in the absence of EGF (or TGF-a) and 
TGF-J3 Under these conditions, FGF potentiates this response but 
is itself unable to induce soft agar growth of NRK-49F cells PDGF 
has also been implicated in a central role in the stimulation of 
growth of the mouse cell line AKR-2B m  soft agar with TGF-/3 In 
this system, TGF-fl stimulates the production of c-sis which codes 
for the PDGF B chain (Leof et al , 1986) TGF-a and fi, PDGF, and 
the FGFs have also been implicated in the soft agar growth of a 
range of cell lines (see below)
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TABLE 4.1 Cell type Factors implicated in soft agar stimulation
NRK-49F TGF-a, TGF-ß, PDGF, (potentiated by FGF) 
Rizzino et al , 1986
ARK-2B TGF-ß, PDGF 
Tucker et al., 1984, Rizzino and Ruff, 1986
Human glioma 
(SNB-19)
bFGF
Morrison et al., 1990
NR-6 bFGF, aFGF, PDGF (potentiated by TGF-ß) 
Rizzino and Ruff, 1986
Rabbit articular 
chondrocyte
TGF-ß, EGF 
Skantze et al , 1985
Murine epithelial 
JB6 cells
TGF-ß, potentiated by EGF 
Wilder and Rizzino, 1991
Serum normally is bought with a shelf life of six months This 
ensures that the activity of the sera can be considered to be 
optimum provided the bottles have been handled and stored 
correctly Three different bottles of batch number 46 were used for 
autocrine assays over a one year period. It was discovered that 
serum from one bottle from this batch could not support soft agar 
growth This was attributed to incorrect handling of the bottle, 
possibly due to too frequent freezing and thawing of the bottle 
during transfer from one freezer to another or during malfunction 
of freezer units.
Because the presence of specific growth factors is critical for the 
stimulation of colony formation, it is important to carefully batch 
test the serum before use. In the course of this work over 20 
different batches of feotal calf serum (FCS), newborn calf serum 
(NBCS) and donor horse serum (DHS) were tested In general the 
greatest batch to batch variability was demonstrated with the FCS 
samples, some of which resulted in excellent stimulation while 
others were very poor The NBCS gave consistently poor results in
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the soft agar assay, while the DHS was consistently average to 
good The criteria used to determine a good batch from a poor batch 
was the occurence of high stimulation of growth in the presence of 
conditioned media with a low backround in the absence of 
conditioned media.
In some published studies, NBCS is prefered to FCS for NRK soft 
agar growth and in growth factor defined systems, DTT-treated NBCS 
and FCS were found to have comparable backround levels of colony 
formation (van Zoelen, 1985) In our studies, it was found that 
NBCS only poorly supported soft agar growth This may be due to 
particulary bad batches being tested. In monolayer assays in 
24-well plates (Dooley et al, unpublished) these batches of NBCS 
were found to be poor compared with 14 batches of FCS and DHS for 
the growth of RPMI 2650 cells, although it supported the growth of 
MSV-3T3 cells, 703D4 hybndoma cells and a primary human fibroblast 
cell line quite well
In general it is believed that the contribution to colony 
stimulation in soft agar from bovine sera is significantly less 
than from sera derived from other species (Rapp et al , 1983)
Here, however, it was found that the background levels exhibited 
in the presence of DHS was less than that seen with many of the FCS 
batches examined The stimulation in the MEM+5%DHS sample, however, 
was high compared with the MEM+5%FCS and MEM+5%NBCS samples, which 
suggests that the background was more dependent on the level of 
serum compared with the FCS and NBCS batches
Because the serum batches used in the autocrine assay supported 
generally low background levels of growth compared to the 
stimulation in the presence of conditioned medium, it was decided 
to continue to use serum containing assay systems for the duration 
of this project, rather than investigating serum free systems The 
batches used also proved to allow for only minimal growth in the 
NRK-49F assay for TGF-fl activity in the presence of EGF while, on 
most occasions no colonies formed in the absence of EGF (for both 
NRK and NRK-49F cells).
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To get an indication of the range of factors that might be involved 
in the stimulation of RPMI 2650 colonies in soft agar, several 
highly purified growth factors obtained from commerical sources 
were assayed in the RPMI 2650 soft agar assay at a number of 
different concentrations Insulin, insulin-like growth factors 
and two heparin binding growth factors (acidic and basic fibroblast 
growth factor) all appeared to stimulate colony formation at higher 
concentrations (50ng/ml of agar) and this activity was 
concentration dependent Interleukin la and 1J3 exhibited dilutable 
inhibition at the concentrations used TGF-fl showed some 
stimulation at approximately 0 2 ng/ml but the extent of 
stimulation was small and variable TGF-a (50-0 5 ng/ml) did not 
stimulate or inhibit colony formation in the assay At 50 ng/ml 
and 10 ng/ml EGF illicted no response, but at 5 and 1 ng/ml the 
effect appeared to be slightly inhibitory.
The fact that the cells are responsive to a number of different 
growth factors suggests that RPMI 2650 cells express receptors for 
each of these factors and that any of the factors that elicit a 
response could be a possible paracrine or autocrine regulator of 
its growth Whether all of these factors operate through specific 
receptors or through a number of common receptors (like the IGF 
family) is uncertain. Each member of the insulin-like growth factor 
family has its own specific high affinity receptor,and it cross 
reacts to the other members' receptors with lower affinity (Perdue, 
1984)
In Section 3 3, it was shown that TGF-like activity (equivalent to 
0 05 ng/ml of TGF-a) and TGF-J3 like activity (equivalent to 1 02 
ng/ml of TGF-J3) were present in the conditioned medium of the RPMI 
2650 cells These values correspond to 0 01 and 0 2 ng per ml of 
agar medium, respectively At 0 2 ng/ml, exogenous TGF-G had no 
effect on the colony formation of RPMI 2650 cells While EGF showed 
very slight stimulation at 0 5 ng/ml, TGF-a was not active 
Concentrations below 0 2 ng/ml were not tested, and may be 
stimulatory
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A lot of literature has been published on the ranges in which TGF-Ji 
can elicit a response It appears that the response is dependent on 
a number of factors, including the end point used to establish 
TGF-13 activity The concentration of maximum response varies from 
the pico-gram per ml range in the case of stimulation of normal
hepatocytes (Braun et al , 1988) to ngs/ml for inhibition of>
chondrocytes (Vivien et al , 1990) and BALB/ML keratinocytes
(Coffey et al , 1988).
The presence of serum in the assay system can also cause a
difference to the cell response to TGF-I3. Hoosein et al (1987) 
found that the human colon carcinoma cell, MOSER, exhibited 
maximum inhibition when it was exposed to about 5 ng/ml of TGF-fi in 
an assay system that contained 10% FBS A similar assay was set up 
under defined conditions without serum, using cells that had been 
adapted to growing in serum free medium In this assay TGF-B was
maximally inhibiting at 20ng/ml This may be due to other growth
factors m  the serum acting on the cells making them less 
responsive to TGF-/3
The TGF-fi response may also be a function of the confluency of the 
indicator cells Centrella et al (1987) looked at 3H-thymidine 
incorporation in sparse, subconfluent and confluent cultures of 
osteoblasts They found that below a certain cut-off concentration, 
TGFfl was stimulatory and above this cut-off it was inhibitory. 
They also showed that the actual cut-off concentration varied with 
the confluency of the culture being examined such that TGFB was 
stimulatory up to 15 ng/ml in confluent cultures but for sparse 
cultures the cut-off limit was only 0 15 ng/ml
Hamburger et al (1991) reported that the number of EGF receptors 
on the breast carcinoma cell line, MDA 468, decreases as the 
confluency of the cells increases This decrease is associated with 
reduced levels of mRNA transcripts.
These findings may be significant with regards to the variability 
of the autocrine assay Although the cells are plated at the same 
concentration for each individual assay, the level of the cells' 
response is quite variable In some assays the background is a lot
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higher than in others In these assays, it is possible that 
because of the higher concentration of cells after a number of days 
the response to the particular growth factor may be different than 
when there is a lower overall background of cell growth.
The possibility that these purified growth factors (TGF-a, EGF and 
TGF-I3) were not biologically active is discounted by the fact that 
they were shown to be active in their specific soft agar assays
i.e the NRK soft agar assay for TGF-a-like activity which showed
that both the EGF and TGF-a were active and the NRK-49F soft agar
assay in which TGF-fi was stimulatory
Monshige et al (1991) found that while TGF-a, at various 
concentrations (0 1, 1 0  and 10 mM), did not cause stimulation in
monolayer cultures of ovarian cancer cells in serum free medium,
monoclonal antibodies against TGF-a (but not EGF) could 
significantly inhibit their growth No explanation was provided for 
this result, but it may prove important for the RPMI 2650 system 
where neither TGF-a, TGF-15 nor EGF caused a significant effect, 
even though TGF-a and TGF-B-like activity levels could be detected
in CM samples
TGF-a-like and TGF-B-like activity were detected in the RPMI 2650 
CM by the NRK and NRK-49F assay systems respectively, but other 
pure growth factors, besides TGF-a and TGF-fl, have been reported 
to bring about similar stimulation
Normal rat kidney cells (clone 49F) have been widely used as a 
non-transformed indicator cell line for studying the role of 
polypeptide growth factors The original studies with this cell 
line in agar containing 10% FCS found that phenotypic 
transformation of this line requires the presence of TGF-fi in
combination with EGF or TGF-a (Anzano et al , 1983) Subsequent
work with plasma-containing media established an additional 
requirement for exogeneous PDGF (Assoian et al , 1984) which
elicts a response in the presence of extracts of human platelets, 
but PDGF alone does not have an effect (stated by Miyagawa et al , 
1991) Because of the contribution of serum to the stimulation of 
colony formation, growth factor defined and serum free methods 
were developed.
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Van Zoelen et al (1985) employed a dithiothreitol treated foetal 
calf serum to eliminate spontaneous colony formation in soft agar 
in the presence of EGF in a growth factor defined assay system 
containing selenite, transferrin, BSA and insulin In such a 
system, insulin (in combination with EGF) was demonstrated to be 
strongly mitogenic for NRK cells in monolayer but insulin alone 
could support very little growth
A serum free medium was designed by Rizzino (1984), containing 
transferrin, EGF (or TGF-a), FGF and high density lipoprotein (HDL) 
which was capable of sustaining growth equivalent to that observed 
with 10% FCS in monolayer cultures while in agar systems, colonies 
formed in the presence of these components plus TGF-J3 Due to 
problems with HDL preparations, lmg/ml BSA was subsequently added 
(Rizzino et al., 1986) Because preparation of human HDL is time 
consuming, expensive and susceptible to batch to batch variation, 
a more readily prepared medium incorporating plasma was designed 
(Rizzino and Ruff, 1986)
An EGF-nonresponsive mutant N-3 from NRK cells has been isolated 
(Hamanaka et al , 1990) in which the anchorage independent growth 
of N3 cells is significantly stimulated by TGF-J3 alone, without a 
requirement for TGF-a/EGF. It was suggested that TGF-fi enhances 
the secretion of EGF (or TGF-a) from N-3 cells into culture medium, 
which may support anchorage- independent growth in the presence of 
TGF-fl alone.
As mentioned before, because of the presence of serum growth 
factors in the assays used here, it is necessary to exercise 
caution when interpreting results with the NRK-49F cells. Other 
factors besides TGF-13, EGF/TGF-a, PDGF and FGF cause a response in 
the NRK-49F assay.
Bovine brain derived growth factor, whose chemical and physical 
properties are similar to those of aFGF, also induces anchorage 
independent growth of NRK-49F cells in the presence of EGF (Huang 
et al , 1986)
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More recently, a recombinant hst-1 protein produced m  silkworm 
cells by a recombinant baculovirus, was found to have transforming 
growth factor activity stimulating anchorage independent growth of 
NRK-49F cells at a concentration as low as 1 ng/ml without a 
requirement for EGF (Miyagawa et al , 1991)
Beacause of the non-specificity associated with the NRK and NRK-49F 
assays, a range of purified growth factors from commerical sources 
were tested in each assay system.
Only the TGF-a-like molecules (TGF-a and EGF) showed high 
stimulation in the NRK assay. IGF I was slightly stimulatory at 
the highest concentration assayed (lOOng/ml) This result would 
indicate that stimulation of NRK colony formation elicited by the 
RPMI 2650 CM was most likely to be TGF-a-like
In the NRK-49F assay system, however, both TGF-13 and IGF I (and to 
a lesser extent IGF II) were stimulatory in the presence of EGF. 
The IGF I used in this set of experiments was a human recombinant 
form from Boehnnger Mannheim GmbH To ensure that this effect was 
not merely a result of this particular source of growth factor, IGF
I from two different sources were examined A fresh vial of human
recombinant IGF 1 derived from E coli (Boehnnger Mannheim GmbbH) 
was compared with a recombinant IGF I derived from S cerevisiae 
(Promega). In this set of experiments, both these factors 
exhibited significant stimulation above that of the medium 
controls It is possible that insulin and IGF potentiate the colony 
formation, at the lower serum levels used in these but cannot 
induce it themselves (as with FGFs), and so the insulin and IGF-I
effect was not documented before
Massague et al (1986) also reported a IGF effect. They found that 
by treating BRL-3A conditioned medium with IGF binding protein, the 
formation of NRK-49F colonies in the presence of EGF and TGF-fl was 
inhibited, and this inhibition could be counteracted by the 
addition of excess IGF II. They suggested that sufficient IGF 
could be provided in the 10% FCS present in the agar so that 
exogeneous IGF II could not elicit a response
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In the experiments set up here, IGF II did cause a small 
stimulation. The reason for this may be the lower level of FCS 
present (5 8%) resulting m  decreased accessibility of the cells to 
individual growth factors m  semisolid medium, rather than unique 
forms of synergism between TGF-a or IGFs and TGF-J3 Massagu6 et 
al (1986) did not examine IGF I effects on TGF-J3 stimulation of 
NRK-49F colony formation
Recently, Sushelnitsky et al (1991) studied the effect of EGF and 
insulin on the number of TGF-13 receptors on NRK-49F cells They 
found that while the affinity of the receptors for TGF-J3 did not
4change, the number of receptors increased from about 5 x 10 to 8
Ax 10 per cell in the presence of insulin. A similar effect may be 
happening in the NRK-49F system presented in this thesis IGF-I 
may increase the number of TGF-J3 receptors on the NRK-49F cells and 
so augment their response to TGF-Ji present in the serum
It is reasonable to conclude from this that the NRK-49F assay 
system is not very specific for TGF-J3 and that other factors can 
stimulate the NRK-49F cells in soft agar.
Transforming growth factors produced by one tumour cell line may be 
able to stimulate the anchorage-independent growth of one type of 
indicator cell but not that of another. Salomon et al (1984) 
showed that normal mouse or rat mammary epithelial cells are better 
than fibroblasts as target cells for TGF's isolated from CM of
breast carcinomas. Such is the case in the NRK systems and the
RPMI 2650 system, whereby a range of different factors stimulate
the RPMI 2650 cells but only a limited number appear to stimulate 
NRK cells
In general, the effect of TGF-iJ and other transforming growth
factors are reversible (Shipely et al , 1986), but the soft agar
growth stimulation of murine epithelial cells JB6 by the tumour 
promoter, TPA, has been shown to be irreversible (Colburn et al , 
1979) Soft agar colonies formed in response to single and multiple 
exposures of TPA have been isolated and shown to retain the 
capacity for anchorage-independant growth in the absence of tumour 
promoters. EGF (Colburn et al , 1981) and TGF-fl (Wilder and
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Rizzino, 1991, Hamel et al , 1988) have also been shown to have
similiar irreversible long-term effects on these cells. It would 
be interesting to examine the reversibility of the autocrine 
response of RPMI 2650 cells and see if it is a charactensic of 
this cell line
4 2 THE AUTOCRINE ACTIVITY
From the initial work of Dooley and Clynes (1986) it had been 
established that RPMI 2650 cells produce a factor or factors into 
their conditioned medium that are capable of promoting colony 
formation of RPMI 2650 cells in culture. In this work I attempted 
to better characterise this activity and to possibly identify it 
either as belonging to a class of growth factors already studied or 
as a completely novel factor
Preliminary stability studies on a concentrated batch of
conditioned medium that exhibited linearity with respect to
concentration, indicated that the autocrine activity was partially 
heat-stable, with on average 26% activity remaining following 
boiling for 20 minutes The activity had only limited pH stability
(pH 7 2-8 5) with residual activity remaining at the extremes of
pH The activity was partially lost on treatment with trypsin 
indicating that a protein or peptide was involved in the response
The detrimental effect of low pH on the CM is particularly 
significant since the pH of collected CM often drops to below pH 7, 
which would result in reduced activity levels This undoubtedly 
contributes to the variation between different batches of CM 
collected The fact that all three batches of CM collected from 
the bioreactor runs which were maintained at pH 7 2-7 3, exhibited 
high levels of activity, supports this hypothesis
The presence of residual activity following acid, base and heat 
treatments indicated that there is more than one autocrine factor 
produced by the cells.
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Subsequent stability work showed that the activity remaining 
following heat treatment was completely sensitive to acid and base 
treatments Also boiling of the pH treated samples indicated that 
the acid-stable activity was very sensitive to heat and the base 
treated activity was also sensitive but not to the same extent. 
Thus all the activity could be eliminated by successive heating and 
pH treatments
Initial size determination experiments using different molecular 
weight cut-off ultrafiltration membranes indicated that dilutable 
activity could be isolated in fractions greater than 30 kDa (R30)
and in fractions between 1 and 30 kDa, with no activity presenting 
m  the filtrates (F30 and FI) (although this is not surprising 
since no activity is usually detected in lx samples)
The stability profiles of each of these fractions were shown to be 
quite different from each other indicating that two separate 
molecules or forms of molecules were isolated m  each fraction
The smaller form (Rl-30) is sensitive to heat, acid and base
treatment and may account for the reduction in activity that is
seen in the bulk R1 CM The larger form (R30) appears to be quite 
stable to extremes of pH and temperature and is sometimes capable 
of being activated under certain conditions (extended boiling for 
20 minutes and base treatment) The presence of this molecule may 
account for the residual activity in the R1 fraction following pH 
and heat treatments
Candidates for the Rl-30 fraction.
Because of its unstable nature the Rl-30 fraction is not likely to 
be one of the more common transforming growth factors (TGF-a or 
TGF-J3), the insulin-like growth factors nor PDGF, all of which are 
acid- and heat-stable The members of the heparin binding growth 
factor family are, however in general unstable molecules with 
molecular weights ranging between 15-19 kDa which would fit the 
activity profile of the Rl-30 fraction
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Very little work has been published on heat-labile transforming 
growth factors. This is probably due to the definition of a TGF 
which describes TGFs as 'heat- and acid-stable peptides' and so 
their purification protocols were designed with this in mind The 
widespread occurrence of acid-stable growth factors and cytokines 
in cell systems may, in fact, point to some actions in acidified 
intracellular compartments (e g lysosomes) which remain to be 
elucidated. Lysosomes of animal cells contain a large array of 
different enzymes including proteases which could activate latent 
precursor forms under acidic conditions
A heat- and acid-labile transforming growth factor was identified 
in 77N1 cell (avian sarcoma virus transformed rat cell line) CM 
with an apparent molecular weight of 11 kDa (Hirai et al , 1983)
that could stimulate the soft agar growth of BALB 3T3 cells This 
TGF, when purified, (Yamaoka et al , 1984) was was found not to 
bind to EGF receptors Subsequently it was suggested that this 
factor may be basic FGF (Rizzino and Ruff, 1986) Murine 
embryonal carcinoma cells produce a heat- and acid-labile growth 
factor that stimulates the soft agar growth of NR6-R cells 
(Rizzino, 1986) which has also been implicated as being bFGF
(Rizzino and Ruff, 1986)
Platelet derived endothelial cell growth factor (Miyazonoet al ,
1987) is heat and acid sensitive but its size precludes it from 
being the heat sensitive fraction {45 kDa)
The interleukins and colony stimulating factors
While the interleukins and colony stimulating factors (CSFs) have 
been generally identified for their action on cells of the immune
system, it is becoming clear that many of them also act on other
cell types, for example liver (Arai et al., 1990) and keratmocytes 
(Sauder et al , 1988)
Interleukin 1 (IL-1), originally identified as a product of
activated macrophages, has since been reported to be produced by 
fibroblasts, endothelial cells, keratmocytes and smooth muscle
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cells (Mizel, 1988). The purification of IL-1 (or hemopoietin 1) 
was described by Jubinsky and Stanley (1985) Conditioned media 
from a human urinary bladder carcinoma cell line (5637) was 
purified m  a four step procedure employing batch DEAE-cellulose 
chromatography, chromatofocusing, gel filtration followed by 
hydrophobic chromatography Active fractions were eluted from the 
chromatofocusing column with 11% Polybuffer 74 (pH 3 9) It is 
unlikely that the Rl-30 fraction is IL-1 since its activity would 
be lost at this pH
Interleukin 2 has been purified to homogeneity from T cells (Stern 
et al , 1984) The procedure employed ammonium sulfate
precipitation, ion exchange chromatography followed by reverse 
phase HPLC The buffers used in the last two steps of the 
purification used were 0 05M NaCl/Hepes (25mM), pH 5 5 and acetic 
acid (9M)/pyridine (0 2M) buffer, pH 4 0 The acidity of these two
buffers would destroy the Rl-30 activity, and so it rules out IL-2
as the factor involved
Interleukin 3 (also called Multi-CSF) has been partially purified 
from the myelomonocytic leukaemia cell line, WEHI-3 (Bazill et al.,
1983) and to apparent homogeneity from a cell line of similar 
origin (Clark-Lewis et al , 1984) Exposure of the purified IL-3
to pH 2 for 30 minutes did not cause any loss in activity This
eliminates IL-3 as a possible candidate for the Rl-30 activity
Interleukin 4 (or B cell stimulating factor (BSF)-l) is also 
discounted on the basis of acid stability IL-4 partially purified 
from the CM of EL-4 thymoma cell line that had been induced with 
4i3-phorbol-12J3-myristate-12a-acetate (PMA) by a procedure which
involved adsorption to and elution from TMS-CpG
(tnmethylsilyl-controlled pore glass beads) followed by reverse 
phase HPCL The CM was acidified to pH 4 0 prior to the adsorption 
step (Ohara et al , 1985)
Chromatofocusing, with acidic buffering systems, has been used in 
protocols for the purification of both interleukin 5 and 6. 
Interleukin 5 (previously called T cell replacing factor (TRF), 
B-cell growth factor II (BCGF II), and others) was purified from T 
cell hybndoma CM by ammonium sulphate precipitation, DE-52
179
chromatography, Mono P chromatography followed by gel permeation 
using a Superose 12 column and RP-HPLC (Takatsu et al , 1987)
Fractions were eluted from the Mono P column with 10% Polybuffer 74 
(pH 6 3-4 0)
Human interleukin 6 (or B Cell Differentiation Factor, BCDF) was 
purified from a T cell leukemia virus-transformed T cell line by 
sequential gel filtration and chromatofocusing, again using a Mono 
P column (Hirano et al , 1985), Fractions were eluted with
Polybuffer 74, pH 4 5, which is outside the pH range at which the 
Rl-30 remains stable
Lymphopoietin 1 (LP-1, now designated IL-7) was purified by a
strategy which revealed that its activity was stable to a wide 
spectrum of conditions that included extremes of pH (2 1-8 0) and 
exposure to high temperatures (Namen et al , 1988) The procedure 
included DEAE-Sephacel chromatography, SP-Tnsacyl chromatography, 
Blue B Chromatography and finally three phases of RP-HPLC
Interleukin 8 (Monocyte derived neutrophil activating peptide, 
MONAP, Neutrophil activating factor, NAF) was acidified to pH 3 0 
prior to ultrafiltration (Schroder et al*, 1988) The retentate 
was further processed by gel filtration followed by RP-HPLC 
Examination of the physiochemical properties of NAF showed that the 
factor was stable to pH 2 and 10 and was not sensitive to trypsin 
Exposing the factor to 95°C for 5 minutes only partially reduced 
its activity (Peven et al , 1988) These results suggest that it
is highly unlikely that the Rl-30 fraction is IL- 8
Interleukin 9 (Leukemia inhibitory factor, LIF) has also been shown 
to be acid and base stable A four step purification strategy 
described by Hilton et al (1988) incorporated anion-exchange 
chromatography (DEAE Sepharose), lentil lectin-sepharose 
chromatography, cation exchange-exchange chromatography
(CM-Sepharose) followed by RP-HPLC The fractions were eluted from 
the cation-exchange column with a sodium acetate buffer, pH 5 0.
Interleukin 10 (originally known as cytokine synthesis inhibitory 
factor, CISF) is an acid-labile homodimer that is produced by T
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helper cells. IL-10 has an approximate molecular weight of 35-40 
kDa, however which may preclude it from being the autocrine factor 
(Mosmann and Moore, 1991)
Biologically active interleukin 11 (IL-11) was distinguished from 
IL-1 by a strategy employing chromatofocusing (Nordan and Potter,
1986) with Polybuffer 74, pH 4 0, suggesting its acid stability.
The colony stimulating factors (CSFs) have also been shown to be 
acid-stable.
Murine granulocyte-macrophage CSF (GM-CSF) was purified from IL-3 
(Multi-CSF) by sequential fractionation using salt precipitation, 
gel filtration, anion and cation exchange chromatographies followed 
by HPLC (Prestidge et al., 1984) This protocol involved 
acidifying the partially purified fractions to pH 3 5 before the 
cation exchange chromatography step
A human lymphokme derived from a bladder carcinoma was purified to 
homogeneity by Watson et al , (1986), using a procedure which
employed 0 9M Acetic acid and 0 2M pyridine, pH 4 0 as a buffer 
during the HPLC step This factor was assigned the name granulocyte 
CSF (G-CSF).
Macrophage CSF (M-CSF) has been reported to lose activity when 
stored for one week at pH 2 1 in the presence of acetonitnle or 
isopropanol These conditions apparently cause subunit dissociation 
and so inactivation The purification strategy however includes 
RP-HPLC from which proteins were eluted in a gradient of aqueous 
sodium chloride (adjusted to pH 2 1 with HC1) and acetonitnle 
When eluted the pH of the fractions was adjusted to pH 6.5 with 
phosphate buffer/Tween (Burgess et al , 1985) The exposure of the 
factor to pH 2 1 would undoubtedly cause loss of activity in the 
Rl-30 fraction
A purification strategy for erythropoietin (EPO) was described 
(Sasaki et al , 1987) in which biologically active EPO was eluted 
from immunoaffinity columns at pH 2 5 This again suggests that EPO 
is not the Rl-30 fraction
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It therefore appears that the autocrine factor present in the Rl-30 
fraction may be a novel growth "factor, although any definitive 
conclusion on this will depend on purification to homogeneity and 
sequencing
Candidates for the R30 fraction.
The R30 fraction on the other hand may belong to any one of the 
families of growth factors mentioned above The IGF molecules are 
about 7 kDa although they are normally found bound to various
larger plasma carrier proteins which would result in a higher
molecular forms (Hossonlop et al., 1990, Baxter and Martin, 1989; 
Kiefer et al , 1991) It may be possible that the larger molecule 
may be acidic or basic FGF in a complex form with either heparin, 
c^-macroglobulin or some other binding protein which would by its 
presence both increase the molecular weight of the molecule and 
protect it from acid, pH and trypsin treatments
The activation of this fraction following boiling and base 
treatment is interesting and was examined further Out of 4
different batches of CM, 2 lots were found to be activated on 
extensive boiling The assays on these samples were carried out 
with the same serum, cell pretreatment, etc each time
Eventhough each CM batch was collected according to the same 
procedure, however, the pH varied from one batch to the next 
While this may not be a direct cause of the differences in activity
in the CM, it may be an indicator of the how the producer cells
were growing during CM collection
Extensive boiling results in the trypsin stable R30 moiety becoming 
trypsin sensitive, again supporting the theory of a binding moiety 
protecting the R30 fraction On boiling this moiety is released 
making the R30 fraction more labile to physical treatments (eg pH 
or proteases) Boiling at low pH resulted in loss of activity.
An alternative theory suggests that the R30 fraction has a 
particular conformation that allows it to be very stable but on 
boiling, this conformation is altered m  some way making the 
molecule more susceptible. The results in Table 3 6 7 corroborates
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the second theory, since the R30 fraction does not appear to be 
broken down into smaller moieties on boiling, although the 
possibility of a very large complex being broken down into subunits 
greater that 30,000 MW must not be discounted.
The data presented in this thesis does not allow for any conclusion 
whether or not the R30 autocrine activity (after boiling or pH 
treatment) becomes identical to the Rl-30 factor, or whether a 
totally different molecular species is involved. The treated R30 is 
pH and trypsin labile and loses activity following boiling at low 
pH, but it cannot be concentrated in the Rl-30 fraction (Section 
3 6 6 )
Molecules have been identified which reversibly bind and with low 
affinity to their ligands and seem to act as carrier molecules 
These binding molecules in some cases have been shown to protect 
the growth factors from proteolytic attack and exposure to extremes 
of pH and temperature
Heparin has been shown to potentiate aFGF-induced proliferation of 
human endothelial cells (Thorton et al , 1983, Schreiber et al , 
1985, Mueller et al , 1989) and rat pheochromocytoma cells (Damon 
et al , 1989) In contrast it exerts positive or negative effects
on the bioactivity of bFGF depending on the cell type and on 
experimental conditions (Neufeld et al , 1987, Barzu et al , 1989,
Shipely et al , 1989, Gospodarowicz et al , 1990) Heparin has 
been shown to protect both acidic and basic FGF from heat and acid 
inactivation (Gospodarowicz and Cheng, 1986), bFGF from plasmin 
(Saksela et al , 1988), trypsin and partially from chymotrypsin
treatments (Sommer and Rifkin, 1989)
An interesting paper was published on the trypsin sensitivity of 
bFGF by Doble and his co-workers (1990). High molecular weight 
(23 7 and 27 kD), immunoreactive bFGFs from bovine pituitary and 
heart extracts were found to be susceptible to proteases which 
break it down to its standard 18 8 kD form This form, which has 
a high affinity for heparin, is apparently stablilised to 
subsequent protease treatment by binding to heparin.
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Heparin is a mucopolysaccharide with molecular weight in the range 
6-20 kDa depending on source (Merck Index). When heparin binds the 
18.8 kDa form of bFGF it forms a complex in the region of 24 - 38 
kDa. Such a complex may be concentrated in the RPMI 2650 R30
fraction On boiling the R30 fraction, the binding component is 
removed (heparin), releasing free bFGF, which should be 
concentrated in the Rl-30 fraction This is not the case however 
since Table 3 6 7 shows that the activity of the R30 fraction does 
not shift into the Rl-30 fraction following boiling Therefore a 
hepann-bFGF complex does not seem to be an explanation for this 
effect.
Endothelial cells have been shown to secrete high molecular mass 
heparan sulfate proteoglycans and glycosaminoglycans which can bind 
bFGF in the same manner as heparin, eliciting similar protective 
effects (Saksela et al , 1988) A similar secretion from RPMI
2650 may account for the presence of a binding protein in the R30 
fraction, which is partially removed on boiling
Binding proteins for a number of growth factors have been 
identified These proteins in general inactivated their ligands and 
so regulate activity by reducing concentration of the free ligand
c^-Macroglobulin (Harpel PC, 1973) a serum protease inhibitor (MW 
280 kDa) has been found to act as a binding protein for PDGF (Huang 
et al., 1984), TGF-B (O'Connor-McCourt, et al , 1987, Huang et 
al , 1988) and bFGF (Dennis et al , 1989) Because of its tight
binding, this protein does not seem to be a carrier protein for 
these factors, rather a means of eliminating it from the 
circulation
i^-Macroglobulin cannot be removed from PDGF by pretreatment with 
either 8M urea, 1M acetic acid, 0 1M NaOH or 1% NaDodS04 at 100°C 
for 10 minutes, which suggests that covalent binding is involved 
Dissociation does occur however following treatment with 2 
mercaptoethanol
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It is important to note that c^-macroglobulin attachment to bFGF 
results in its lack of affinity with heparin (Dennis et al , 1989) 
This may be significant to the R30 factor which as shown in Table 
3 8.3 does not bind heparin sepharose.
a^-Macroglobulin complexes with either TGF-J3 or bFGF are unlikely 
to be the R30 factor, since dissociation would result in autocrine 
activity concentrating in the Rl-30 fraction and not remaining in 
the R30 fraction PDGF is a dimer with a molecular weight of 
approximately 30 kDa It is possible that dissociation of this 
complex from a^-macroglobulin would result m  the activity 
remaining in a form that could be concentrated in the R30 fraction 
PDGF is however acid-stable, so removal of the a^-macroglobulin 
should result in an acid-stable moiety which is not the case with 
the R30 fraction
a2-Macroglobulin binding results in loss of biological activity, 
which is not the case with the R30 fraction which is active prior 
to boiling Therefore, for a number of reasons it is unlikely that 
c^-macroglobulin is involved in complex formation with the 
autocrine activity in the RPMI 2650 R30 fraction
The binding proteins for IGFs appears to play a similar role to 
a2-macroglobulin Various forms of IGF-carrier protein complexes 
have been described, with 5 different IGF binding proteins 
(IGF-BP) been reported to date Their native molecular weight on 
SDS-PAGE under non-reducing conditions is shown m  the table below
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TABLE 4.2 IGF binding proteins
Native MW Reference
IGFBP-1 28-30 Hossenlopp et al., 1990,
IGFBP-2 33-35 ibid
IGFBP-3 38 5, 41.5 Baxter and Martin , 1989,
IGFBP-4 22 6 Kiefer et al , 1991,
IGFBP-5 26 ibid
In serum, IGF is found in two m a m  fractions of about 50 and 150
kDa (Zapf et al , 1975) The smaller complex is made up of IGF and
the binding proteins 1, 2, 4 or 5, The 150 kDa complex is composed 
of three subunits; an acid labile 80-85 kDa subunit, IGFBP-3 and 
either IGF I or IGF II.
It is unlikely that IGFBP is responsible for the stability (and 
possible stimulation) of the RPMI 2650 R30 activity for a number of 
reasons IGFBPs block binding of IGF to its receptor and so inhibit 
its action, while activity is present in the untreated R30 sample 
Also, acid treatment of the IGFBP-IGF complex releases free IGF 
(heat-stable) (Smith et al , 1987), whereas acid treatment
results m  the R30 fraction becoming heat-labile (see Table 3 6 5)
TGF-i3 has also been shown to bind reversibly to the extracellular
matrix proteoglycan, decorin, via its core protein (Yamaguchi et 
al , 1990) Association of the complex results in loss of TGF-B
activity, indicating again that this type of complex formation is 
not a factor in the autocrine activity present m  the R30 fraction
TGF-J3 is secreted in latent forms consisting of the active 
molecule, a N-terminal peptide (LAP) (Gentry et al , 1989) and a
high molecular weight binding protein (Miyazono et al , 1988)
This latent form can be activated by acidification (Pircher et al ,
1984) and/or trypsin treatment (Lyons, 1988) which is not the case 
with the R30 fraction where acid treatment and treatment with 
trypsin left the autocrine activity unchanged. Other reports
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suggest that brief heat treatment may activate latent TGF-I3 (Brown 
et al , 1990), although again short heat treated did not activate
the R30 fraction, it required extensive boiling.
Lyons et al (1988) found a large (62 kD) inactive form of TGF-13 
in the CM of NRK-49F and HT-1080 cells which could be activated by 
treatment with plasmin but not by acid or urea, indicating that 
there could be different latent forms of TGF-J3, one of which may 
account for the R30 activity
The large molecular weight factor may also be due to covalently 
linked carbohydrate moieties, which on their removal reduces the 
molecular weight of the molecule without loss in activity, such is 
the case with the human colony-stimulating factors (CSFs) Human 
CSFs (GM-CSF, G-CSF, M-CSF and IL-3) are glycosylated polypeptide 
chains with native molecular weights of 18-30, 20, 45-90 and 15-30 
respectively (Metcalf, 1991) Cloning of these factors has shown 
that removal of the carbohydrate moieties does not impair their 
biological function, while reducing their respective molecular 
weights to 14.7; 18 6; 21 and 18, and 15.4 kD. Although it has
not been reported in this case, the loss of the carbohydrate 
moieties may result in decreased stability and increased 
susceptibility to proteolytic attack Working on the basis of 
size, none of these homeopoetic growth factors is likely to be the 
R30 fraction, although a similar effect could result from other 
glycoprotein growth factors
Also, a 17 kDa protein has been identified which binds both acidic 
and basic FGF (Wu et al , 1991) in a non-covalent, reversible way. 
Binding causes inhibition of the biological activities of both 
acidic and basic FGF But both the binding and inhibition are 
abolished by the presence of heparin
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From these stability results a number of hypotheses are suggested.
(a) There are (at least) two distinct components in the R30 
fraction Component I is inactive in the assay and cannot be 
activated until after extensive boiling/base treatment. Component 
II is particularly heat-stable and is able to withstand prolonged 
boiling In some batches of CM component I is not present or at 
very low concentrations, which would account for CM batches which 
could not be activated on boiling Component I may be a latent form 
of growth factor (e g TGF-13) or associated with a blocking 
binding molecule (e.g. a2-macroglobulin).
(b) There are (at least) two distinct components in the R30 
fraction Component I is only partially active and its activity is 
enhanced by boiling and so it contributes to the overall R30 
(unboiled) activity Component II is partially heat-stable, and its 
loss in activity on boiling is overshadowed by the activation of 
component I The actual ratio of component I * component II is CM 
batch dependent
(c) There is one major component in the R30 fraction but in 2 
different conformational forms, one of which is heat-stable and a 
second that is capable of activation Again the concentration of 
the inactive or subactive form is a function of the CM
(d) There is one stimulatory and one inhibitory component in the 
R30 fraction. Boiling results in the distruction of the heat-labile 
inhibitor, but does not effect the stimulator which continues to 
elicit a response m  the conditioned medium
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4 3 PURIFICATION
Before further characterisation of the autocrine response could be 
undertaken, a fraction with higher purity was required A number of
strategies were examined to try to purify the factor.
Ion exchange and hydrophobic interaction chromatographies were not 
particularly successful due to a combination of the effect of pH 
extremes and dialysis (in the case of ion-exchange chromatography) 
and dialysis alone (in the case of hydrophobic interaction). The 
autocrine growth activity had been shown previously to be
dialysible (Dooley, 1987, Section 3.14.1), but in the experiments
described in this thesis, activity was lost in the controls 
compared with undialysed CM retentates It is possible that this 
was due to the particular batch of dialysis tubing used for these 
experiments
Interestingly, Bazill et al (1983) found that dialysis led to 
variable loss of IL-3 activity, while it was possible to 
ultrafiltrate the activity using YM ultrafiltration membranes 
Similar findings were reported by Burgess et al (1980) during the 
purification of GM-CSF from T19 1 cells
Originally, Dooley (1987, thesis) carried out a purification 
strategy which incorporated dialysis against 1M acetic acid and 
Bio-gel P60 and P30 gel chromatographies using 1M acetic acid as a 
running buffer. Some activity was isolated although this was not 
compared to the original CM activity so the yield of the eluted 
fractions was difficult to determine The activity presenting in 
these experiments was most likely due to the acid-stable R30 
fraction and not to the bulk activity in the bulk conditioned 
medium
Because of the stimulatory effects of acidic and basic fibroblastic 
growth factors m  the autocrine assay, heparin sepharose 
chromatography was examined as an alternative to ion-exchange, gel 
filtration and hydrophobic interaction chromatographies.
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Heparin sepharose chromatogrpahy is a well established procedure
*  i ^for purifying members of the fibroblast growth factor family. 
Heparin is a natural mucopolysaccharide with anticoagulant 
properties It consists of D-glucosamine and D-glucuronic acid 
residues and a large number of amino groups combined with sulphate 
groups As a result of its composition, heparin is a general 
ligand and can combine with a number of proteins and polycationic 
organic compounds, by either specific or ionic mechanisms
For every run through the heparin sepharose column, two distinct 
fractions were isolated, a fraction that bound weakly to heparin
which could be eluted with 0 5M NaCl and a fraction that appeared
to have no affinity for heparin
In the initial run activity was eluted following addition of 0 5 M 
NaCl with some activity being eluted at 0 25 M NaCl Above this 
concentration of NaCl no further activity was eluted Initially 
this was attributed to growth inhibition by high salt 
concentrations In these experiments the control medium samples
supported low colony formation and so the assay was unable to pick
up inhibition But subsequent diafiltration of pooled fractions 
showed that while the high salt concentration did in fact cause 
some inhibition, no autocrine activity was eluted above 0 5M NaCl
The broad specificity of heparin sepharose chromatography makes 
identification of the heparin binding moiety difficult Many 
proteins have a stronger affinity for heparin than the RPMI 2650 
factor
Heparin-binding growth factors are isolated primarily by their 
strong affinity for heparin which requires salt concentrations of 
higher than 1M NaCl for elution Acidic and basic FGFs elute from 
heparin sepharose at 1 0M and 1 5  M NaCl respectively (Shing et 
al., 1984) FGF4 (hst/K-fgf) and FGF 5 have similar affinities 
(Klasgsburn, 1989) FGF3 {mt-2) appears to be non-heparin 
binding KGF, the seventh member of the FGF family has been 
reported to elute from heparin sepharose columns at 0 6M NaCl 
(Rubm et al., 1989).
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A heparin-binding EGF was also described (Higashiyama et al , 1990, 
Higashiyama et al., 1992), this elutes from heparin sepharose at 
1 0 to 1 2 M NaCl.
Two heparin-binding growth factors have been isolated from rat 
brain. Pleiotrophin, an 18 kDa neunte-promoting factor (also 
called HB-GAM and FGF-8 ) (Li et al , 1990, Merenmies and Rauvala,
1990) binds heparin tightly, being eluted at salt concentrations of 
1 5M NaCl (Rauvala and Pihlaskan, 1987). The sequence shows, 
however, that it is not a member of the heparin-binding growth 
factor family and cannot be designated FGF 8 as previously assigned 
(Merenmies and Rauvala, 1990). A 30 kDa component (p30) was 
isolated in these studies as a major neuron-binding protein, and 
was suggested to have a regulatory role in neuronal growth (Rauvala 
and Phlaskan, 1987) p30 is detached from heparin sepharose at
0 75-1 0M NaCl in salt gradients
The protein encoded by the MK gene has been identified as a heparin 
binding protein (Tomomura et al , 1990) This gene was expressed
temporarily during the early stages of retinoic acid-induced 
differentiation of embryonal carcinoma cells as well as during the 
midgestation period of mouse embryogenesis (Kadomatsu et al ,
1988). This study led to the isolation of a 19 kDa heparin-binding 
protein secreted by chicken embryos (Vigny et al , 1989) which can
be induced by retinoic acid, called retinoic acid induced-heparin 
binding (RI-HB) protein This protein can be eluted from heparin
sepharose columns at 1-1 1 M NaCl and it has the same apparent
biological activities as HB-GAM (neunte outgrowth and
proliferation of PC12 cells) (Raulais et al , 1991). RI-HB and
HB-GAM have very similar N-termmal sequences It is not known if 
the MK protein is the mammalian counterpart of RI-HB or whether 
they are two distinct members of the same family
Other growth factors bind heparin sepharose less tightly and can be 
eluted at lower salt concentration, similar to that of the bound 
RPMI 2650 activity.
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Vascular endothelial cell growth factor (VEGF), a mitogen for
endothelial cells, has been isolated from a variety of sources
including bovine pituitary folliculo-stellate cells (Ferrara et 
al , 1989, Gospodarowicz et al , 1989); rat glioma cells (Conn et
al., 1990) and a human epidermoid carcinoma line (Myoken et al , 
1991). This 40-46 kDa protein elutes from heparin sepharose columns 
at 0 3 M NaCl
Epithelial transforming growth factor (TGFe) (Halper and Moses, 
1983) was originally isolated in a 59 kDa form that did not bind
heparin Subsequently a lower molecular weight form of this 
molecule was isolated from bovine kidney (Dunnington et al , 1990,
Parnell et al , 1990) which could be eluted from heparin sepharose 
at 0 5 M NaCl.
Also, an IGF-II-like peptide isolated from fetal bovine serum was 
shown to have a weak affinity for heparin and could be eluted from 
heparin sepharose columns at about 0 5 M NaCl (Li et al., 1990) In 
this same study IGF I was also applied to a heparin sepharose 
column and was found to bind, being eluted at salt concentrations
less than 0 5M.
PDGF also has been shown to bind heparin and can be eluted with 0 5 
M NaCl (Shing et al., 1984, Klagsbrun et al , 1985).
Mouse embryonal carcinoma (EC) cells have been shown to produce two 
heparin-binding factors one, thought to be related to PDGF, which 
is eluted at low salt (0 3-0 5M NaCl) and a second, related to 
bFGF, which is eluted at high salt concentrations (Tiesman et al ,
1988)
Granulocyte-macrophage colony stimulating factor (GM-CSF) and 
interleukin 3 (IL-3) (Roberts et al., 1988), as well as melanoma 
growth stimulatory activity (MGSA)/gro, Interleukin 8 (IL-8 )
(Derynck et al., 1990) and connective tissue activating peptide 
(CTAP III) (Castor et al , 1991) are all eluted from heparin at
low salt concentrations
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Secreted Int-1 protein from a cloned fibroblast cell line 
(MXI-5/R2) was found to bind heparin agarose and to be eluted with 
a salt concentration of about 0 6M NaCl (Bradley and Brown, 1990)
Many purified growth factors are presumed not to be 
heparin-binding, but in a lot of cases these studies are carried 
out using a running buffer of 0 6M NaCl, which would preclude any 
factors weakly binding heparin sepharose (such as those secreted by 
RPMI 2650 cells) and would not isolate factors that might bind to 
heparin sepharose under physiological salt concentrations Examples 
of such running systems are presented in the table below
TABLE 4 3 Examples of heparin sepharose systems using running 
buffers containing NaCl
Source of growth factor NaCl (M) 
of running 
buffer
Reference
Human malignant gliomas 
Chick basement membrane 
Mouse mammary tumour
0 6 
0 65 
0 6
Rutka et al , 1989 
Vigny et al , 1989 
Kasayama et al , 1991
Other growth factors have no affinity for heparin sepharose These 
include EGF, TGFa, TGFI3, Tumour necrosis factor (TNF)-a and IL-1 
(Klagsburn, 1989)
To get a better idea of what factors could be present in the 
fraction bound and unbound to the heparin sepharose, stability 
studies similar to those carried out on the bulk conditioned media 
and on the samples fractionated by ultrafiltration were done These 
results indicated that the unbound fraction exhibited 
characteristics similar to that seen in the R30 retentâtes (i e 
acid- and base-stable, and stable to boiling for 6 minutes, with an
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activation after 20 minutes), while the fraction bound to the 
heparin was acid- and base-labile and sensitive to temperature 
(similar to the Rl-30 fraction)
The similarity of the bound activity to the Rl-30 activity and the 
unbound to the R30 warranted further investigation Samples 
fractionated by ultrafiltration into Rl, Rl-30 and R30 fractions 
were applied to heparin sepharose in the same manner as before. The 
Rl fraction gave similar results to the straight CM with activity 
distributed between the bound and the unbound fractions. The Rl-30 
fraction was found to be predominantly heparin-binding while the 
R30 fraction was predominantly non-heparin binding This result 
gives an indication of the sizes of the factors involved and may be 
used along with stability information to narrow down the number of 
characterised growth factors that may be acting in the RPMI 2650 
system
The number of pH and temperature sensitive growth factors that 
weakly bind heparin is limited
Basic and acidic FGF are both heat-labile. While acidic FGF can 
withstand acidic conditions, basic FGF, when exposed to a pH lower 
than 4 0, losses 95-97% of its potency (Gospodarowicz et al ,
1985) However, aFGF and bFGF have higher affinities for heparin 
than the bound RPMI 2650 fraction, being eluted from heparin 
sepharose columns at salt concentrations of above 1M NaCl KGF is 
also heat and acid labile (Rubin et al , 1989) but has been found 
to be eluted at salt concentrations of 0 6M NaCl and so is unlikely 
to be the RPMI 2650 factor Other members of the FGF family are 
not well characterised as regards acid and heat stability but can 
be discounted as a possible candidate for the Rl-30 factor since, 
besides FGF-3, they all have higher affinities for heparin
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TABLE 4 4 The Fibroblast Growth Factor Family
Name
Elution from 
heparin sepharose 
(M NaCl)
Size
(kDa)
Stability 
Heat acid
aFGF 1 - 1 2 15-18 L S
bFGF 1 5-2 16-18 5 L L
int-2/FGF3 0 28 5
hst-1/FGF4 1 - 1 2 17.5
FGF5 1 0
hst2/FGF6 1 0
KGF 0 6 28 L L
S=stable L=labile
The bound fraction is not likely to be VEGF which is eluted from 
heparin sepharose at 0 3M NaCl This factor has been reported to be 
stable to boiling for 5 minutes and to acidification to pH 2 5 for 
5 hours (Myoken et al , 1991) Also glioma derived and pitiutary
folliculo-stellate cell derived VEFGs are discounted as being the 
heparin-binding fractions since their molecular weights were each 
determined to be 46 kDa (Conn et al , 1990, Gospodarowicz et al ,
1989).
TGFe has been shown to be stable to boiling for 5 minutes following 
a purification procedure which employed acidic running buffers 
(Halper and Moses, 1987), and so could not be the bound factor
IGF I and II are bioassayed following acidification to remove 
binding proteins (Tamura et al , 1989, Greenstem et al., 1987),
indicating their acid stability
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MGSA has been designated a member of a family of acid- and 
heat-stable polypeptides, which includes CTAP III, that act in an 
autocrine fashion to stimulate the growth of malignant melanoma 
cells in serum free medium, (Richmond et al., 1986) so it is 
unlikely that the bound factor in the RPMI 2650 system belongs to 
this family
PDGF has been well characterised as a heat stable growth factor 
(Antoniades, 1981) and purified preparations are routinely stored 
in 1 M acetic acid (-20°C) without loss of activity for several 
months (Heldin et al , 1987).
As described previously GM-CSF, IL-3 and IL- 8 are also acid stable.
The Rl-30 factor is unlikely to be int-1 since this protein is 
eluted at 0 6M salt The size restriction also rules out the 
possibility of the secreted int- 1 protein being the factor 
involved Bradley and Brown (1990) have shown that the int-1 
protein has a molecular weight of 44 kDa under reducing conditions
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TABLE 4 5 Non-FGF Heparin-binding Growth Factors
Name
Elution from 
heparin sepharose 
(M NaCl)
Size
(kDa)
Stability 
Heat acid
HB-EGF 1 - 1 2 19-23
VEGF 0 3 46 S S
TGFe 0 5 11 S S
IGF II 0.5 16,8,7 S S
IGF I <0.5 7 S s
PDGF 0 5 28-36 s s
GM-CSF 0 5 22 s s
IL-3 0.5 25 s s
MGSA 0 5 8 s s
IL-8 0 5 8 s s
int- 1 0 6 44
A range of adhesive molecules bind weakly to heparin sepharose 
These include mouse laminin, which is eluted at salt concentrations 
of 0 2-0 4M NaCl (Engvall et al , 1983) Fibronectin has also a
weak affinity for heparin and is eluted from hepann-agarose 
columns with 0 5M NaCl (Bober Barkalow and Schwarzbauer, 1991) 
These factors are not likely to be the heparin binding entity in 
the RPMI 2650 CM since these factors normally have a much larger 
molecular weight than would be concentrated in the Rl-30 fraction
Affinity for heparin reflects binding to heparin-like molecules on 
cell surfaces, in extracellular matrices and basement membranes In 
general the affinity of a protein for heparin sepharose is higher 
than its affinity with heparan sulfate Such is the case with the 
19 kDa protein isolated from chick embryos (Vigny et al , 1989,
ibid) and bFGF (Vigny et al , 1988) In the case of the 19 kDa
protein, elution from heparin sepharose occured at 1-1.1 M NaCl 
which it could be displaced from the basement membranes at only 
0.5M NaCl Thus the weak affinity of the RPMI 2650 factor for
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heparin does not necessarily imply that the factor is bound under 
normal physiological conditions to heparan sulfate chains of 
proteoglycans m  the extracellular matrix
It has been known for some time that heparin inhibits growth of 
non-transformed BHK/21/13 cells m  agarose (Sanders and Smith, 
1970) Whether this may be simply a matter of heparin taking growth 
factors out of the autocrine circulation system or whether heparin 
is a true inhibitor is not clear. Heparin however does not affect 
the growth of RPMI 2650 colonies in soft agar.
An interesting study was undertaken by Seno et al (1990), where 
they constructed terminally truncated bFGF in £. coh  The first 
group of truncated proteins lacked the basic region present at the 
carboxyl-terminus of bFGF (including one of the heparin binding 
sites Arg107 Ser108 Arg109 Lys110) and was eluted from heparin 
sepharose in a single peak at 0 3M NaCl, and retained weak 
mitogenic activity on BALB/c 3T3 cells The second group had the 
heparin binding site but lacked Phe^39, Leu140 and Pro141 This 
group is present in cell membranes and is also eluted m  a peak of 
0 3M NaCl along with an equal sized peak at 1-1 3M NaCl As the 
number of amino acids truncated was reduced, the affinity of the 
protein for heparin appeared to shift to the 1 3M NaCl eluted form 
and high mitogenic activity
Any of the characterised growth factors that have no affinity for 
heparin listed above (EGF, TGFa, TGFfi, TNF, IL-1) could account for 
the non-heparin binding fraction of conditioned medium, since each 
are stable to acid and heat treatments Alternatively, the unbound 
fraction may be a result of heparin- or heparan sulfate-bound FGF
Heparin protects FGF from heat, pH and protease treatments and
also blocks binding to heparin sepharose columns (as described 
before)
An interesting result was presented in Table 3 8 4, where TGF-J3
activity in the R1 and R30 samples was predominantly heparin
binding with considerably lower levels of activity in the unbound 
fractions This is unexpected since TGF-B has not been previously 
reported as being heparin binding (Klagburn, 1989) It has been 
reported, however that IGF I and II have a weak affinity for
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heparin sepharose This together with the results presented 
previously that IGF I and II caused a positive response in the 
NRK-49F assay system, would indicate that possibly RPMI 2650 cells 
produce an IGF-like molecule which binds heparin sepharose and can 
be detected by the NRK-49F soft agar bioassay. This hypothesis 
could easily be discounted if this TGF-G-like activity was heat 
sensitve since both IGF I and II are heat-stable molecules
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a 4 SCALE-UP OF THE GROWTH AND AUTOCRINE FACTOR PRODUCTION
FROM RPMI 2650 CELLS
Routinely conditioned media from RPMI 2650 cells were collected 
from roller bottle cultures This involved seeding the cells from 
one large flask into a roller bottle and growing the culture for 
one week, after which collection of CM is possible Up to 600 mis 
of CM could be collected from each roller bottle over one week (100 
mis daily, discarding the first collection) The collection 
procedure is long (2 weeks from innoculation to final collection), 
quite labour intensive and the contamination risk is high
The large-scale aspect of this project was designed to improve on 
this procedure by producing more (active) conditioned medium m  a 
shorter time, with less risk of contamination This was to be 
achieved in a computer controlled bioreactor (1*8 litre capacity) 
Before this capacity could be attempted, a number of preliminary 
questions had to be addressed Can microcarriers be used, and what 
type? Can the cells grow in suspension? What is the most 
appropriate medium and sera to use’ Does agitation rate effect 
growth factor production’ Does oxygen levels effect growth factor 
production9
Microcarrier cultures
RPMI 2650 cells grow in monolayer on plastic ( m  tissue culture 
flasks) and on glass (in roller bottles) In the first set of 
experiments different types of microcarrier beads were examined for 
their suitability as regards growth and autocrine activity 
production.
Microcarriers (van Wezel, 1967) are small spherical beads 
suspended in culture medium which provide a surface for cell 
attachment and allow monolayer cell growth to occur The beads 
must have a continuous even surface for the cells to attach and be
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large enough that the curvature of the surface will not affect 
growth (ideally about 200-300pm) It is important that the 
distribution in size of the beads is narrow This ensures that the 
cells on each bead become confluent at the same time The beads 
are slightly more dense than water, so they settle quickly, but can 
be kept in suspension with little agitation.
The first type of bead examined were glass, plastic and collagen 
coated Biospheres (Whatman) (plastic matrix, density 1 02 g/ml, 
diameter 150-210f¿m). Although they allowed attachment and growth of 
cells, they were found to be unsuitable since, because the beads 
were not translucent, it was difficult to make routine observation 
of the cells The dextran Cytodex beads (Pharmacia) had excellent 
optical properties and therefore had more potential as a scale-up 
tool for the RPMI 2650 cells
The surface coating of the bead is very important for attachment 
and growth Plastic coatings (sulphonated polystyrenes) mimic the 
surface of culture flasks, and so the cells should grow and 
secrete product in the same manner as culturing them in flasks The 
main disadvantge of this type of bead is its optical properties. 
Glass beads provide a negatively-charged surface and this allows 
rapid cell attachment and detachment Because of its high density, 
glass is usually coated on less dense materials (e.g plastic), so 
it can be kept in suspension more easily The growth of cells on 
these beads is similar to growth in roller bottles. In practice, 
however, the growth rate from both these bead types is also 
affected in spinner flasks by shear effects (discussed later) and 
so it cannot be considered identical to conventional monolayer 
systems.
The connective tissue protein, collagen, has been widely used as a 
cell culture substrate Cytodex 3 microcarrier beads are coated
with a surface layer of denatured collagen covalently bound to a
matrix of cross-linked dextran The denatured collagen (MW
60,000-200,000) is derived from pig skin type I collagen which has 
been extracted and denatured by acid treatment, concentrated and 
purified by ion-exchange before coupling to dextran Collagen is
present m  basement membranes on which cells adhere in vivo and has 
a high affinity for fibronectin which promotes cell attachment and 
spreading (Kleinman et al , 1981)
Cytodex 1 and 2 consist of dextran beads cross-linked with 
positively-charged molecules N,N-diethylaminoethyl (DEAE) groups 
are distributed evenly through the dextran matrix in Cytodex 1 
beads. Whereas Cytodex 2 beads have an outer layer of positive 
charges (N, N,N-tnmethyl-2hydroxy-aminopropyl groups) (See
Appendix E). Because Cytodex 2 beads do not have charged groups 
present inside their matrix, negligible binding of medium 
components and cell products occurs
The exchange capacity of microcarrier beads has been considered a 
critical factor for attachment and growth of animal cells. This
parameter is based on the total protonation of the molecules
attached to the supporting backbone polymers Complete protonation 
occurs at very low pH levels (below pH 2 0) At pH 7 4, only a 
portion of the molecules are protonated Thus the charge density 
under physiological conditions is the actual critical parameter 
(rather than exchange capacity) for cell attachment (Himes and Hu,
1987).
Cell attachment to Cytodex 1 microcarrier beads has been found to 
be primarily an electrostatic effect. Attachment rates can be 
reduced in the presence of serum (Himes and Hu, 1987) However, 
the cells remain rounded and do not spread until after serum has 
been added Because of this some researchers suggest that the 
initial attachment of cells onto the beads should be done in PBS 
rather than in medium supplemented with serum.
The overall growth kinetics of RPMI 2650 cells on each of the
Cytodex beads tested were similar However, the production of
autocrine activity was variable depending on the bead type When 
the activity was calculated on a 'per cell' basis, the results 
indicated that the cells growing on the Cytodex 3 microcarrier 
beads were not producing autocrine activity or else the autocrine 
activity was being adsorbed onto the bead Either way, the level 
of activity collected in the CM was negligible compared with the CM 
collected from cultures of cells grown on Cytodex 1 or 2
-i
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The studies on attachment rates described in the literature are 
based on how quickly the cells attach to the beads, in terms of 
minutes. In the work presented in this thesis the percentage of 
attached cells is calculated on a daily basis This gives a better 
indication of the performance of the beads during a culture run 
(with agitation), and is probably more appropriate for deciding the 
suitability of the bead type.
The fact that quite a large number of cells could grow well in 
suspension implied that the cells were capable of anchorage 
independent growth Microcarrier culture is an excellent way of 
propagating large numbers of anchorage-dependent cell lines But if 
the cells could grow well and produce CM containing reasonable 
levels of autocrine activity without a surface to attach to, there 
would be no need to use them
Suspension cultures
The remainder of the scale-up work m  this thesis was carried out 
on cells grown in suspension The cells did not grow as single 
cells (like hybndoma cells) but rather in small clumps or floes 
This type of system is termed a "cell aggregate suspension" 
culture This system has been optimised for other anchorage 
dependent cell lines for example HepG2 and 293 (Hu and Peshwa, 
1991) Some transformed cell lines have also been cultivated as 
aggregrates (Tolbert et al , 1980)
In microcarrier cultures the ratio of the settled bead volume to 
culture volume is low This is a major disadvantage as it 
difficult to maintain a homogeneous suspension while keeping shear 
on the cells low (Hu and Wang, 1986) Compared with a microcarrier 
culture, the settled volume of the solid phase in an aggregate 
culture is much lower at the same cell concentration
Different methods have been used to induce aggregate formation for 
cells which normally grow on or prefer to grow on surfaces This 
usually involves the use of medium containing a low concentration 
of calcium m  conjunction with a moderately high agitation rate
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This method of cell cultivation allows for an easier cell retention 
m  perfusion systems due to the large size of the particles, and 
thus high cell concentrations can be acheived
There has been some studies on lectin-induced agglomeration of 
cells after trypsinisation (Jones and Perry, 1980). But this 
approach has not been developed any further.
Aggregate cultures can also be induced by adding microspheres to 
the cells (Goetghebeur et al , 1990, Goetghebeur and Hu, 1991/92).
Microspheres are similar to conventional microcarriers but are much 
smaller in size (10-60 ¡jm) The method of action is similar to the 
seeding of crystals in a crystallization process to induce crystal 
growth The cells attach preferentially to the microsphere surface 
rather than to each other An aggregrate is formed by outgrowth of 
cells and/or by agglomeration of a number of beads
The RPMI 2650 cells were 'encouraged' to grow in suspension by 
siliconising the culture vessel before autoclaving This made the 
glass surfaces hydrophobic and so prevented the cells sticking and 
attaching The cells then apparently used each other as attachment 
substrates and formed tight, discrete clumps
The initial suspension work done with RPMI 2650 cells used standard 
MEM media (supplemented with foetal calf serum) (Gibco) containing 
200 mg/litre calcium chloride The cells grown in suspension with 
this medium formed tight aggregates which were very difficult to 
trypsinise and count
MEMS (Gibco) (see Appendix G for composition) performed much better 
in the RPMI 2650 system The cells grew well and formed loose 
floes This type of floe formation has a number of other 
advantages Oxygen and nutrients can pass easily through the floe 
to the cells growing in its core. Waste products can pass out into 
the surrounding medium Therefore loose aggregates provide a more 
homogeneous system Also, CM collected from the MEMS culture 
system exhibited higher levels of autocrine activity than that from 
the MEM culture after a three day period
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Unlike in monolayer cultures, the batch of serum used does not 
appear to have a dramatic affect on the rate of growth of the 
suspension cultures A number of different batches of donor horse 
sera were examined and compared with the batch of FCS that had been 
used for routine culture of RPMI 2650 cells Comparable growth 
curves were generated This may be a reflection of the variable 
presence of attachment factors in the sera which do not hold the 
same importance in suspension cultures as they would have in 
anchorage dependent systems
Following these experiments a growth and production protocol was 
set up for the RPMI 2650 cells in suspension. This involved seeding 
the cells at approximately 105 cells per ml into MEMS supplemented 
with the chosen batch of DHS The cells were grown for 4 days The 
media was then removed from the cells and replaced with fresh MEMS 
without serum The cells conditioned the medium for three days 
after which time the CM was collected and processed (ultra- 
filtration or heparin sepharose chromatography) This reduced the 
length of time from flask to last collection of CM from 2 weeks, 
for roller bottles, to one week and the process could be easily 
scaled up using the bioreactor with the potential of collecting 1 8 
litres in one week.
Agitation Effects
The agitation rate had a dramatic effect on RPMI 2650 growth in 
serum-free medium At high agitator speeds the cell count was
reduced from 5 x 105 cells/ml to about 2 x 104 cells/ml, after two 
days in medium without serum At lower rates the drop was not as 
great (down to 3 x 105 cells/ml)
Historically, it has been believed that suspended animal cells are 
extremely fragile relative to other microrganisms However, when 
the effects of mechanical agitation alone were properly examined 
experimentally, it was found that cells of both insect and 
mammalian origin were generally far more robust than expected (Oh 
et al , 1989)
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Estimating shear effects is a complex procedure Hybndoma cells 
may be grown successfully in slowly stirred laboratory vessels, but 
are increasingly difficult to handle when the systems are scaled 
up This difficulty may be associated with the damaging effects of 
turbulent shear which are more predominant on a larger scale While 
the average bulk shear stress in small and large reactors may be 
comparable, the modes of operation in the two may differ. There a 
tendency at very large scale towards turbulent flow, rather than 
the less damaging laminar flow, with the possibility of both 
macroturbulence (large eddy formation due to impeller action) and 
microturbulence (smaller eddies, at a cellular level, formed by 
dissipation of larger eddies) (Bliem and Katinger, 1988) 
Presumably, therefore, scaling this 100 ml culture to production 
scale could increase the detrimental effects of shear on the cell 
number and viability
Initial work by de St Groth (1983), reported that the growth rates 
of ten different hybndoma cell lines were 15% lower in a stirred 
vessel, with minimal agitation, than in a stationary culture This 
work was subsequently discounted by Dodge and Hu (1986) as lacking 
proper controls to account for the possibility of localised
concentrations of conditioning factors in the stationary culture 
that might improve cell growth In their study they found 
detrimental effects on hybndoma growth only at agitation rates 
which were four times that required to keep the cells in 
suspension Lee et al (1988) looked at the effects of shear caused 
by agitation in the stationary and decline phases of batch growth 
of hybndoma cells (when a significant portion of monoclonal
antibody is secreted (Velez et al , 1986) It was found that
cells in stationary and decline phases of growth were sensitive to
shear forces, but cells in the growth phase seemed less sensitive 
The shear sensitivity of hybndoma cells has been shown to be 
increased by ammonia accumulation and pH changes (Petersen et al ,
1988), decreases in culture medium viscosity (Croughan et al ,
1989), decreases in concentration of sera (Kunas and Papoutsakis,
1990) and the absence of surface active agents (Michaels et al.,
1991), at low temperature and on depletion of nutrients (Al-Rubeal 
et al., 1990)
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The protecting effect of serum is interesting m  relation to the 
work presented in this thesis It has been shown that progessively 
higher concentrations (up to 10%) of FCS reduces cell death and 
allows growth of cells at substantially higher agitation rates 
(Kunas and Papoutsakis, 1990, Lee et al , 1989) The possible
mechanism of serum protection has not been fully elucidated and may 
be either fluid-mechanical (Kunas and Papoutsakis, 1990) or 
biological (Michaels et al , 1991)
The RPMI 2650 cells appear to be dramatically shear sensitive, with 
a huge reduction in cell numbers over a relatively small agitation 
range (20-60 rpm) Whether this is due to the absence of serum or 
due to the nature of the cells themselves, cannot be elucidated 
from the results presented here To study the hypothesis that serum 
protects the RPMI 2650 cells from increasing shear rates, 
additional controls would need to be included For example, flasks 
could be treated in the same manner as described here, but instead 
of being set up in serum free medium, the cultures could be grown 
at various levels of serum and exposed to different agitation
rates.
The response to shear exposure are diverse at the cellular level, 
depending on both the type of cell and on the intensity and length 
of exposure to shear Schurch et al (1988) found that the 
hybndoma cells remaining viable after exposure to shear stress 
showed growth and monoclonal antibody production rates similar to 
unexposed cells
At shear rates below fatal levels, while DNA synthesis rates are 
inhibited, metabolic rates (measured by the MTT assay) may be 
increased with increasing shear (Al-Rubeai et al , 1990) Frangos
et al (1988) followed the metabolism of arachidonic acid by
primary human umbilical vein endothelial cells, by measuring the 
production rate of prostacyclin They found that maximising shear 
stress caused subsequent increases in metabolite production.
Cyclic adenosine monophosphate (cAMP) levels in osteoblasts in vivo 
were shown to increase by increasing shear (Reich et al., 1990).
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Increasing shear stress in human embryonic kidney cells showed that 
above a critical shear level, the viability of the cells dropped 
but the surviving cells produced up to 2 5 times more urokinase 
than the untreated controls (Stathopoulos and Heliums, 1985).
Giard et al. (1979) previously found that human fibroblasts 
secrete up to 30-fold greater amounts of interferon when maintained 
on microcarriers in spinner flasks compared to cells in roller 
bottles They suggest that this may be attributed to the shear 
effects in the spinner flasks
In one report the levels of bFGF mRNA was monitored for increasing 
shear rates (Diamond et al , 1990) Primary cultures of umbilical
vein endothelial cells were either maintained in stationary phase 
or exposed to arterial levels of shear stress (25 dynes/cm2) for 24 
hours. Total cellular RNA was isolated and levels of bFGF mRNA 
were determined using a coupled reverse transcriptase/polymerase 
chain reaction method The level was compared with similarly 
prepared glyceraldhyde 3-phosphate dehydrogenase (GAPDH) and tPA 
mRNAs It was found that the levels while the levels of tPA mRNA
increased with shear, bFGF and GAPDH mRNAs remained unchanged. In 
a follow up study Nollert et al., (1991) found that these cells 
secreted decreased levels of endothelin peptide and mRNA in 
response to increasing shear rates.
Steady shear stress has also been shown to induce a transient
increase in PDGF A and B mRNAs levels in human umbilical vein
endothelial cells (Hsieh et al , 1991), which appears to be 
mediated by protein kinase C activation (Hsieh et al , 1992)
Neither autocrine nor TGF-B activity levels varied with increasing 
agitation rate m  the RPMI 2650 spinner flasks studied. TGF-a 
levels were higher at the higher rate indicating a possible
correlation, although more work would have to be done at a range of 
agitation rates to verify this result. Presumably, also, scaling
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up this process into production levels would result in even greater 
increases in TGF-a levels because of the associated increase in 
turbulent shear
Following this small scale experiment, It was decided not to change 
the agitation speed in the culture for the CM production phase, 
since it did not affect the autocrine activity
Oxygen Effects
The next step was to scale-up the 100 ml suspension cultures to 1.8 
litres This was achieved with the Braun Biostat MC bioreactor, 
which provided temperature, agitation, pH and dissolved oxygen 
control pH was maintained at 7 3 by means of C02 gas and sodium 
bicarbonate (1M) addition The oxygen level was maintained by a 
balance of nitrogen and air. The gases (C02, nitrogen and air) 
were introduced into the system indirectly by a silicone tubing 
aeration basket and directly by surface aeration
In a number of preliminary runs, the oxygen levels were controlled 
at 40-60% for the growth phase, which lead to consumption of 
excessive amounts of gases. Because of this it was decided not to 
have an upper oxygen limit on the medium and to allow natural 
depletion of the dissolved oxygen levels (due to cellular metabolic 
activities) A lower limit of 40% DO was imposed below which air 
would be added This lower limit was never reached in the growth 
phases of the three runs carried out The profile of oxygen
depletion was different for the runs described This, however,
was not indicative of the growth of the cells from one run to the 
next
Based on the curves generated in Figure 3 9 9, the average oxygen 
uptake rate for RPMI 2650 cells is in the region of 0 0010 to 
0 0018 mmol oxygen/hour for a cell population of about 1 0^/ml in a 
culture of 1 8 litres Reported values for oxygen uptake rates
range from 2-10 x 10~ 12 g/cell/hour (Speir and Griffiths, 1984) or
0 0531-0 59 mmol O^/litre/hr for cultures of 10^ cells per ml
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(Glacken et al , 1983) or from 0 1 (Vero) to 0 05 (human intestinal 
cells) g 0 2 /litre/hr for cultures of 4xl06/ml (Freschaker and 
Sinskey, 1981, Wang et al , 1988) As shown in Appendix F RPMI 
2650 cells may be considered to have a particularly low oxygen 
consumption rate
On average the oxygen was consumed at a rate of approximately 
0.3-0 5 % per hour It would take this culture of RPMI 2650 cell
8-13 days approximately to deplete this level of oxygen Therefore, 
at a two-litre-scale oxygen limitation is not a problem over a four 
day batch run Although at higher cell densities it may become rate 
limiting (Pugh, 1988).
The effect of three different oxygen levels on serum-free growth 
and viability of RPMI 2650 cells were examined Cell viability 
remained high for the culture run at 40% DO (Mid oxygen) and the 
number of cells increased At the high and low oxygen levels, the 
total cell count dropped and the viabilities were lower Around 40% 
appears to be optimum for this system This correlates with 
figures for most cell lines Typical oxygen concentrations are 
estimated between 2-4 mg/litre (i.e. 32-64% of saturated levels)
(MacMichael, 1989) In batch culture, oxygen levels between 8% and 
1 0 0% were found to have no real effect on the cell growth of the 
hybndoma cell line, NB1 (Boraston et al , 1987) Reuveny et al 
(1985) found that the optimum dissolved oxygen level for growth of 
hybndoma cells was between 50% and 60%
At low levels of oxygen (less than 50%), Reuveny et al. found that 
glucose ultilisation was reduced, and the cells retained viability 
longer, although the maximum cell concentration was not as high 
As DO is decreased, lactic acid formation is increased (Miller et 
al , 1987) Lactic acid production rates decrease four fold (from 
0 3 mg of lactic acid per 10^ hybndoma cells per day) when the 
dissolved oxygen level is increased from 25% to 75% (Reuveny et 
al , 1986) High lactic acid levels at low oxygen concentration
are due to incomplete glutamine oxidation resulting in the 
consumption of glucose as the primary energy source
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At high levels of oxygen, cells die due to the cytotoxic effects of 
hyperoxia The oxygen-derived radicals formed can attack all 
cellular components, leading to membrane peroxidation, enzyme 
inactivation and nucleic acid alterations (Freeman and Crapo, 
1982) To protect against these reactive species, cells contain low 
molecular weight molecules like ascorbic acid, a-tocopherol, 
glutathione and anti-oxidant enzymes such as superoxide dismutase 
(SOD), catalase, glutathione peroxidase and glutathione reductase 
(Fndovich, 1986)
Michiels et al (1990) carried out a comparative study of oxygen 
toxicity m  human fibroblasts and endothelial cells They found 
that the endothelial cells were more sensitive to the increased 
oxygen tension Looking at levels of intracellular anti-oxidants 
present m  each cell type after oxygen exposure, they found that 
levels of most of the antioxidants listed above are lower in the 
endothelial cells than in the fibroblasts, which may account for 
the differences m  sensitivity.
Sullivan et al (1991) reported that replacement of media in cell 
cultures during exposure to hyperoxia was found to alter oxygen 
toxicity in Chinese hamster fibroblast cells Membrane 
peroxidation during hyperoxia gives rise to lipid breakdown 
products, such as hydroperoxides and aldehydes, which are also 
highly reactive and are capable of causing tissue injury (Spitz, et 
al., 1990) Sullivan et al (1991) suggest that replacing the 
medium removes these toxic aldehydes and replaces them with 
additional substrates for the synthesis of biomolecules required 
for the repair and/or detoxification reactions
The expresssion of PDGF, its receptor and related genes was 
measured m  the lung tissue of rats exposed to air and 85% oxygen 
(Han et al , 1992) While the PDGF-A chain mRNA was unaffected by 
exposure to 85% O2 , transcription of the PDGF-B chain mRNA was 
increased
Low levels of oxygen can also effect product formation 
Erythropoietin (EPO) is a glycoprotein hormone that regulates 
erythrocyte production, and thus, blood oxygen-carrying capacity in
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mammals Steady state EPO mRNA levels increase when Hep3B human 
hepatoma cells (Goldberg et al , 1987, Goldberg et al , 1988) are
made hypoxic
Low levels of oxygen have also been implicated in a transient 
multiple drug resistance (MDR) in EMT6/R0 cells (Sakata et al ,
1991), which does not seem to be associated with P-glycoprotein- 
associated MDR When the cells return to a normal oxygen 
environment, they lose their resistance. This oxygen effect has 
serious implications as regards control of tumour growth vivo.
Hypoxia also induces TGF-/31 mRNA levels in infant rat brains, where 
TGF-I31 is speculated to be involved in post-asphyxial repair 
mechanisms (Klempt et al , 1992)
Autocrine activity did not vary with DO levels, but when this 
activity was separated into heparin binding and non-heparin binding 
fractions, differences were apparent At mid and low levels of 
oxygen, the activity was predominately non-heparin binding But at 
high oxygen levels the activities of bound and unbound fractions 
were comparable, with the level of unbound activity reduced at 
higher oxygen and the level of bound activity increased.
TGF-a activity also dramatically increased with oxygen levels (16 
fold), while TGF-fl activity appears to drop slightly The limited 
results presented do not clearly demonstrate whether these results 
are indicative of the relatively low viability or represent a a 
direct effect of oxygen itself
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CONCLUSIONS AND FUTURE DIRECTION OF PROJECT
5.0 CONCLUSIONS AND FUTURE DIRECTION OF THE PROJECT
The results in this thesis show that RPMI 2650 cells produce at 
least three different growth stimulatory activities, which can be 
collected in their conditioned medium, a TGF-a-like activity, a 
TGF-B-like activity and an autocrine activity
While the TGF-a-like assay was specific for TGF-a and EGF, IGF-I 
and to a lesser extent IGF II could cause a positive response as 
well as TGF-B in the NRK-49F assay
The autocrine activity could be fractionated into two distinct 
activities
Fraction 1 = Heparin-binding, acid-, base- and heat-labile 
activity concentrating in the range 1-30 kDa, 
Fraction 2 = Non-heparin-binding, acid-, base- and
heat-stable activity greater than 30 kDa 
Boiling renders labile to acid and trypsin
The published information on the stability and fractionation 
properties of acid- and heat-labile growth factors is unlike the 
activity profile of Fraction 1, which is eluted from heparin 
sepharose gels at low concentrations of salt
The properties of Fraction 2, however, may correspond to those of 
previously characterised growth factor in association with either a 
specific binding protein (like the IGF-BP family), a non-specific 
binding protein (e.g. o^-macroglobulin) or a mucopolysaccharide 
(e g heparin) Because the free growth factor is not
concentrated in the Rl-30 fraction (following extensive boiling), 
Fraction 2 is unlikely to be one of the common transforming growth
factors (TGF-a, TGF-fi, PDGF, aFGF, bFGF, IGF I or II)
Alternatively, the stable nature of the R30 fraction may be 
accounted for by a particularly stable protein conformation, which 
can be modified by boiling without loss in activity
The work presented in this thesis is by no means final. Many 
questions remain to be answered For example the heat stability 
profile of the R30 fraction is unusual Why did boiling for 3
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minutes cause a drop m  autocrine activity in the 
non-heparin-binding fraction, while extensive boiling appears to 
activate it? Other pertinent questions should be addressed
What determines the ratio of the activity m  the Rl-30 fraction 
to that of the R30 fraction?
Are the Rl-30 and the R30 effects additive’
What other treatments cause a similar response to 
extensive boiling’
Would glycosidases have an effect on activity’
Is the effect of the autocrine factor reversible or
irreversible (as in the case of murine epithelial cells, 
Wilder and Rizzino, 1991)?
For definitive conclusions on the identity of the two factors, 
N-terminal sequencing is an obvious step Before this could be 
attempted, it would be necessary to have a very pure fraction To 
achieve this, other purification steps would need to be 
investigated and most likely combined with heparin sepharose 
Hydrophobic interaction chromatography may be considered as a 
possible candidate, since preliminarly experiments did indicate 
some fractionation on the phenyl sepharose column Gel 
chromatography under non-acidic conditions may also be considered 
If the factors proved to have homology with previously reported 
sequences, neutralising antibodies against these factors could be 
used to ascertain their autocrine mechanism
If either of the fractions appears to be novel at this stage, 
polyclonal antibodies could be raised against them These could 
then be used in affinity columns to aid purification and, possibly 
more interestingly, could be used as probes to study if these 
autocrine growth factors are extensively expressed in different 
tumour cell lines or tissues, or whether they have a role in normal 
cell growth.
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8 0 APPENDICES
APPENDIX A
Interleukins and hemopoietic growth factors
IL-1 IL-2 IL-3
IL-la IL-lfi
Proprotem 271 aa 269 aa 153 aa 152 aa
30 6 kDa 30 7 kDa 
Mature protein 159 aa 153 aa 133 aa 133 aa
MW (kDa) 38,31,17, 38,31,17 19-22 28
15,4 2 15,4,2
Structure Monomer or non colvalent polymer Monomer
Chromosome 2 2 4 5
Proprotein 
Mature protein 
MW (kDa) 
Structure 
Chromosome
IL-4
153
129
20
Monomer
5
IL-5 
133 
125 
45, 60 
Dimer, trimer 
5
IL-6
212
184
21
Monomer
7
Proprotein 
Mature protein 
MW (kDa) 
Structure 
Chromosome
IL-7
177
152
20-28
Monomer
IL-8
90
72
8
Monomer
IL-9
202
179
21-41
Monomer
7
IL-10 IL-11 IL-12
Proprotein 
Mature protein
MW (kDa) 24 23
Structure
Chromosome
EPO GM-CSF ' G-CSF M-CSF
Proprotein 193 aa 144 aa 207 aa 224 aa
Mature protein 166 aa 127 aa 177 aa 127 aa
MW (kDa) 27-60 22 23 40-45
Structure Monomer Monomer Monomer Homodimer
Chromosome 7 5 17 5
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APPENDIX B
Interleukin Alternative names
IL-1 Endogenous pyrogen (EP), Lymphocyte-activating factor
(LAF), B-cell activating factor (BAF), Leukocyte 
endogenous mediator (LEM), Catabolm, Mononuclear cell 
factor (MCF)
IL-2 T-Cell Derived Growth Factor (TCGF), T-cell Maturation/
Stimulating factor (TMF/TSF), Killer Helper Factor 
(KHF), T-Cell Replacing Factor {TRF)
IL-3 Mast cell growth factor (MCGF), P-cell stimulating
factor (PSF), Burst promoting activity (BPA), 
Haematopoietic cell growth factor (HCGF), Erythroid 
colony stimulating factor (ECSF), Megakaryocyte colony 
stimulating factor (MEG-CSF), Eosinophil colony 
stimulating factor (Eo-CSF), Multiple colony 
stimulating factor (Multi-CSF)
IL-4 B Cell growth factor (BCGF), B cell stimulatory
factor-1 (BSF1), B-cell stimulatory factor pl(BSFpl), 
Macrophage fusion factor (MFF), Macrophage Activating 
Factor (MAF)
IL-5 T-cell Replacing Factor (TRF), Eosinophil
differentiating factor (EDF), B Cell growth factor II 
(BCGFII), Killer helper factor (KHF), IgA-enhancing 
factor (IgA-EF), Eosinophil colony stimulating factor 
(Eo-CSF), IL-4
IL-6 HP-1, Plasmacytoma growth factor (PCT-GF), Hybndoma
growth factor (HGF) , IFN-J32, B-cell stimulatory 
factor-2 (BSF-2), hybndoma/plasma-cytoma growth factor 
(H/PGF), B-cell differentiation factor (BCDF), B cell 
stimulatory factor p2 (BSFp2)
IL-7 Lymphopoietm-1 (LP-1)
IL-8 Monocyte-derived neutrophil chemotatic factor (MDNCF),
neutrophil activating factor (NAF), Monocyte-derived 
neutrophil activating peptide (MONAP), 
lymphoccyte-derived neutrophil activating peptide 
(LYNAP), granulocyte chemotatic peptide (GCP), 
macrophage-derived inflammatory protein 2 (MIP-2)
IL-9 Human interleukin for DA cells (HILDA), leukemia
inhibitory factor (LIF), differentiation inhibiting 
activity (DIA)
IL-10 B cell derived T cell growth factor (B-TCGF)
cytokine synthesis inhibitory factor (CISF)
(Oppenheim et al , 1986, Dmarello, 1985, Di Giovine and Duff, 
1989, MacNeil et al , 1990)
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APPENDIX C
Calculations of TGF-a-like activity
TG Fa(n g/ml)
FIGURE C 1 Standard curve of TGF-a in the NRK agar assay
RPMI ?650 CM CFE+SEM CFE-C
Equilavent 
TGF-a (ng/ml)
R1 lOx 1.1810 19 1 14 0 50
5x 0 39±0 06 0 35 off scale
lx 0 00±0 00 -0 04 off scale
High C>2 10x 9 82±0 81 9.82
/ /
7 74
Low 02 10x 1 45±0 65 1 45 0.47
Controls (C)
MEM 0 04±0 05
MEMS 0 0010 00
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APPENDIX D
Calcuiat ions of TGF-fl-1ike activity
0 4------------ •-------------I-----------------------------  -■------------
0 25 0 50 1 00 2 00 5 00 10 00
TGF0(ng/m l)
FIGURE D 1 Standard curve of TGF-fi in the NRK-49F agar assay
RPMI 2^50'CM - CFE1SEM CFE-C TGF-ÎÎ (ng/ml)
RPMI 2650 R30 lOx 3 69±0 13 3 51 off scale
5x 2 47±0 03 2.29 3 25
Ix 1 65±0 01 1 47 1 17
R5-30 lOx 1 41±0 02 1 31 1 OO
5x 0 94±0 01 0 76 0 56
lx 0 21±0 01 0 03 off scale
BSC-1 RIO lOx 2 85±0.06 2 67 4 00
lx 0 43±0 01 0.25 0 34
MSV 3T3 R1 lOx 0 0410 01 -0 27 off scale
5x 0 3210 01 0 01 0 00
lx 0 1310 01 -0 18 off scale
Controls
MEM 0 1810 01
DME 0.3110 01
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APPENDIX E
Structures of Cvtodex microcamer bead side chaina
Cytodex 1
CH2CH3
charges A  /
throughout I * * ) cross linked dextran -  O CH CH - N HCt
matrix V .* J X CH2CH
Cytodex 2 ^ ^
OH yCH
surface layer if  \ \  ■ ^  &
of chafgeasyer (  )) cross-hnked dextran -  O -  CH2 -  CH -  CHa -eN -  CH3
\  J  Cl0 X CH3
Cytodex 3
j / OHcollagen layer/ \ i
coupled to I  f cross-linked dextran -  O -  CH2 -  CH -  CH2 -  NH -  (tLvs COLLAGEN)
surface
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APPENDIX F
Calculation of oxygen consumption rates
Low Oxygen Mid Oxygen High Oxygen
Hrs DO Hrs Rate DO Hrs Rate DO Hrs Rate
0 97 0 98 2 92 0
10 87 0 10 -9 4* 92 7 10 -5 5 87 2 10 -4 9
20 83 8 10 -3 8 88 5 10 -4 2 82 5 10 -4 7
29 79 3 9 -3 2
30 81 0 10 -2 8 84 3 10 -4 2
31 63 5 2 -15 8*
40 78 8 10 -2 2 80 7 10 -3 6 73 3 9 -3 6
50 75 9 10 -2 9 77 0 10 -3 7 69 2 10 -4 1
60 74 8 10 -1 1 72 7 10 -4 3 63 9 10 -5 3
70 71 0 10 -3 8 67 8 10 -4 9 58 3 10 -5 6
80 68 5 10 -2 5 61 8 10 -6 0 52 1 10 -6 2
90 65 8 10 -2 7 54 9 10 -6 9 46 0 10 -6 1
Average
Rate 0 273 %/hr 0 481 %/hr 0 494 !%/hr
Oxygen Solubility = 6 4 img/litre (0 2mmol/litre)
(Oiler et al, 1989)
100% DO in 1 8 litres = 6 4 x 1 8 = 11 5 mg iof O2
=
0 2 x 1 8 = 0 36 mmol 02
Average
Consumption 0 031 mg/hr 0 055 mg/hr 0 057 mg/hr
Rate 0 0010 mmol/hr 0 0017 mmol/hr 0 0018 mmol/hr
Reported Consumption Rates
Speir and Griffiths (1984)
2 - 10 x 10 12 g/cell/hr
= 2 - 10 x 10-9 mg/cell/hr 
RPMI 2650 culture = approximately 1 x 105 cells/ml m  1 8 litres
= 1 8 x 108 cells 
Rate = (2 - 10 X  10"9) x (1 8 x 108) rag/hr
= 0 36 - 1 8 mg/hr
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Glacken et al (1983)
0 0531-0 59 mmol 02/109 cells/hr 
= 0 0096-0 1062 mmol 02/l 8xl08 cells/hr 
= 0 31 - 3 40 mg/hr
Fleischaker and Sinskey (1981)
0 1 - 0 5 g 02/4x 109 cells/hr 
= 0 0045-0 0225 g/1 8xl08 cells/hr 
= 4 5 - 22 5 mg/hr
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APPENDIX G
Composition of Minimum Essential Media (MEM and MEMS) (Gibco Brl )
MEM (lOx) 
with Earl's salts 
without L-glutamine, 
without sodium bicarbonate 
(Cat No 042-01430)
MEMS (lOx)
Modified for suspension cultures 
with Earl's salts (modified) 
without L-glutamine, 
without sodium bicarbonate 
(Cat No 042-01650)
(mg/litre) (mg/litre)
Inorganic Salts 
CaCl2 2H20 
KC1
MgS04 7H20 
NaCl
NaH2P04 2H20
2640 00 
4000 00 
2000 00 
68000 00 
1580 00
4000 00 
2000 00 
68000 00 
15800 00
Other Components 
D-Glucose 
Phenol Red
10000  00 
100  00
10000  00 
100 00
Amino Acids
L-Arginine HCl 1260 00 1260 00
L-Cystine 240 00 240 00
L-Histidine HCl H20 420 00 420 00
L-Isoleucine 520 00 520 00
L-Leucine 520 00 520 00
L-Lysine HCl 730 00 730 00
L-Methionine 150 00 150 00
L-Phenylalanine 320 00 320 00
L-Threoine 480 00 480 00
L-Tryptophan 100 00 100 00
L-Tyrosme 360 00 360.00
L-Valine 460 00 460 00
Vitamins
D-Ca Pantothenate 10 00 10 00
Choline Chloride 10 00 10 00
Folic Acid 10 00 10 00
i-Inositol 20 00 20 00
Nicotinamide 10 00 10 00
Pyndoxal HCl 10 00 10 00
Riboflavin 1 00 1 00
Thiamine HCl 10 00 10 00
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